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Abstract
Critical care is provided to patients who require intensive monitoring
and often the support of failing organs. Cardiovascular and circula-
tory diseases and dysfunctions are extremely common in this group of
patients. However, cardiac disease states are highly patient-specific
and every patient has a unique expression of the disease or under-
lying dysfunction. Clinical staff must consider many combinations
of different disease scenarios based on frequently conflicting or con-
fusing measured data on a patient’s condition. Successful diagnosis
and treatment therefore often rely on the experience and intuition of
clinical staff, increasing the likelihood for clinical errors.
A cardiovascular (CVS) computerized model that uniquely represents
the patient and underlying dysfunction or disease is developed. The
CVS model is extended to account for the known physiologic mecha-
nisms during spontaneous breathing and mechanical ventilation, thus
increasing the model’s accuracy of representing a critically ill patient
in the intensive care unit (ICU). The extended CVS model is validated
by correctly simulating several well known circulatory mechanisms
and interactions.
An integral-based system parameter identification method is refined
and extended to account for much smaller subsets of available input
data, as usually seen in critical care units. For example, instead of
requiring the continuous ventricle pressure and volume waveforms,
only the end-systolic (ESV) and end-diastolic (EDV) volume values
are needed, which can be even further reduced to only using the global
end-diastolic volume (GEDV) and estimating the ventricle volumes.
These changes make the CVS model and its application to monitoring
more applicable to a clinical environment.
The CVS model and integral-based parameter identification approach
are validated on data from porcine experiments of pulmonary em-
bolism (PE), positive end-expiratory pressure (PEEP) titrations at
different volemic levels, and 2 different studies of induced endotoxic
(septic) shock. They are also validated on 3 adrenaline dosing data
sets obtained from published studies in humans. Overall, these studies
are used to show how the model and realistic clinical measurements
may be used to provide a clear clinical picture in real-time.
A wide range of clinically measured hemodynamics were successfully
captured over time. The integral-based method identified all model
parameters, typically with less than 10% error versus clinically mea-
sured pressure and volume signals. Moreover, patient-specific param-
eter relationships were formulated allowing the forward prediction of
the patient’s response towards clinical interventions, such as admin-
istering a fluid bolus or changing the dose of an inotrope. Hence, the
model and methods are able to provide diagnostic information and
therapeutic decision support.
In particular, tracking the model parameter changes over time can as-
sist clinical staff in finding the right diagnosis, for example an increase
in pulmonary vascular resistance indicates a developing constriction
in the pulmonary artery caused by an embolus. Furthermore, using
the predictive ability of the model and developed methods, different
treatment choices and their effect on the patient can be simulated.
Thus, the best individual treatment for each patient can be developed
and chosen, and unnecessary or even harmful interventions avoided.
This research thus increases confidence in the clinical applicability
and validity of this overall diagnostic monitoring and therapy guid-
ance approach. It accomplishes this goal using a novel physiological
model of the heart and circulation. The integral-based parameter
identification methods take dense, numerical data from diverse mea-
surements and aggregate them into a clearer physiological picture of
CVS status. Hence, the broader accomplishment of this thesis is the
transformation, using computation and models, of diverse and often
confusing measured data into a patient-specific physiological picture
- a new model-based therapeutic.
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Chapter 1
Introduction and Motivation
Critical care is provided to patients who are amongst the sickest in the hospital.
They have potentially severe physiologic instability and require intensive moni-
toring as well as frequently requiring the support of failing organs. Therapeutic
and diagnostic support is fundamental for the optimal management of critically ill
patients. However, excess information can exceed human decision making limits.
In contrast, insufficient and limited data can confuse the clinical picture. There-
fore, critical care patient management requires balancing information levels and
clarity to optimize decision making.
Cardiovascular diseases are extremely common and claimed nearly 1 million
lives in the United States in 2004, which equals 36.6% of all deaths or 1 of every
2.8 deaths (American Heart Association, Cardiovascular Disease Statistics). It
has been estimated that more than 50% of postoperative deaths are caused by
cardiac events (Mangano, 1994; Ramsey, 1999). Many admissions to the intensive
care unit (ICU) are for cardiac or circulatory monitoring or dysfunction, and
many unplanned ICU admissions are for treatment of acute cardiovascular and
circulatory dysfunctions that occur intraoperatively (Ramsey, 1999).
Even in non-cardiac surgery patients, about one third have coronary artery
disease (CAD) or two or more major risk factors for CAD or are older then 65
years (Mangano, 1994). Therefore, it can almost be expected that in this large
group of patients, when subjected to stress during the perioperative period, car-
diovascular complications develop. Overall it is estimated that approximately 1
million patients will suffer severe perioperative cardiac morbidity following non-
cardiac surgery in the United States. Thirty three billion USD in costs are at-
tributable to these cardiovascular complications following an operation each year
(Mangano, 1994).
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Thus, circulatory dysfunctions and associated diseases, such as various kinds
of circulatory or cardiac shock account for a significant amount of ICU admis-
sions. In particular, severe sepsis and septic shock have long been a challenge for
intensive care clinicians because of their frequent occurrence, significant mortality
rates of 30-50%, and high associated costs (Karlsson et al., 2007). Another recent
study found the following disease conditions leading to ICU admission and their
occurrence rates for patients aged 65-74 years in Olmsted County, Minnesota:
Cardiovascular (58.2%), Respiratory diseases (17.4%), Gastrointestinal (8.5%),
Neurologic (6.5%), Toxin/trauma (2%), Other (7.5%) (Seferian & Afessa, 2006).
Again, cardiovascular dysfunction accounts for a dramatic majority of admissions.
However, managing these patients is challenging. In particular, both diagnosis
and therapy can be very difficult, as cardiac disease state is highly patient-specific.
Every patient has an unique expression of a given disease or dysfunction. Hence, it
is difficult to accurately diagnose due to the often limited measurements available.
In addition, the body’s natural reflex responses to restore circulatory equilibrium
can often mask the underlying symptoms.
Hence, clinical staff must consider many combinations of different disease sce-
narios based on frequently conflicting data on a patient’s condition, including
clinical history and non-invasive and/or invasive studies (Grenvik et al., 1989).
Thus, successful diagnosis and treatment often rely on the experience and intu-
ition of clinical staff, increasing the likelihood for clinical errors. Unfortunately,
clinical error rates are common (1-50%) and occur frequently (Abramson et al.,
1980; Donchin et al., 1995; Morris, 2001; Suresh et al., 2004).
As difficult as diagnosing cardiac disease states is, it is also not trivial to treat
them properly. In particular, all patients are different and may have different
responses towards the same treatment and therapy. Moreover, the multitude of
interacting mechanisms in the cardiovascular system makes successful reasoning
about therapy effects very difficult. These difficulties are further aggravated by
the various disease states that change the physiological relationships.
Thus, the primary issue is integrating the diverse clinical data available into
a complete and accurate assessment of patient state. This integration is based on
the mental models and understanding of clinical staff. A physiological, identifiable
and validated computer model offers several potential advantages in diagnosis and
therapy selection. In particular, the ability to aggregate diverse patient data into
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a compact, patient-specific, clinically relevant assessment of circulatory status,
can offer significant potential advantages in creating a clear physiological picture.
1.1 Hemodynamic Monitoring in ICUs
Critically ill patients in the ICU are hemodynamically monitored to identify
cardiovascular insufficiency as well as the probable cause and potential response
to therapy. The following list summarizes 3 arguments that can be made for
using specific monitoring devices (Pinsky, 2007):
 Prior experience has shown that monitoring can identify diseases and/or
complications, even though the link between monitored variable and disease
may not be known.
 Monitoring is used to define the cardiovascular status of the patient and
it is assumed that a restoration to normal physiologic values will prevent
further organ injury and reduce mortality.
 Monitoring-treatment protocols can influence and determine the therapy in
otherwise unexpected ways.
However, when monitoring devices do not drive treatment protocols, they cannot
improve outcome. In particular, only treatment can improve outcome for pa-
tients, but not monitoring alone. Clearly, as several studies (Connors et al., 1996;
Pinsky, 2007; Sandham et al., 2003; Yu et al., 2003) have shown, just inserting a
catheter to make measurements without a defined and effective treatment proto-
col requiring such information, is unlikely to result in improved patient outcomes.
Thus, over the years, treatment protocols have been developed and established
that link monitored variables, such as mixed venous oxygen saturation (Sv¯O2),
to special treatment options.
The goal in this research is to integrate the CVS model into this process
chain, starting from ICU admission and transferring to diagnosis and therapy.
The CVS model and methods developed not only assist clinical staff in finding
the right diagnosis, but can also provide information about therapy responses.
The result can enable more consistent care and reduce variation. Importantly,
variation in clinical management is linked to suboptimal outcomes for patients,
as well as increased costs and lengths of stay in the hospital. Tools for assisting
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with diagnosis and therapy guidance can help in reducing variation in clinical
practice, resulting in more consistent care, which in turn has a positive impact
on patient outcomes.
1.1.1 Application of Computerized Models and Protocols
Over the last few years, evidence-based and (early) goal-directed therapeutic
protocols have become much more popular and commonly used, as they can be
applied for complex clinical problems to create patient-specific therapy. Clinical
trials in the emergency department by Rivers et al. (2001) have clearly docu-
mented improved outcome, especially if the goal-directed therapy is initiated as
early as possible. Importantly, in the study by Rivers et al. (2001), the total
amount of administered fluids was similar in the treatment and control groups,
but the treatment group received the fluids early when the control group did not
require them based on traditional hemodynamic measures such as mean arterial
pressure (MAP) and right atrial pressure (Pra). This result shows that the earlier
the treatment is begun, the better the likely outcome for the patient.
The cardiovascular (CVS) model in this research could favorably be integrated
into this process of decision making by offering clinicians the possibility of collect-
ing the diverse data into a clearer physiological picture. As such, it can help in
diagnosis as well as allowing testing of different therapeutic procedures and their
likely effect on the patient. Early in the treatment process, the CVS model could
be used to give valuable insight into the patient-specific condition and underly-
ing dysfunction, where typically measured variables may still be at normal target
levels. The best individual treatment for each patient could thus be chosen, and
unnecessary or even harmful interventions avoided.
1.2 Motivation and Goals for this Research
This PhD research employs a physiologically validated minimal CVS model based
on (Smith, 2004; Smith et al., 2004), capable of capturing patient dynamics com-
monly seen in an ICU. In an ICU, catheters are often already in place and special
monitoring devices are used. As a result, a larger, more useful range of mea-
surements is available. However, it has to be mentioned that the more invasive
measurements that are performed, the greater the potential risk for the patient
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(Metnitz et al., 2004). Thus, one goal of this research is to investigate how us-
ing only a relatively small number of physiological variables can still result in
accurate model identifications, resulting diagnosis, and therapy predictions. The
use of minimized clinical data is especially important, as most ICUs still only
measure blood pressure (BP), heart rate (HR) and oxygen saturation by pulse
oximetry (SpO2), as they have done for the last 20 years (Pinsky, 2007).
A highly efficient model implementation method (Hann et al., 2005) provides
the necessary simplicity, flexibility and rapid forward simulation required in a
clinical environment. Finally, a linear, convex and integral-based identification
method based on Hann et al. (2006) allows virtually all the model parameters to
be identified, and is employed to create patient-specific models from clinical data.
These patient-specific models are tuned to the individual patient and uniquely
represent their condition. The combination of rapid patient-specific parameter
identification and fast accurate forward simulation enables the potential for real-
time diagnosis and therapy selection decision support in the ICU.
The main goals of this PhD research are to clinically validate the CVS model
and make improvements where needed based on these results. The identification
process is revisited and transferred from a theoretical framework into clinically
applicable methods that allow real-time identification of the model parameters
and ensure the accuracy of the identified parameters. The final results presented
in this thesis are the first clinical validations of these models and methods using
porcine animal experiments and data from human trials in an intensive care
setting.
1.2.1 Example for a Potential Use of the CVS Model
For hemodynamically unstable patients admitted to the ICU, there are usually
3 important functional questions that have to be asked by the clinical staff. The
answers determine the type of treatment that will be initiated (Pinsky, 2007):
 Will cardiac output (CO) increase with fluid resuscitation and if so, by how
much?
 In the hypotensive patient, is the vasomotor tone increased, decreased or
normal?
 Is the heart capable of sustaining an effective cardiac output (CO) once
arterial pressure is restored or will it go into failure?
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To answer the first question and assess the preload responsiveness of the patient,
intravascular fluid challenges are commonly administered. In this case, a bolus
of fluid is rapidly infused and the subsequent changes in specific flow-dependent
variables (CO, MAP, Sv¯O2 and Pra) are measured. However, the problems with
performing a fluid challenge for clinical decision making are multiple (Pinsky,
2007):
 Only half of the hemodynamically unstable patients administered a volume
challenge will respond with an increase in CO (Michard & Teboul, 2002).
Thus, the correct treatment may have been delayed in the other half of the
patients.
 In the half not responding and who are thus not preload responsive, volume
loading may be directly injurious, as for example in left ventricle (LV)
failure.
 Dynamic measures, such as stroke volume variation (SVV), pulse pressure
variation (PPV) and systolic pressure variation (SPV) are usually used to
predict fluid responsiveness. However:
– They assume a constant R-R interval and are thus unreliable for vary-
ing R-R intervals as in atrial fibrillation.
– They may lose accuracy if tidal volume varies from breath to breath
as may occur with assisted and spontaneous ventilation (Backer et al.,
2005; Reuter et al., 2003). Thus, these approaches are limited to only
a small amount of ICU patients.
– Preload responsiveness does not mean that a patient requires volume
resuscitation, as healthy subjects are also preload responsive (Pinsky,
2004).
Hence, there is a scenario where the outcome or situation is unknown. Typical
clinical response cannot distinguish between significantly contrasting treatment
options from the data and methods available.
The CVS model could potentially be used in this difficult scenario to answer
the first question by forward simulating and predicting the patient’s response
towards a fluid challenge. Even different types and amounts of fluids could be
simulated and the most appropriate chosen for the patient. Moreover, the CVS
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model could still be used where normal hemodynamic variables (for example SVV
in atrial fibrillation or for assisted ventilation) are unreliable or cannot be used
at all.
Finally, although specific patterns of hemodynamic variables exist that de-
scribe specific types of diseases, they do not predict individual patient response
to therapy. However, the goal of this research is, to develop a CVS model and
parameter identification process that can be used as a basis for a diagnostic as-
sistance system and in guiding therapy. This system could then potentially help
overcome such problems by allowing realistic and physiologically correct predic-
tions of patient-specific responses to different treatment choices.
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Chapter 2
Cardiovascular Physiology
This chapter gives a brief introduction in cardiovascular and respiratory anatomy
and physiology. It is designed to provide the reader with the essential background
information needed to understand the discussions and explanations in the follow-
ing chapters.
2.1 Circulation
The circulatory system is responsible for transporting blood through the body
to its cells. This flow provides an adequate amount of nutrients and oxygen,
also assuring the removal of metabolic end products. The heart connects the
two major parts of the circulation, the systemic circulation and the pulmonary
circulation. In the pulmonary circulation, blood is pumped through the right
atrium and ventricle of the heart to the lungs, where carbon dioxide is exchanged
for oxygen. The oxygenated blood returns to the heart via the pulmonary vein. It
then circulates through the left atrium and ventricle and exits the heart through
the aorta. The blood vessels in the systemic circulation transport the blood
throughout the rest of the body. Systemic circulation provides nourishment for
all of the body’s tissues, except for the heart and lungs. Figure 2.1 shows an
overview of the circulation, including the systemic and pulmonary circulation.
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Figure 2.1: Overview of pulmonary and systemic circulation (McKinley &
O’Loughlin, 2007)
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2.1.1 Arterial and Venous System
The arteries are the blood vessels that initially transport the oxygenated blood
from the heart under high pressure to the tissues. The arterioles are the last small
branch of the arterial system through which blood is released into the capillaries.
The capillaries are very small, thin-walled blood vessels where the exchange of
gases, nutrients, and waste products takes place between the cells and the blood.
Blood flows with almost no resistance in the larger blood vessels, but in the
arterioles and capillaries, considerable resistance to flow occurs because these
vessels are so small in diameter that the blood must squeeze all its contents
through them. The venules collect blood from the capillaries and gradually feed
into progressively larger veins. The venous system thus transports the blood from
the tissues back to the heart. The walls of the veins are thin and very elastic and
can fold or expand to act as a reservoir for extra blood, if required.
2.1.2 Capillary System
The capillary system delivers what is needed to the cells and removes what is
not needed. They are made up of a single layer of endothelial cells with a wall
thickness of 0.5−1.0µm and an average diameter of about the size of a red blood
cell, thus around 7− 8µm. There are about 40 billion capillary cells in the body
and they are distributed such that no cell is further away than 0.1mm from a
capillary. This prevalence and proximity is the basis for the diffusion of nutrients
and waste products into and out of the tissue cells (Mehler & Sompayrac, 2001).
Capillaries form a network of parallel connections between the arterioles and
venules, as shown in Figure 2.2.
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from heart
Arteriole
Capillaries
Venule
to heart
Figure 2.2: Capillary system: connecting arterial and venous sides of the circu-
lation.
2.2 Anatomy of the Heart
The heart is the muscular pump that connects the systemic and pulmonary vas-
cular systems. It has two separate sides. One is designed to pump deoxygenated
blood into the pulmonary circulation where the blood becomes oxygenated. The
second, is designed to pump the oxygenated blood into the systemic circulation
where the blood is transported through the body to the tissue cells. Each of these
sides consists of one ventricle and one atrium.
The left ventricle (LA) and atrium form the so-called left heart and pump
oxygenated blood from the pulmonary system into the systemic circulation. The
right heart is formed by the right ventricle (RV) and atrium and pumps deoxy-
genated blood from the vena cava into the pulmonary circulation. The right and
left ventricle share a common wall, the interventricular septum.
The heart also consists of four heart valves which ensure a unidirectional flow
and prevent backwards flow (regurgitation). The right atrium is separated from
the right ventricle by the tricuspid valve (tc), the left atrium and left ventricle by
the mitral valve (mt). The pulmonary valve (pv) lies between the right ventricle
and the pulmonary artery and the aortic valve (av) between the left ventricle and
aorta. Figure 2.3 shows the internal architecture of the heart.
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Figure 2.3: Internal view of the heart (McKinley & O’Loughlin, 2007)
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2.3 Normal Cardiac Electrical Activation
The action potentials generated by the sinoatrial (SA) node spread through
the atria. The conduction velocity of action potentials in the atrial muscle is
about 0.5m/s. As the wave of action potentials depolarizes the atrial muscle,
the cardiomyocytes contract by a process termed excitation-contraction coupling
(Klabunde, 2004).
In a healthy heart, the only pathway available for action potentials to enter
the ventricles is through a specialized region of cells, the so-called atrioventricular
(AV) node, which is located in the interatrial septum. The AV node is a dis-
tinct conducting tissue that slows the impulse conduction substantially to about
0.05m/s. It thus allows time for complete atrial depolarization and contraction
(systole) prior to ventricular depolarization and contraction.
Subsequently, the impulses enter the ventricle at the Bundle of His and follow
the left and right bundle branches along the interventricular septum. These spe-
cialized fibers conduct the impulses at a high velocity of about 2m/s. The bundle
branches divide into the so-called Purkinje fibers that conduct the impulses at a
velocity of about 4m/s through the ventricles. This action results in depolariza-
tion of ventricular myocytes and ventricular contraction (Klabunde, 2004). This
conduction system is thus very important for an organized depolarization and
repolarization of the ventricle myocytes to generate an adequate pressure during
the different phases of the cardiac cycle. The conduction times are different in
the left and right ventricle whereby the right ventricle is activated after around
0.21s and the left ventricle after 0.23s. This sequence and timing of activation is
depicted in Figure 2.4.
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Figure 2.4: Sequence of cardiac electrical activation and times to reach specific
locations (Klabunde, 2004).
2.4 Mechanical Properties of the Heart
Assessment of left and right ventricular systolic and diastolic pump properties is
vital for understanding cardiovascular physiology. Since 1895, when Otto Frank
(Frank, 1895) published the first cardiovascular investigations, numerous articles
have been published on this topic. As a result, greater insight has been gained
into the fundamental concepts of cardiovascular physiology and pathophysiology,
as well as the fundamental mechanics of the heart muscle in different states.
Important information about the functioning of the left ventricle can be ob-
tained by examining the commonly measured Pressure-Volume (PV) loop. This
loop is obtained when plotting the left ventricle volume (Vlv) versus the left ven-
tricle pressure (Plv). Figure 2.5 shows a PV loop labelling the critical points and
actions in the cardiac cycle. Point A marks the opening of the mitral/tricuspid
valves and thus the beginning of the filling process, which ends at point B with
the closing of the two heart valves. The ejection period starts at point C with
the opening of the aortic/pulmonary valves and finishes at point D where the
valves close again. Vd is the unstressed chamber volume and Vo the volume at
zero pressure.
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Figure 2.5: PV loop for the cardiac cycle and the variations in end-diastolic
(EDPVR) and end-systolic (ESPVR) pressure-volume relationships.
The PV loops change whenever significant dysfunction occurs. For example, when
the preload, which is the hemodynamic stretch or load that is exerted on the heart
during diastole, is rapidly changed, such as through a vena cava occlusion, the
PV loops will change in a characteristic way. This behaviour or change can be
seen in Figure 2.6. In particular, the end-diastolic volume (EDV) decreases, but
nothing else is modified about the heart or arterial system properties. From this
figure it can be seen how the PV loop is confined by the end-diastolic pressure
volume relationship (EDPVR) and the end-systolic pressure volume relationship
(ESPVR).
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Figure 2.6: Pressure- Volume (PV) loop for several heart beats during simulated
vena cava occlusion showing the ESPVR and EDPVR. The end-diastolic volume
decreases (moves left) as the occlusion and its effect become larger.
2.4.1 EDPVR
The end-diastolic pressure-volume relationship (EDPVR) represents the elastance
of the ventricle in the frozen state of end-diastole, at maximum filling and relax-
ation. The EDPVR is a non-linear relationship, which intercepts the x-axis at
Vo, which is defined as the volume at zero pressure.
EDPV R = P0(e
λ(V−Vo) − 1) (2.1)
where λ, P0 and Vo define curvature, gradient and volume at zero pressure.
2.4.2 ESPVR
The end-systolic pressure volume relationship (ESPVR) represents the elastance
of the ventricle in the state of end-systole, thus in an activated state of con-
traction. The ESPVR intercepts the x-axis at a positive volume value Vd, which
indicates that some amount of volume must be in the ventricle before a pressure is
17
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generated. It can be assumed that Vd = Vo, which will introduce a comparatively
small error, but simplify further discussions (Burkhoff, 2002).
ESPV R = Ees(V − Vd) (2.2)
where Vd is the unstressed chamber volume and Ees the end-systolic elastance.
2.4.3 Time-Varying Elastance Function E(t)
Only the elastances of the ventricle in the two states of end-systole and end-
diastole have been so far examined. In between these two states (B-C and D-A
in Figure 2.5) the elastance changes in a characteristic way from EDPVR to
ESPVR during systole and back during diastole. These changes in elastance
are the largely vertical portions of the PV loop during isovolumetric contraction
(B-C) and relaxation (D-A). This change is illustrated in Figure 2.7.
ESPVR
EDPVR
time
Figure 2.7: Time-Varying Elastance E(t) from diastole to systole
All these pressure- volume relationships are approximately linear and share
a common x-axis intercept Vd. It is thus possible to describe the time course of
change in ventricle elastance, and therefore in the ventricle properties, by plotting
the slope of the pressure- volume relations versus time (Burkhoff, 2002). Figure
2.8 illustrates the time-varying elastance function E(t) throughout the cardiac
cycle for a heart beat period of 0.8s obtained using this approach.
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Figure 2.8: Normalized time-varying elastance E(t) for one cardiac cycle
2.5 Basic Concepts: Preload, Afterload and Con-
tractility
This section explains some of the basic concepts and metrics with regard to
cardiovascular physiology. These concepts are of vital importance for all further
discussions as they are commonly used to describe cardiovascular and circulatory
states. It is important to appreciate that stroke volume (SV) and blood pressure
(BP) are determined by the interaction between the heart, the arterial system
(afterload) and the venous system (preload). This fundamental concept is often
used clinically to simply characterize the cardiovascular state by the relationship
between these major “players”.
2.5.1 Preload
Preload can be defined as the initial stretching of the myocardium prior to ejection
(Klabunde, 2004). Preload in the right ventricle is determined by the systemic
venous return (VR) that flows back to the heart, more specifically to the right
atrium. Left ventricle preload is correlated to the left ventricle end-diastolic
volume (LVEDV) and thus influenced by the pulmonary flow into the left atrium.
Changes in ventricular preload have a crucial effect on stroke volume and
thus on cardiac output. The mechanism by which increased preload or ventricular
19
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filling increases stroke volume is called the Frank-Starling mechanism. In the 19th
century, Otto Frank discovered that the ventricles contract with more strength
when they are stretched prior to contraction, that is when preload increases.
By doing so the ventricle contracts more forcefully and more volume is ejected.
Ernest Starling continued these observations in the 20th century.
A change in preload can easily be seen in a PV loop diagram as shown in Figure
2.9. Subfigure ‘A’ represents the baseline PV loop and subfigure ‘B’ the new PV
loop with increased preload. Figure 2.9 shows how an increased preload increases
the end-diastolic volume (EDV) and thus the stroke volume (SV). However both
afterload and contractility remain unchanged, as will be explained in subsequent
sections and Figures 2.10 and 2.11.
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Figure 2.9: Effect of increased preload on pressure-volume loop.
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2.5.2 Afterload
Afterload is the hydraulic load imposed on the ventricle during ejection (Burkhoff,
2002) or the force against which the heart must pump. Under normal, healthy
conditions afterload is imposed on the heart by the arterial system. Under patho-
logic conditions, for example when the mitral valve is insufficient or the aortic
valve stenotic, afterload is determined by factors other than the properties of the
arterial system. There are various measurements or surrogates that determine
and characterize afterload, including (Burkhoff, 2002):
 Aortic or arterial pressure (Pao)
 Systemic resistance (Rsys)
 Arterial impedance
 Myocardial peak wall stress (σmws)
Aortic (or arterial) pressure (Pao) provides a measure of the pressure that the
ventricle must overcome to eject blood. However, it has the disadvantage that
it is not constant during ejection. In addition, it does not provide a measure of
only the arterial properties, but of the combined arterial system and ventricle.
Systemic arterial resistance (Rsys), also called total peripheral resistance (TPR),
is the ratio between the mean pressure drop across the arterial system and mean
flow in and out of the arterial system. It is thus the ratio of the pressure gradi-
ent (Pao − Psys) and stroke volume (SV). In the CVS model, the parameter Rsys
represents or characterizes this definition of afterload.
Two other surrogates for afterload are arterial impedance and myocardial
peak wall stress. Arterial impedance is an analysis of the relationship between
pulsatile flow and pressure waves in the arterial system. It is based on the theories
of Fourier analysis in which flow and pressure waves are decomposed into their
harmonic components and the ratio between the magnitudes of pressure and
flow waves are determined on a harmonic-by-harmonic basis. Thus, in simplified
terms, impedance provides a measure of resistance at different driving frequencies.
Unlike TPR, impedance allows one to relate instantaneous pressure and flow
(Burkhoff, 2002).
Wall stress (σmws) is the force per unit cross sectional area of muscle and is
simplistically interrelated to intraventricular pressure (Plv) using Laplace’s law:
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σmws = Plv · r
h
(2.3)
where r is the internal radius of curvature of the chamber and h is the wall
thickness. In terms of the muscle performance, the peak wall stress relates to the
amount of force and work the muscle does during a contraction. Therefore, peak
wall stress is sometimes used as an index of afterload (Burkhoff, 2002).
A measure of afterload can be obtained from the PV loop, where the left or
right ventricular pressure is plotted against the ventricular volume. Specifically,
an index of afterload can be represented on the PV diagram, called Ea, which
stands for effective arterial elastance and is closely related to Rsys. This value is
shown schematically in Figure 2.10.
The hemodynamic consequences of an increase in left ventricular afterload
are shown in the PV loop in Figure 2.10. Afterload Ea is represented by the
slope of the dotted line connecting end-diastolic volume (EDV) on the x-axis and
end-systolic pressure (Pes) on the y-axis. The first plot to the left (denoted by
‘A’) represents the baseline PV loop, plot ‘B’ to the right shows both the baseline
PV loop and the PV loop with increased afterload. Point “a” represents Pes for
loop 1 and “c” Pes for loop 2, respectively. As preload and thus EDV remain the
same for both PV loops, it can clearly be seen in subfigure ‘B’ that loop 2 has
an increased afterload represented by the increased slope of the Ea- line. It can
also be noted, that the stroke volume (SV) is decreased for PV loop 2 as a result
of having to pump against increased resistance or afterload.
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Figure 2.10: Effect of increased afterload on pressure-volume (PV) loop. The
slope of the Ea- line increases for PV loop 2 and the SV decreases. Points “a”
and “c” represent the end-systolic pressures (Pes).
2.5.3 Contractility
Myocardial contractility can be defined as the intrinsic ability of the myocardial
muscle fibre to contract at a given fibre length. Physiologically, this intrinsic abil-
ity depends on the degree of binding between myosin and actin filaments within
the fibre. The degree of binding in turn depends on the calcium concentration in
the cell.
Effects of an increase in left ventricular contractility are shown in the PV
loop in Figure 2.11. Subfigure ‘A’ represents the baseline PV loop and subfigure
‘B’ the PV loop with increased contractility. Contractility is represented by the
slope of the end-systolic pressure volume relationship (ESPVR), which connects
end-systolic pressure (Pes) with the x-axis volume intercept (V0). Afterload (line
Ea) and preload (EDV) remain unchanged. However, the contractility line, as
denoted by “a” for the baseline loop and “c” for the increased contractility loop,
respectively, is increased. In Figure 2.11 it can also be seen how the stroke
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volume (SV) increases with increased contractility, illustrating how more blood
is pumped per cycle as contractility of the heart muscle is increased.
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Figure 2.11: Effect of increased contractility on pressure-volume loop.
2.6 Ventricular Interaction
The right and left ventricle are connected via the interventricular septum. Ven-
tricular interaction describes the interaction between the two ventricles. Thus,
a change in the characteristics in one of the ventricles influences the other ven-
tricle. Ventricular interaction across the interventricular septum is also called a
direct interaction, whereas the delayed interaction via the pulmonary or systemic
circulation is named a series interaction. The interventricular septum is shown
in Figure 2.3 and a schematic given in Figure 2.12.
Septal motion can be obtained from echocardiographic observations (Hess
et al., 1979; Laurenceau & Dumesnil, 1976; Vieillard-Baron et al., 2002) and nor-
mal motion is characterized by a leftward motion towards the left ventricle during
systole. This motion occurs because in the healthy heart, the septum is bulged
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convexly in a right anterior direction due to the comparatively high pressure in
the left ventricle and the different anatomic shapes of the two ventricles. During
systole and septal activation, the septum shortens and thus moves towards the
left ventricle (Laurenceau & Dumesnil, 1976).
Despite the increasing transmural pressure gradient (Pspt) , which favours a
rightward movement, the active septum continues to move leftwards until the end
of systole (Chung et al., 1997; Olansen et al., 2000). During diastole, the septum
becomes more compliant and thus more receptive towards changes in Pspt. The
septum moves back towards the right ventricle. Figure 2.12 shows a schematic of
the normal septal shape at the end of diastole.
Pspt = Plv- Prv
RV LV
S
Figure 2.12: Schematic representation of the septum at end-diastole. During
systole, the septum shortens, and posterior motion is observed (Laurenceau &
Dumesnil, 1976). LV = left ventricle, RV = right ventricle and S = Septum.
In contrast to this normal septal shape, Figure 2.13 shows a schematic of the
septal shape at end-diastole for an overloaded right ventricle. In this scenario,
an anterior septal motion occurs as result of the septal shortening during systole
(Laurenceau & Dumesnil, 1976).
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Pspt = Plv- Prv
RV LVS
Figure 2.13: Septal shape at end-diastole for a significantly overloaded right ven-
tricle (Laurenceau & Dumesnil, 1976). LV = left ventricle, RV = right ventricle
and S = Septum.
2.6.1 Pericardium
The pericardium is a thin fibrous sac that surrounds the heart and consists of two
layers, the visceral and parietal pericardium. An illustration of the pericardium
is given in Figure 2.14. As the pericardium is relatively rigid, it prevents the
ventricles from extensive dilation and thus plays an important role in ventricu-
lar interaction (Elzinga et al., 1974; Little & Freeman, 2006). Furthermore, the
pericardium appears essential for immediate bi-ventricular compensatory mech-
anisms in response to sudden changes in ventricular volumes (Kroeker et al.,
2003).
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Figure 2.14: Illustration of the pericardium, obtained from The Ohio Heart and
Vascular Center (Per, 2008).
2.7 Anatomy of the Lung
The lung consists of two parts, which are on either side of the heart. The left lung
consists of two lobes, whereas the right lung has three lobes. Two main bronchi
resulting from the bifurcation of the trachea enter the root of the lung where they
continue to further divide. The lung’s principal function is to transport oxygen
into the bloodstream during inspiration, and to exchange it with carbon dioxide
from the bloodstream during expiration. This gas exchange is accomplished by
specialized cells that form millions of tiny, thin-walled air sacs. These alveolar
sacs are made up of clusters of alveoli, like individual grapes within a bunch. The
individual alveoli are tightly wrapped in blood vessels, and gas exchange occurs
by diffusion. Figure 2.15 shows the anatomical overview of the lung and Figure
2.16 shows the more detailed view of the alveolar sacs within the lung.
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Figure 2.15: Overview of the lung (McKinley & O’Loughlin, 2007)
Figure 2.16: Overview of lung alveoli (McKinley & O’Loughlin, 2007)
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2.8 Respiratory Physiology and Cardiopulmonary
Interactions
Spontaneous breathing and ventilation can have extensive effects on thoracic
cavity pressure and thus on cardiovascular function. These effects are usually well
tolerated in healthy subjects, but may cause detrimental hemodynamic effects
in critically ill patients, where pulmonary and/or cardiovascular diseases and
dysfunction are present. It is thus important to understand the cardiopulmonary
interactions and account for them when modelling the cardiovascular system.
2.8.1 Spontaneous Breathing
Spontaneous inspiration is characterized by a decrease in intrathoracic pressure
(Pth), whereas expiration causes an increase in Pth. Intrathoracic pressure (Pth) is
the pressure within the thoracic cavity. The following subsections briefly explain
the different effects of Pth and pulmonary function on both ventricles. It has
to be mentioned that in healthy patients the effects on the right heart usually
predominate.
2.8.1.1 Cardiovascular Effects on the Right Ventricle
Preload Because the right atrium is an intrathoracic structure, changes in in-
trathoracic pressure directly affect right atrial pressure (Pra). When intratho-
racic pressure decreases, such as during inspiration, Pra decreases. As a result,
the backward pressure for venous return (VR) decreases, increasing VR. Reflex
mechanisms will restore the pressure gradient by increasing the upstream pres-
sure and thus regulate venous return to a steady value. Conversely, increases in
Pth will increase Pra and thus decrease RV preload and VR as happens during
expiration.
Afterload Spontaneous inspiration will increase RV afterload. As inspiration
decreases Pth and as both the heart and the pulmonary vessels are surrounded
by Pth, the pressure load against which the RV must eject is given as pulmonary
artery pressure (Ppa) relative to Pth. Conversely, expiration will have the opposite
effect on RV afterload (Fessler, 1997).
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2.8.1.2 Cardiovascular Effects on the Left Ventricle
Preload The left ventricle is affected by a change in venous return by direct
and series ventricular interaction. Series interaction is effective through the pul-
monary circulation and as the right ventricle output decreases so will eventually
the left ventricle input from the pulmonary veins. The second mechanism is di-
rect ventricular interaction. When venous return increases and the RV distends,
the septum is shifted leftwards and the LV compliance during diastole is reduced.
Thus, less blood will enter the LV during diastole and LV preload is reduced
(Miro & Pinsky, 2005).
Afterload LV afterload is defined as systolic transmural LV pressure, which
is given as intraluminal LV pressure minus Pth. (Fessler, 1997; Miro & Pinsky,
2005). From this fact it follows that at constant aortic pressure, when Pth de-
creases, LV afterload increases and vice versa. Usually, the preload effect of the
RV dominates the afterload effect of the LV.
2.8.2 Positive Pressure Ventilation (PPV)
Positive pressure ventilation in critical care is common and increases Pth. When
a positive end-expiratory pressure (PEEP) is added, Pth will be increased during
the whole respiratory cycle. The hemodynamic consequences are similar to those
already described, but with the salient difference that here Pth is always increased,
even during inspiration.
The positive effects of positive pressure ventilation are, amongst others, that
as Pth increases, LV afterload decreases. This outcome is desirable in patients
with impaired myocardial function where a lowered afterload can help in restoring
normal hemodynamic function (Shekerdemian & Bohn, 1990). Another benefit
is that mechanical ventilation can reduce the cost or work of breathing and thus
help to restore an adequate oxygen supply-demand relationship (Miro & Pinsky,
2005).
Figure 2.17 illustrates the different components of the airway pressure during
mechanical ventilation, shown for an inspiratory-hold maneuver (Beers, 2006).
Peak airway pressure is measured at the opening of the airway and is routinely
displayed by ventilators. The peak airway pressure represents the pressure that
is needed to overcome the inspiratory inflow resistance, the elastic recoil of the
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lung and chest wall, and the alveolar pressure at the beginning of the breath.
PEEP in the alveoli is normally the same as atmospheric pressure.
However, a distinction has to be made between intrinsic PEEP (autoPEEP)
and therapeutically applied PEEP. Intrinsic PEEP is due to the aveoli failing to
empty completely because of airway obstruction, airflow limitation or shortened
expiratory time (Beers, 2006). Whereas, whenever PEEP is mentioned in this
research, it refers to the externally applied PEEP, which is applied throughout the
respiratory cycle. This therapeutic PEEP increases end-expiratory lung volume
and reduces airway closure at the end of expiration, thus improving oxygenation
and lung unit recruitment.
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Figure 2.17: Components of airway pressure during mechanical ventilation, illus-
trated by an inspiratory-hold maneuver (Beers, 2006). The shaded areas indicate
inhalation and expiration, respectively.
2.9 Summary
This chapter provided an overview of the cardiovascular anatomy and the basic
cardiovascular and circulatory physiology concepts, such as preload, afterload and
contractility were explained. Furthermore, the basic principles of ventricular in-
teraction and heart-lung interactions during spontaneous and mechanically aided
ventilation were presented. These fundamental ideas and concepts are used to
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develop the cardiovascular system (CVS) model, which is presented in the next
two chapters.
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Chapter 3
Cardiovascular System (CVS)
Model
This chapter describes the extended CVS model developed and utilized in this
research. It thus explains how and why it was developed as it is for this diagnostic
and decision support application. The first section provides a short overview of
the physical and electrical background on how to calculate pressures, volumes and
flows, and relates them to their corresponding equivalents in an electrical circuit.
The remaining sections develop the model from these well-accepted fundamentals.
3.1 Overview of Cardiovascular System (CVS)
Models
Mathematical representations can usually be divided into two categories: dis-
tributed and lumped. Distributed models are commonly described by using par-
tial differential equations. Applications include modelling the velocity patterns
in the heart and describing flows and pressures in arteries. Examples of such
models are given in e.g. (Pedley, 1980; Peskin & McQueen, 1992; Smith et al.,
2003). Lumped models are obtained by discretizing the partial differential equa-
tions, yielding a system of ordinary differential equations and each discretized
variable represents a compartment within the CVS model, e.g. (Chung et al.,
1997; Noordergraaf, 1978; Ottesen et al., 2004; Smith et al., 2004).
There are many CVS models in the literature ranging from very complex finite
element models (Hunter & Smaill, 1991; Legrice et al., 1997; McQueen et al., 1982;
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Pedley, 1980; Peskin & McQueen, 1992) to relatively simpler pressure volume ap-
proaches (Chung et al., 1997; Stergiopulos et al., 1999; Ursino, 1999). However,
the focus is often on only specific areas of CVS dysfunction, such as modelling
the arterial tree (Lanzarone et al., 2007), simulating cardiovascular dynamics for
healthy and diseased heart valves (Korakianitis & Shi, 2006), simulating barore-
flex control (Schulz et al., 1998) or simulating the effect of a left ventricular assist
device (LVAD) on energetic relationships inside the left ventricle (Lazzari et al.,
1994). This list contains a selective few examples of many in the full literature.
There are full CVS models available (Kappel et al., 2007; Liang & Liu, 2005;
Olansen et al., 2000; Ottesen et al., 2004). However, patient-specific parameter
optimization is either not considered or restricted to small subsets of the overall,
much larger parameter set to describe specific aspects of the CVS, e.g. (Mukka-
mala & Cohen, 2001; Ottesen et al., 2004). This approach dramatically limits
the range of CVS disturbances that can be detected, thus prohibiting use as a
broader diagnostic or monitoring tool. It equally limits the patient-specificity
obtained with equal outcome. For relatively larger, more complex system models
computational cost and feasibility can also be a major issue limiting or negating
patient-specific modelling.
3.1.1 Windkessel Models
The simplest, fundamental model compartments are usually described using a
Windkessel model, which was first described by the German physiologist Otto
Frank in 1899 (Frank, 1899). ‘Windkessel’ is the German word for ‘air chamber’
and in the Windkessel model, a closed hydraulic circuit with a water pump is
connected to a chamber. This circuit is filled with water except for a pocket of
air in the chamber. As water is pumped into the chamber, the water compresses
the air in it and water is pushed out of the chamber, back to the pump. The com-
pressibility of the air in the chamber simulates the distensibility of the arteries, as
blood is pumped into them (representing the compliance C ). The resistance that
the outflowing water encounters while flowing back to the pump, represents the
resistance of the arterial tree and capillaries (resistance R). Finally, the inertia
of the blood flow is represented by the inertance L.
34
3.1 Overview of Cardiovascular System (CVS) Models
3.1.2 Electrical Circuit Analogy
The cardiovascular system (CVS) can be modelled in terms of electrical circuits
and many CVS models use an electrical analogy (Olansen et al., 2000; Ottesen
et al., 2004; Smith, 2004). The CVS model in this research is also developed based
on electrical circuits. Thus, a short overview about the cardiovascular-electrical
correspondences is given in the following paragraphs.
In the electrical analogy used, electrical charge (Q) represents blood volume
(V), while potential (U) represents pressure (P) and current (I) corresponds to
flow rate (Q). An overview of these variables is given in Table 3.1.
Electrical and cardiovascular correspondences
Electrical Cardiovascular
Electrical charge (Q) Blood volume (V)
Potential (U) Pressure (P)
Current (I) Flow (Q)
Resistance (R) Resistance (R)
Table 3.1: Electrical and cardiovascular correspondences used to model the car-
diovascular system.
In the CVS model, a vessel or group of vessels is described by the appropriate
combination of resistors, capacitors and inductors, as shown in Figure 3.1 for the
left ventricle. Blood vessel resistances, such as determined by the vessel diameter
and blood viscosity, are modelled by resistors. The ability to accumulate (‘store’)
and release blood due to elastic recoil is modelled by capacitors (compliance).
Blood inertia is modelled using inductors. Finally, the heart valves are modelled
as diodes to capture the one way nature of flow.
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R L
Figure 3.1: Electrical circuit analogy for CVS model (left ventricle).
Figure 3.1 shows the electrial components and Figure 3.2 the corresponding
cardiovascular elements, as simulated for the left ventricle (LV) and aorta (ao).
lv lv
av
av
ao ao
av
R L
Plv Pao
Figure 3.2: Cardiovascular elements for CVS model (left ventricle).
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Equivalent systems of equations can be derived that govern the electrical and
cardiovascular circuits:
Electrical resistance  vessel resistance
U = R · I (3.1)
as given by Ohm’s law. From Equation 3.1 it follows that:
R =
U
I
(3.2)
R =
P
Q
(3.3)
Capacitance  vessel compliance
I = C · dU
dt
(3.4)
From Equation 3.4 it follows that:
Q = C · dP
dt
(3.5)
Q =
1
E
· dP
dt
(3.6)
dP
dt
= E ·Q (3.7)
P = E ·
∫
Qdt (3.8)
P = E · V (3.9)
Inductance  blood inertia
U = L · dI
dt
(3.10)
From Equation 3.10 it follows that:
P = L · dQ
dt
(3.11)
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Diode  heart valve
I =
{
0 if U ≤ 0
U
R
if U > 0
(3.12)
From Equation 3.12 follows:
Q =
{
0 if P ≤ 0
P
R
if P > 0
(3.13)
Table 3.2 summarizes the analogies used in Equations 3.1-3.13.
Electrical and cardiovascular correspondences
Electrical Cardiovascular
Electrical resistance (R) Vessel resistance (R)
U = I ·R P = Q ·R
Electrical capacitance (C) Vessel compliance (C)
I = C · dU
dt
Q = C · dP
dt
Inductance (L) Blood inertia (L)
U = L · dI
dt
P = L · dQ
dt
Diode Heart valve
I =
{
0 if U ≤ 0
U
R
if U > 0
Q =
{
0 if P ≤ 0
P
R
if P > 0
Table 3.2: Further Electrical and cardiovascular correspondences used to model
the cardiovascular system.
Finally, from Equations 3.1-3.13 it follows that the overall system equations can
be defined.
∆P = PL + PR (3.14)
∆P = L · dQ
dt
+Q ·R (3.15)
(P1 − P2) = L · dQ
dt
+Q ·R (3.16)
dQ
dt
=
(P1 − P2)−Q ·R
L
(3.17)
From Equation 3.17 for example, the flow out of the left ventricle and across the
aortic valve Qav can be determined.
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Q˙av =
(Plv − Pao)−Qav ·Rav
Lav
(3.18)
Similarly, equations for the right ventricle and pulmonary and systemic circula-
tions are formulated, as detailed in the next section.
3.2 Definition of the CVS Model
The CVS model is a lumped parameter model that was previously developed by
(Smith, 2004; Smith et al., 2004) and is based in part on earlier similar work
(Chung et al., 1997; Lu et al., 2001; Olansen et al., 2000; Ottesen et al., 2004).
The original model consisted of six elastic chambers, with two active chambers
for the left and right ventricle, respectively (Smith, 2004; Smith et al., 2004).
These pressure-volume chambers are each characterized by the flow in and out
of the chamber, the pressure up- and downstream, the resistances of the heart
valves, and inertia of the blood.
Figure 3.3 gives an overview of the volumes and pressures included in this CVS
model for capturing clinically observed cardiovascular and circulatory dynamics.
The original model has been extended in this research. An overview schematic
of this new, extended model is given in Figure 3.4.
The following overall pressure and volume equations are derived:
Vlv = Vlvf + Vspt (3.19)
Vrv = Vrvf − Vspt (3.20)
Vpcd = Vlv + Vrv (3.21)
Ppcd = P0pcd · (eλpcd(Vpcd−V0pcd) − 1) (3.22)
Pperi = Ppcd + Pth (3.23)
where Vpcd represents the volume in the pericardium and Ppcd is the corresponding
pressure across the pericardium and given by a time-varying P-V relationship.
Pperi is the fluid pressure in the pericardial space. Volumes Vlvf and Vrvf are the
left and right ventricle free wall volumes and Vspt is the septum volume. The
flows in and out of the ventricles are defined:
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Q˙av =
(Plv − Pao −Qav ·Rav)
Lav
(3.24)
˙Qmt =
(Ppu − Plv −Qmt ·Rmt)
Lmt
(3.25)
Q˙pv =
(Prv − Ppa −Qpv ·Rpv)
Lpv
(3.26)
Q˙tc =
(Pvc − Prv −Qtc ·Rtc)
Ltc
(3.27)
where Q is the flow across the corresponding heart valve, L is the inertance and
R the resistance. The subscripts av, pv, mt and tc stand for the aortic, pulmonary,
mitral and tricuspid valves, respectively.
The pressures, volumes and flows in the pulmonary vein and artery, vena cava,
aorta, and systemic and pulmonary capillaries are defined:
Pressures :
Ppu = Epu · (Vpu − Vdpu) + Pth (3.28)
Ppa = Epa · (Vpa − Vdpa) + Pth (3.29)
Pvc = Evc · (Vvc − Vdvc) + Pth (3.30)
Pao = Eao · (Vao − Vdao) (3.31)
Psys = Esys · (Vsys − Vdsys) (3.32)
Pcap = Ecap · (Vcap − Vdcap) (3.33)
V olumes :
V˙pv = Qpulout −Qmt (3.34)
V˙pa = Qpv −Qpulin (3.35)
V˙vc = Qvr −Qtc (3.36)
V˙ao = Qav −Qsys (3.37)
V˙sys = Qsys −Qvr (3.38)
V˙cap = Qpulin −Qpulout (3.39)
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Flows :
Qsys =
(Pao − Psys)
Rsys
(3.40)
Qvr =
(Psys − Pvc)
Rvr
(3.41)
Qpulin =
(Ppa − Pcap)
Rpulin
(3.42)
Qpulout =
(Pcap − Ppu)
Rpulout
(3.43)
Figure 3.3: Volumes and pressure definitions used for modelling the heart and
septal interaction (Chung et al., 1997)
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Figure 3.4: Overview of the extended CVS model used in this research with all
major variables labelled.
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3.2.1 Activation (Driver) Function
As discussed in Section 2.4, the time-varying elastance relates the ventricular
pressure to its volume. In the CVS model we also need such a mechanism to
relate the ventricle volume to its pressure. There are different ways of representing
this time-varying elastance. In Section 2.4 the simplest possible relationship, a
linear relationship, was used to show the basic concepts. To be more realistic
and physiologically correct, a better mathematical representation is needed and
introduced in this section as the activation (driver) function.
The linear ESPVR and non-linear EDPVR lines are defined (Chung et al.,
1997):
ESPV R = Eeslvf · (Vlvf − Vdlvf ) (3.44)
EDPV R = P0lvf · (eλlvf (Vlvf−V0lvf ) − 1) (3.45)
The driver function is then implemented as a sum of Gaussian terms (Chung
et al., 1997):
e(t) =
3∑
i=1
Ai · e−Bi(t−Ci)2 (3.46)
where A, B and C are parameters corresponding to the magnitude, width and
delay of the Gaussian curves, and are given in Table 3.3.
Driver Function e(t)
Parameter [Unit] i = 1 i = 2 i = 3
Ai[unitless] 0.9556 0.6249 0.018
Bi[s
−2] 255.4 225.3 4225.0
Ci[s] 0.3060 0.2026 0.2491
Table 3.3: Driver Function e(t) parameters.
Thus, the ventricle pressure is related to the ventricle volume by the relationship:
Plvf = driL · ESPV RLV + (1− driL) · EDPV RLV (3.47)
Prvf = driR · ESPV RRV + (1− driR) · EDPV RRV (3.48)
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Substituting Equations 3.44 and 3.45 into Equations 3.47 and 3.48 yields the
equations for the pressures in the left and right ventricles:
Plvf = driL · Eeslvf · (Vlvf − Vdlvf ) + (1− driL) · P0lvf · (eλlvf (Vlvf−V0lvf ) − 1)
(3.49)
Prvf = driR · Eesrvf · (Vrvf − Vdrvf ) + (1− driR) · P0rvf · (eλrvf (Vrvf−V0rvf ) − 1)
(3.50)
Plv = Plvf + Pperi (3.51)
Prv = Prvf + Pperi (3.52)
with driL and driR being the driver functions for the left and right ventricle,
respectively. Elastances Eeslvf and Eesrvf are the end-systolic elastances, and
P0lvf and P0rvf are the end-diastolic elastances. Note that Eeslvf and Eesrvf are
a measure of the ventricles’ contractilities, whereas P0lvf and P0rvf are a measure
of ventricle stiffness during diastole.
It can be seen from Equations 3.49 and 3.50 that the pressure is not completely
linearly related to the volume throughout the cardiac cycle, but is represented as
a sum of the “systolic” and “diastolic” terms. During systole, the right term of
Equations 3.49 and 3.50 decreases and becomes zero at end-systole. At that point
the pressure is only given by the ESPVR line using a linear relationship. During
diastole the left term decreases, as the driver decreases, and the pressure is solely
defined by the EDPVR line via the non-linear exponential term. Figure 3.5 shows
the pressure that results from using this driver function in Equations 3.49-3.50
for a ventricle volume from 74ml to 127ml, with Eeslvf = 2.38, Polvf = 0.56,
λlvf = 0.033, Vo = Vd = 0 and a heart beat period of 0.8s.
3.2.1.1 Driver Functions for the Left and Right Ventricle
Figure 2.8 shows the time-varying elastance derived from the mechanical prop-
erties for the left ventricle. The time tmax, which defines the time when the
maximum elastance Emax and therefore full depolarization is achieved, is approx-
imately 0.3s. It has been previously shown in human subjects that when the
time-varying elastance E(t) is normalized by its amplitude Emax, as well as the
time tmax, the normalized EN(tN) has a remarkably consistent shape, even in
presence of a wide variety of cardiac dysfunctions (Senzaki et al., 1996).
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ESPVR
EDPVR
Figure 3.5: Relationship between ventricle volume and pressure via the driver
function using Equations 3.49-3.50.
Hence, it can be assumed that this basic shape can be used as a general driver
function for the CVS model. The shape of the driver function will thus remain
constant. However, depending on the heart beat period, the function will need to
either be compressed or stretched to account for the different electrical activation
times.
For a healthy heart and assuming a normal electrical activation, it can be seen
in Figure 2.4 that the impulse conduction through the left and right ventricle dif-
fers slightly. The right ventricle finishes depolarization a few milliseconds before
the left ventricle. However, in a healthy heart these differences can be neglected
and only one driver function proves to be sufficient (Chung et al., 1997; Olansen
et al., 2000).
Given that assumption, it may be useful to simulate different electrical acti-
vation patterns. For example, in cases where electrical dysfunctions are present,
such as bundle branch blocks. Hence, it might prove useful to allow different
timing effects for the left and right ventricle.
To accomplish this possibility, the basic shape of the driver function remains
constant, but the timing for the left and right ventricle will be different. For
example, for a left bundle branch block (LBB) , the left ventricle and septum
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will have a delayed activation. To account for such a difference, the normal-
ized EN(tN) is transformed using two different activation durations, one for the
left and one for the right ventricle. Figure 3.6 demonstrates the two resulting
driver functions for three heart beats and zoomed into one heart beat for better
comparison of the two functions.
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Figure 3.6: Left ventricle (LV) and right ventricle (RV) driver functions
During this research, it has turned out that using one driver function and
keeping this driver function constant throughout the identification process, has
several advantages for the consistent identification of the model parameters dur-
ing developing disease states. This choice is physiologically justifiable as long as
it can be assumed that there is no developing abnormality in impulse conduction.
Second, keeping the driver function fixed, guarantees that all effects attributable
to an enhanced ventricle pressure generation are because of a change in con-
tractility and thus because of a change in the ESPVR. In contrast, if the driver
function were to be changed, the effect of a change in ESPVR and the two ventri-
cle contractilities (Eeslvf , Eesrvf ) would be lost, which would potentially impact
diagnostic capability. Consequently it would be much more difficult to correctly
identify all the parameters of the CVS model as a change in the driver function
may have unforeseen or masking effects on the other CVS model parameters iden-
tified. Therefore, in this research the driver function, as given by Table 3.3, is
kept constant.
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3.2.2 Ventricular Interaction
Ventricular interaction is an important dynamic because it directly relates the
hemodynamic functioning of one ventricle to the other, as described in Section
2.6. It thus needs to be taken into account when modelling the heart, as it can
be a factor for significant differences between left and right ventricle output sig-
nals such as volumes and pressures that otherwise cannot be explained. This
requirement is especially valid in cases of abnormal pathological conditions, such
as overloaded right ventricles during pulmonary hypertension where direct ven-
tricular interaction contributes significantly to LV filling impairment (Gan et al.,
2006).
3.2.2.1 Septum Volume Calculation
Ventricular interaction is included in the CVS model by modelling the septum as
given in Equations 3.19 and 3.20. These equations are repeated here for clarity:
Vlv = Vlvf + Vspt (3.53)
Vrv = Vrvf − Vspt (3.54)
where Vlvf and Vrvf are the right and left ventricle free wall volumes, Vlv and
Vrv are the volumes in the left and right ventricle, and Vspt is the volume of
the interventricular septum. From Equation 3.53 follows that an increase in Vlv
results in an outward displacement of the left ventricular free wall and thus in a
displacement of the septum towards the right ventricle. Thus, a rightward shift of
the septum from the left towards the right ventricle is represented by an increase
in Vspt, whereas a leftward shift is represented by a decrease in Vspt. The septum
volume is described by a time-varying P-V relationship defined (Chung et al.,
1997):
Pspt = driS · Eesspt(Vspt − Vdspt) + (1− driS) · P0spt(eλspt(Vspt−Vospt) − 1) (3.55)
where the driver function driS describes the activation of the septum. The sep-
tum volume Vspt can be determined analytically using the methods given in Hann
et al. (2006):
Vspt = a/b (3.56)
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with a and b defined:
a =
(
driS · Eesspt · Vdspt
+ driL · Eeslvf · (Vlv − Vdlvf )
− driR · Eesrvf · (Vrv − Vdrfv)
− (1− driS) · P0spt · (bspte−λsptVospt − 1)
+ (1− driL) · P0lvf · (blvfeλlvf (Vlv−Volvf ) − 1)
− (1− driR) · P0rvf · (brvfeλrvf (Vrv−Vorvf ) − 1)
)
(3.57)
b =
(
driS · Eesspt
− driL · Eeslvf − driR · Eesrvf
+ (1− driS) · P0spt · aspte−λsptVospt
− (1− driL) · P0lvf · alvfeλlvf (Vlv−Volvf )
+ (1− driR) · P0rvf · arvfeλrvf (Vrv−Vorvf )
)
(3.58)
where aspt, alvf , arvf , bspt, blvf and brvf are defined:
x1 = Vspt,old +4Vspt (3.59)
x2 = Vspt,old −4Vspt (3.60)
aspt =
eλsptx2 − eλsptx1
x2 − x1 (3.61)
alvf =
eλlvfx2 − eλlvfx1
x2 − x1 (3.62)
arvf =
eλrvfx2 − eλrvfx1
x2 − x1 (3.63)
bspt = e
λsptx1 − (eλsptx2 − e
λsptx1
x2 − x1x1) (3.64)
blvf = e
λlvfx1 − (eλlvfx2 − e
λlvfx1
x2 − x1x1) (3.65)
brvf = e
λrvfx1 − (eλrvfx2 − e
λrvfx1
x2 − x1x1) (3.66)
(3.67)
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where Vspt,old is the Vspt in the previous time step and 4Vspt = 0.1ml.
Figure 3.7 shows in the upper panels the right and left ventricle free wall
volumes (Vlvf , Vrvf ) and in the bottom panel the septum volume (Vspt). The
solid lines represent a healthy heart, where the septum moves towards the left
ventricle during systole. The dotted lines represent a left bundle branch block
(LBB) with a delayed left ventricle and septum activation, as explained earlier
in Section 3.2.1.1. In the lower panel it can be seen that Vspt shows an abnormal
(paradoxical) septal motion towards the right ventricle during systole, as clinically
observed during LBB conditions (Olansen et al., 2000). The LBB condition was
simulated choosing a time delay of 60ms for the left ventricle and 20ms for the
septum.
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Figure 3.7: Left ventricle free wall (Vlvf ), right ventricle free wall (Vrvf ) and
septum volume (Vspt) during normal electrical activation (solid lines) and LBB
(dotted lines).
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3.3 Summary
This chapter gave an overview of the different approaches to model the cardiovas-
cular system and explained how the extended CVS model used in this research
was derived using well-accepted electrical circuit analogies. Additionally, all CVS
model pressures, volumes and flows were defined and the direct ventricular in-
teraction was described in terms of systolic and diastolic interdependencies. The
activation (driver) function was revisited and an example of an abnormal electri-
cal impulse conduction provided.
Appendix A summarizes the CVS model equations for the ventricle volumes
and flows in Equations A.1-A.9. The remaining CVS model pressures, volumes
and flows are given in Equations A.10-A.25. Additionally, the driver (activation)
function is summarized in Equation A.26 and Table A.1. The definition of ven-
tricular interaction and the septum volume calculation are available in Equations
A.34-A.44.
50
Chapter 4
Integration with
Cardiopulmonary System and
Circulation
This chapter outlines the interactions between the cardiovascular, cardiopul-
monary systems and circulation. As mentioned in Section 2.8, the respiratory
system and cardiovascular system are coupled and heart-lung interactions occur
with every breath. These heart-lung interactions are usually not very profound
in healthy subjects, but are often exaggerated in critically ill patients (Fessler,
1997; Miro & Pinsky, 2005; Pinsky, 2005; Smith et al., 1982).
4.1 Hemodynamic Effects of Ventilation
Section 2.8 gave a brief overview of the different effects spontaneous and mechan-
ical ventilation have on the left and right ventricle pump performance. The CVS
model was developed and formulated in Section 3.2 to account for these occur-
rences. This section gives a more detailed description of how the CVS model
works and how respiration-specific phenomena are captured by the model.
Note that in Section 3.2, the intrathoracic pressure, Pth, in Equations 3.28-
3.43 is added only to the pulmonary artery, vein and vena cava. However, it
is not added to the aorta and pulmonary capillaries. This modelling choice has
been made to correctly represent the specific anatomy where the pulmonary ar-
teries and veins, and the vena cava are within the thoracic cavity. However,
neither the aorta, as modelled as part of the systemic circulation, nor the lung
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capillaries, surrounded by alveolar pressure, are surrounded by Pth. As a result,
the cardiopulmonary interactions during spontaneous or mechanical ventilation
can be correctly simulated, based on an accurate physiological representation of
pulmonary pressures. A brief summary of these interactions and the expected
hemodynamic changes as caused by changes in Pth are given in Table 4.1.
Cardiopulmonary Interactions
Pth RV - RV - LV - LV -
afterload preload afterload preload
increase ↑ decrease ↓ decrease ↓ decrease ↓ decrease ↓
decrease ↓ increase ↑ increase ↑ increase ↑ increase ↑
Table 4.1: Cardiopulmonary interactions as caused by changes in intrathoracic
pressure Pth.
Usually the preload effect of the RV is predominant over the afterload effect
of the LV. By substituting an increased or decreased value for Pth into Equations
3.28 - 3.43, it can be seen that an increase in Pth causes the RV preload to
decrease, as the pressure gradient for VR is reduced by this change. RV afterload
is also decreased not by increasing the pressure gradient for flow out of the RV,
but by increasing the pressure gradient for flow into the lung (Qpulin). Thus,
the resistance Rpulin is a direct measure for RV afterload in this CVS model.
Furthermore, it can be seen that LV preload decreases as the pressure gradient
for flow out of the lung (Qpulout) decreases and LV afterload decreases as the
pressure gradient for ejection from the LV increases. Opposite effects can be
observed when Pth decreases.
4.1.1 Transient Effects
As respiratory-induced changes in Pth are transmitted directly to all vessels in
the thoracic cavity, fluctuations obtained when measuring pressure signals, such
as the pressures in the pulmonary artery (Ppa) or vena cava (Pvc), implicitly
give information about the magnitude of changes in Pth (Miro & Pinsky, 2005).
These variations are known as transient effects because they occur during any
given respiratory cycle. Figure 4.1 summarizes the different transient effects
on RV and LV venous return caused by changes in Pth. During spontaneous
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inspiration, Pth decreases and VR increases. The opposite effect occurs during
positive pressure inspiration, where Pth increases and VR drops.
Figure 4.2(a) shows these transient effects for Ppa (upper panel) and Pvc (mid-
dle panel) during spontaneous inspiration where Pth decreases during the respi-
ratory cycle. However, the fluctuations in the pressure in the aorta (Pao, lower
panel) are much lower. This is an expected result because the aorta in the CVS
model is modelled outside the thoracic cavity. Thus, strictly speaking, it does
not represent the aorta specifically, but instead covers the aorta and the arterial
system of the systemic circulation. Hence, the fluctuations are lower because they
do not extend to the entire arterial system, captured by this model compartment.
Figure 4.2(b) shows the venous return flow for the RV (Qvr) in the upper
panel and the venous return to the LV (Qpulout) in the lower panel. It can clearly
be seen that when Pth decreases during inspiration, Qvr and Qpulout increase.
Clinically and physiologically, this result is also as expected.
Figures 4.2 and 4.1 were obtained by running the CVS model with chang-
ing values for Pth. During spontaneous inspiration, intrathoracic pressure (Pth)
decreases, but on positive-pressure ventilation (PPV), inspiration occurs by an
increase in intrathoracic pressure. Therefore, for spontaneous breathing Pth var-
ied from 0mmHg to −6mmHg during inspiration and back to 0mmHg during
expiration. For positive pressure ventilation (PPV) Pth decreased from 2mmHg
to 6mmHg during inspiration and dropped back to 2mmHg during expiration,
representing a PEEP of 2.72cmH2O.
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Figure 4.1: Transient effects during spontaneous breathing (solid line) and PPV
(dotted line)
4.1.2 Steady-State Effects
Steady-state effects are prolonged effects in the cardiovascular system. They are
characterized by changes in cardiac output and/or changes in blood volume distri-
bution caused by mechanical and compensatory reflex mechanisms. Mechanical
ventilation, for example PPV with additional PEEP, can cause profound steady-
state effects in critically ill patients.
More specifically, it is known that PEEP often reduces VR and thus cardiac
output (CO) (Cassidy et al., 1948; Fessler, 1997; Miro & Pinsky, 2005; Shek-
erdemian & Bohn, 1990). Over the years there has been some controversy about
how, exactly, PEEP alters VR. Some investigators have concluded that PEEP de-
creases VR by reducing the pressure gradient (Psys−Pra) (Johnston et al., 1989;
Wise et al., 1981). Note that clinically Psys is the mean systemic pressure, which
is also known as mean circulatory filling pressure (MCFP). Furthermore, because
the CVS model does not explicitly model the right atrium, but lumps it together
with the vena cava, Pra is represented in the model by Pvc. In contrast, other
researchers have demonstrated that Psys and Pra change equally during positive
airway pressure, and thus a change in the driving pressure gradient cannot be
the reason for decreases in VR during PEEP (Fessler, 1997; Jellinek et al., 2000;
Peters et al., 2001). Recent publications suggest that the main effect by which
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(b) Venous return flow for RV (Qvr, top) and LV
(Qpulout, bottom)
Figure 4.2: Heart-lung interactions, as simulated during spontaneous breathing
PEEP decreases venous return is by increasing the resistance to venous return
(Fessler, 1997; Miro & Pinsky, 2005; Shekerdemian & Bohn, 1990), as modelled
by Rvr in the model.
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4.1.2.1 Simulating PEEP in the CVS Model
To accurately simulate different values of PEEP in the CVS model, certain model
parameters need to be adjusted whenever PEEP is applied. These parameters are
the resistance to VR, Rvr, and to a lesser extent Rpulout. Another parameter that
needs adjusting is the venous capacitance or the venous vascular tone, which
together with the amount of stressed and unstressed blood volume determines
how much blood is contained in the venous vascular system. Figure 4.3 illustrates
the relationship between unstressed (Vdsys) and stressed (Vsys) vascular volume,
systemic elastance (Esys), and the mean systemic pressure (Psys).
It can be seen from Figure 4.3 that several factors affect venous volume,
which in turn plays an important part in determining venous return to the right
heart. When the compliance of the venous system decreases, or the elastance Esys
increases, Psys is increased and so is the pressure gradient for VR. This pressure
gradient is also elevated when volume is increased either by an infusion, as part
of fluid resuscitation or therapy, or a shift from the unstressed to the stressed
volume.
During PEEP, VR is decreased not by altering the pressure gradient (Psys −
Pra) but by increasing Rvr. Thus, different PEEP levels are simulated in the CVS
model by adjusting the values for Rvr. However, reflex response mechanisms of
the body then act to counter this effect by decreasing unstressed volume and thus
increasing stressed volume. This action, in turn, leads to a rise in the effective
systemic volume (Vsyseff ) and thus in Psys. This overall net action helps to sustain
the pressure gradient for VR (Jacobsohn et al., 1997; Peters et al., 2001).
These reflex response mechanisms have to be taken into account when mod-
elling the hemodynamic effects of PEEP. However, during hypovolemia, PPV and
PEEP may inhibit the additional fluid absorption from the tissues to increase
stressed plasma volume. This occurs because the elevated venous pressures may
cause fluid losses into the interstitium from the capillaries (Peters et al., 2001).
To summarize, the effect of PEEP is therefore simulated in the CVS model
by a/an:
 Increase in Pth (Fessler, 1997; Miro & Pinsky, 2005; Pinsky, 2005)
 Volume shift from ITBV to systemic volume ⇒ decrease in PBV and de-
crease in Vdsys ⇒ increase in Vsyseff (Jacobsohn et al., 1997; Nanas &
Madger, 1992; Peters et al., 2001)
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Vsyseff = Vsys-Vdsys
Vdsys
Psys = Esys *Vsyseff
Csys ↓ ⇒ Esys ↑
Vdsys ↓ ⇒ Vsyseff ↑
⇒ Vsys ↑
(a) Relationship between Vdsys, Vsys, Esys and Psys
Csys ↓ ⇒ Esys ↑
Vdsys ↓ ⇒ Vsyseff ↑
Vsys ↑
Psys = Esys *Vsyseff
(b) Systemic Pressure Volume Relationships
Figure 4.3: Factors influencing venous return by increasing Psys (Peters et al.,
2001)
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 Decrease in RV preload ⇒ increase in Rvr (Fessler, 1997; Miro & Pinsky,
2005; Pinsky, 2005)
 Increase in pulmonary vascular resistance as caused by lung inflation at
high lung volumes⇒ increase in Rpulin (Fessler, 1997; Miro & Pinsky, 2005;
Pinsky, 2005)
 Decrease in LV afterload⇒ decrease in Rsys (Fessler, 1997; Miro & Pinsky,
2005; Pinsky, 2005)
4.2 Volume Effects in the CVS Model
Following from these considerations, it is obvious that the systemic volume Vsys
is not only modelled using Equation 3.38, but that the effects of reduced or
increased stressed and/or unstressed volume have to be taken into account as well.
The same logic applies for the volume associated with the pulmonary capillaries
compartment, Vcap.
Note, that for reasons of simplicity, the unstressed volumes in all other volume
compartments are omitted. This omission is justifiable, as basically only one
compartment on either side of the pulmonary and systemic circulation is necessary
for simulating the clinical and physiological actions where changes in stressed
and/or unstressed volume occur. These compartments should logically be the
compartments where the most volume is contained and where any changes occur
in stressed and unstressed volume. Thus, choosing Vsys and Vcap makes sense as
they are the largest volumes and the compartments where exchanges in volume
occur. The other volume compartments in the CVS model, such as Vvc, Vao,
Vpa and Vpv mainly serve as blood ‘transferring’ compartments moving stressed
volume around the circulation.
Note that one significant limitation of this simplification process is introduced
by setting the unstressed volume zero (Vd = 0) for the left and right ventricle
volumes. Figure 4.4 shows the different ESPVR curves that are obtained for the
same P-V loop with Vd1 = 0ml compared to Vd2 = 10ml. Thus, the identification
process would obtain somewhat inaccurate contractility values when Vd = 0 is
incorrectly assumed.
However, as for most of the experiments, the ventricle volumes Vlv, Vrv are
not measured, but only estimated. Thus, there is no way to prevent this issue as
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it is not possible to identify both Ees and Vd due to the limited amount of data
that is readily available. Therefore, for reasons of comparability and consistency
Vd is set to 0 for all identifications. However, as a result, when interpreting the
value of the identified Ees value one has to take the effects of Vd into account.
ESPVR1
EDPVR
Vd2= 10 mlVd1= 0 ml
ESPVR2
Figure 4.4: Different ESPVR curves are obtained for different Vd values, but the
same P-V loop in all other respects.
59
4. INTEGRATION WITH CARDIOPULMONARY SYSTEM AND
CIRCULATION
There are no such similar problems for the other volume compartments. It does
not matter how much volume these compartments contain as only the compart-
ment pressures are important. In other words, as the pressure is the product of
volume and elastance, the more volume these compartments contain, the smaller
the elastance will be (the bigger the compliance) and vice versa. However, these
peripheral compartment elastances are not measurable to specific values and not
clinically important aside from trends as condition changes. Thus, not accounting
for Vd 6= 0 has little outcome effect.
More specifically, it can be shown in the CVS model that different volumes
in these compartments do not significantly affect the other model parameters.
Importantly, similar parameters are identified in these parametric studies, inde-
pendent of how the initial volume estimates are chosen. The only difference that
can be expected are changes in the elastances to compensate for changes in the
volumes as discussed previously. Of course, it must be ensured that all volume
estimations are within a reasonable physiological range to avoid elastance and
other parameter values that are completely unphysiological.
As mentioned before, Vsyseff = Vsys−Vdsys, the stressed (or effective) volume,
should be independent from changes in Qvr and Qsys to find the new steady-state
baseline value. Once this new baseline for Vsyseff is found by either adding or
subtracting volume, the change in Vsys can be modelled as in Equation 3.38 as
the difference between the in- and outflow into/from the Vsys compartment.
The mechanisms by which the effective systemic volume is regulated are mani-
fold. Here, Vsyseff is modelled as (Vsys−Vdsys), where the unstressed volume Vdsys
includes not only the intravascular, unstressed volume, but also the extravascular
volume that is lost from the capillaries into the tissues. Hence, Vdsys is defined:
Vdsys = Vunstressed + Vextravascular (4.1)
where the unstressed volume changes with, for example, different PEEP values as
has been reported by Nanas & Madger (1992), who showed that increasing PEEP
values decrease Vdsys. The simplest approach to modelling the extravascular
volume and thus capillary-tissue fluid balance is to set the inflow and outflow to
be equal in steady state. Thus, the extravascular volume will remain constant
for a given hemodynamic state and so will the effective systemic volume Vsyseff
as long as no additional fluids are given or lost from the body. A more advanced
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approach to modelling capillary fluid exchange would include modelling the fluid
transfer in the form of a net driving force (NDF) (Klabunde, 2004):
NDF = (PC − PT )− σ(piC − piT ) (4.2)
with σ = reflection coefficient (represents permeability of the membrane), PC =
capillary hydrostatic pressure, PT = tissue hydrostatic pressure, piC = capillary
plasma oncotic pressure and piT = tissue fluid oncotic pressure. If NDF is positive,
filtration into the tissues occurs, and if negative, reabsorption into the capillaries.
4.2.1 Volume Calculations Based on TBV and GEDV
The parameter identification process needs the two ventricle volumes Vlv, Vrv as
input signals to accurately determine some of the parameters. More specifically,
the end-diastolic and end-systolic volumes (EDV, ESV) are needed. However,
these volumes are usually not available in a clinical environment and thus need
to be estimated. Currently, the LVEDV and RVEDV are estimated based on
an estimated total blood volume (TBV) and the measured global end-diastolic
volume (GEDV). As the stroke volume (SV) is a measured variable, ESV can be
calculated by subtracting SV from EDV. The total blood volume is estimated
as 85 ml/kg, with 25 ml/kg being stressed volume and 60 ml/kg unstressed
volume (Rothe, 1979). GEDV is the end-diastolic volume of the left and right
ventricle and the two atria. Furthermore, from data of several studies e.g. (Luecke
et al., 2004; Neumann, 1999; Nirmalan et al., 2004; Preisman et al., 2002), it can
be reasoned that the right ventricle usually contains more blood than the left
ventricle and that within the heart, blood is distributed with 60% in the ventricle
and 40% in the atrium. Hence the LVEDV and RVEDV are given by following
equations:
LV EDV = GEDV · 2
3
· 0.4 (4.3)
RV EDV = GEDV · 2
3
· 0.6 (4.4)
Note, that GEDV is corrected here by a factor of 2
3
as the CVS model only
models the ventricles and not the two atria. The volume in the pulmonary capil-
lary and vein compartments (Vcap, Vpv) are given by the pulmonary blood volume
(PBV) which is calculated as:
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PBV =
GEDV
4
(4.5)
Equation 4.5 can be derived from the following two Equations (Pulsion Med-
ical Systems, 2005):
ITBV = GEDV + PBV (4.6)
ITBV = 1.25 ·GEDV (4.7)
where ITBV is the intrathoracic blood volume. It is assumed, that the pulmonary
blood volume is distributed with 60% in the pulmonary vein and 40% in the
pulmonary capillaries resulting in:
Vcapeff = PBV · 0.4 (4.8)
Vpv = PBV · 0.6 (4.9)
The volumes in aorta and pulmonary artery are also directly given, as the
pressures Pao and Ppa are given or readily measured clinically and the elastances
Eao and Epa may be calculated, as presented in detail in Section 5.2.1. The two
volumes Vao and Vpa are thus given by following equation:
V =
P
E
(4.10)
As mentioned previously, the unstressed volumes are omitted for all volume
compartments except the systemic and pulmonary volume compartments (Vsys,
Vcap). The latter two are both modelled using stressed and unstressed volumes.
Further, as a result of these estimations, some specific detailed clinical questions
may not be answerable because information is lost on how one ventricle expands
relative to the other (e.g. RVEDV/LVEDV expansion index). However, whenever
the ventricle volumes are not measured directly, it is not as important to identify
specific ventricular volumes as it is to identify the change in SV, which is always
directly given as a measured signal.
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4.2.2 Volume Calculations Based on Blood Distribution
More critically, it is important to keep volume calculations consistent. Otherwise,
different or mixed methods of calculating volumes can have a profound effect on
the model simulation output. The clinical outcome, when using the model for
diagnosis, is that it would become very difficult to observe accurate and true
clinically relevant trends in the identified parameters.
As already mentioned, the volumes in the ventricles are either directly mea-
sured or estimated based on GEDV and SV measurements. The volumes in the
pulmonary capillary and vein compartments are always estimated based on PBV.
The volumes in aorta and pulmonary artery are directly given via Equation 4.10.
The remaining model volumes Vvc and Vsys are then estimated based on known
blood distributions (Guyton & Hall, 2000; Klabunde, 2004).
The volume in the vena cava compartment (Vvc) does not have a significant
effect on the parameter identification process as noted previously. This lack of
effect occurs because only the pressure (Pvc) is used for the identification integrals
discussed in detail in Chapter 5. Thus, a slightly overestimated Vvc will lead to
a decrease in identified Evc and vice versa, effectively cancelling any moderate
error in a clinical efficacy sense. However, keeping the estimation of Vvc consistent
and physiologically realistic ensures that no unphysiological changes in Evc occur.
Hence, any subsequent changes in Evc are more likely to be attributable to real
physiological events. For example, an increase in Evc is expected during a vena
cava compression.
The volume Vvc is estimated as being proportional to the volume leaving the
right ventricle, which is the stroke volume (SV). This assumption makes sense
because there should be a correlation between the volumes entering and leaving
the right ventricle, just as there is a correlation between the venous return and
systemic flow entering and leaving the heart. More specifically, venous return
and cardiac output are interrelated by the Frank-Starling Mechanism. Hence,
Vvc can be estimated as:
Vvc = κ · SV (4.11)
with a typical value of κ = 1.25. This value is approximated from the relationship
between the known blood distribution in the vena cava and a normal and healthy
63
4. INTEGRATION WITH CARDIOPULMONARY SYSTEM AND
CIRCULATION
SV (Klabunde, 2004). Finally, Vsyseff can be estimated as the residual stressed
volume, defined:
Vsyseff = TBVeff − Vao − LV EDV −RV EDV − Vpa − Vcapeff − Vpv − Vvc
(4.12)
with TBVeff , the stressed total blood volume, given as 25 ml/kg for a healthy
state (Rothe, 1979). Note that TBVeff changes during volume losses or fluid
therapy.
The unstressed volumes Vdsys and Vdcap are calculated as:
Vdsys = TBVineff · 0.8 (4.13)
Vdcap = TBVineff · 0.2 (4.14)
where TBVineff is the unstressed TBV, which baseline value is given as 60 ml/kg
(Rothe, 1979).
4.2.3 Volume Calculations for Stressed and Unstressed
Volume
The unstressed total blood volume (TBVineff ) is given as 60 ml/kg and the
stressed volume as 25 ml/kg (TBVeff ) for a healthy state (Rothe, 1979). How-
ever, adjustments to these two values have to be made during changes in hemo-
dynamic and volemic conditions, such as hypo- and hypervolemia and venous
or arterial constriction and/or dilation. Hence, they must adapt for use in a
real-time diagnostic model.
The terms ‘vasoconstriction’ and ‘vasodilation’ can relate to either arterial
or venous constriction or dilation. The term ‘vaso’ is derived from the Latin
‘vas’, which simply means ‘vessel’. Arterial vasoconstriction and/or -dilation is
represented in the CVS model by a change in Rsys. Venous constriction and/or
-dilation are also termed ‘venoconstriction’ and ‘venodilation’, respectively. The
majority of the circulating blood is held in the venous system. The modelling of
venodilation and -constriction is described in this section, as they determine the
stressed and unstressed circulating blood volume.
Figure 4.5 shows the effect of a blood infusion (hypervolemia) or loss (hypo-
volemia) on the stressed and unstressed systemic volume. It can be seen that
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during a volume infusion or volume loss, the unstressed volume remains constant
and is not significantly affected. However, the stressed volume decreases or in-
creases, which in turn changes MCFP or Psys, the effects of which thus alter the
circulation and cardiovascular performance, as expected.
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Figure 4.5: Effect of volume infusions and blood loss (hypovolemia) on MCFP
(Psys) and the distribution of stressed and unstressed blood volume.
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Figures 4.6 and 4.7 illustrate the effects of venous constriction and dilation on the
stressed (Veff ) and unstressed (Vd) volumes. Venoconstriction is a constriction of
the smooth muscle surrounding the veins, usually caused by sympathetic reflex
mechanisms or vasoconstrictor substances such as catecholamines and angiotensin
II (Klabunde, 2004). Figure 4.6 displays how venoconstriction causes a shift
from the unstressed to the stressed volume, thereby decreasing Vd and increasing
Veff . Additionally, venous compliance is decreased (elastance is increased), which
increases MCFP.
Figure 4.7 displays how venodilation affects Vsys and MCFP (Psys). Venous
dilators are often used in treating cardiovascular disorders to reduce MCFP and
thus RV preload, which in turn reduces the oxygen demand (Klabunde, 2004).
Another main purpose of reducing MCFP is to reduce capillary fluid filtration and
thus the formation of edema (Klabunde, 2004). In Figure 4.7 it can be seen how
MCFP decreases (venous compliance increases) and how the unstressed volume
Vd increases.
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Figure 4.6: Effect of venoconstriction on MCFP (Psys) and the distribution of
stressed and unstressed blood volume.
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Figure 4.7: Effect of venodilation on MCFP (Psys) and the distribution of stressed
and unstressed blood volume.
4.2.3.1 Volume Infusion and Blood Loss
Changes in total effective and ineffective blood volume (TBVeff , TBVineff ), as
caused by volume infusions and blood losses, are accounted for by:
TBVeff = 25ml/kg ·KG+BV (4.15)
TBVineff = 60ml/kg ·KG (4.16)
with KG = patient weight in kilograms and BV = value of lost or added blood
in ml. Note that it would also be possible to change both, TBVeff and TBVineff
with regard to a blood infusion or loss (BV). However, as can also be seen in Fig-
ure 4.5, only the effective (stressed) volume, and not the ineffective (unstressed)
volume, is affected by a volume loss or infusion (Guyton & Hall, 2000; Peters
et al., 2001).
4.2.3.2 Venoconstriction and Venodilation
Venoconstriction is modelled as a shift from the unstressed volume to stressed
volume, thus increasing the effective volume TBVeff and reducing TBVineff .
Venodilation is modelled by the opposite shift, increasing TBVineff and reducing
TBVeff . Equations 4.15 and 4.17 are therefore extended:
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TBVeff,norm = (25 +4)[ml/kg] (4.17)
TBVineff,norm = (60−4)[ml/kg] (4.18)
TBVeff = TBVeff,norm ·KG+BV (4.19)
TBVineff = TBVineff,norm ·KG (4.20)
where 4 represents the severity of venoconstriction and -dilation. Note, that a
negative 4 < 0 represents venodilation and a positive 4 > 0 venoconstriction.
The combined effect of volume infusion/loss together with the compensatory
reflex mechanism of either venoconstriction (for blood loss) or venodilation (for
volume infusion) is shown in Figure 4.8. The normalized TBVeff (TBVeff,norm)
decreases during volume infusion (BV = positive values), reflecting the venodi-
lation mechanisms at work. However, during hypovolemic states (negative BV
values) TBVeff,norm increases, reflecting the action of reflex mechanisms associ-
ated with venoconstriction.
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Figure 4.8: Effect of volume loss and infusion on the normalized effective
(stressed) TBV, as given in ml/kg, BV = change in blood volume.
This relationship between TBVeff,norm and BV is implemented in the CVS
model as:
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TBVeff,norm = 4.2 · e(−0.002·BV ) + 21.5 (4.21)
The constant values (4.2;−0.002; 21.5) were found by fitting an exponential to
experimental data obtained from porcine experiments during levels of hypo-,
normo- and hypervolemia (Lambert et al., 2007). Note that Equation 4.21 only
reflects healthy subjects, which are able to adjust to different volemic levels using
adequate reflex responses. Equation 4.21 might also need to be adjusted during
different disease or drug induced circulatory states, where, for example, higher
levels of venoconstriction have to be accounted for.
4.3 Simulating the Circulation
When creating a physiological simulation model it is important that the derived
equations are a physiologically correct representation of the real world, at least
to the degree of abstraction wanted for the intended use of the model. Therefore,
some basic principles observed in the human circulatory system are simulated
with the CVS model as a means of validating the model structure and its com-
ponents.
Central venous pressure (CVP) or mean capillary filling pressure (MCFP)
are key measurements for a functioning circulatory system. Both an increase in
systemic volume (Vsyseff ) and venous vasoconstriction, which in the latter case
reduces the compliance of the veins and thus increases their elastance, increase
CVP. Similarly, arterial dilatation will increase CVP (represented by Psys in the
model), as additional amounts of blood on the arterial side are allowed through
to enter the veins. Arterial dilatation can be simulated by a decrease in systemic
vascular resistance (Rsys), which in turn leads to a higher systemic flow Qsys
entering the venous side. This increase in Qsys in turn increases Vsyseff result-
ing in an expected increase in Psys. The end result is that an increase in Psys
increases the venous return (VR) back to the right heart, concomitantly increas-
ing the ventricular filling and consequently SV and CO. Therefore, the following
relationship can be observed (Mehler & Sompayrac, 2001):
CV P ↑→ CO ↑ (4.22)
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Figure 4.9: Simulated increase in Psys, as caused by a simulated decrease in
Rsys. The solid line represents the baseline simulation signal and the dotted line
represents the simulation output signal resulting from a decrease in Rsys.
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Figure 4.10: Resulting increase in left ventricular stroke volume and thus in
cardiac output. The solid line represents the baseline simulation signal and the
dotted line represents the resulting increase in SV and hence CO.
Figures 4.9 and 4.10 show the simulation results obtained for simulating an in-
crease in Psys, which leads to a subsequent increase in CO, as expected.
Similarly, the following relationship holds true (Mehler & Sompayrac, 2001):
CV P ↓→ CO ↓ (4.23)
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Figures 4.11 and 4.12 show the simulation results obtained for simulating a de-
crease in Psys, which leads to a subsequent expected decrease in CO.
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Figure 4.11: Simulated decrease in Psys, as caused by a simulated increase in
Rsys. The solid line represents the baseline simulation signal and the dotted line
represents the resulting decrease in Psys as simulated by an increase in Rsys.
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Figure 4.12: Resulting decrease in left ventricular stroke volume and thus in
cardiac output. The solid line represents the baseline simulation signal and the
dotted line represents the resulting decrease in SV and hence CO.
Furthermore, it can be observed that a rise in CO lowers CVP, and that a reduc-
tion in CO raises CVP. Hence, CO and CVP are inversely related. This inverse
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relationship can be explained by looking at the venous return. If VR is raised
and subsequently increases SV and thus CO, more blood is taken out from the
venous side and put into the arterial side, thus lowering Psys. Consequently, the
following equation can be derived (Mehler & Sompayrac, 2001):
CO ↑→ CV P ↓ (4.24)
Figures 4.13 and 4.14 show the simulation results obtained for simulating an
increase in VR and thus CO, which leads to the subsequent expected decrease in
Psys.
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Figure 4.13: Simulated increase in VR and CO, as caused by a simulated decrease
in Rvr. The solid line represents the baseline simulation signal and the dotted
line represents the resulting increase in CO as simulated by a decrease in Rvr.
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Figure 4.14: Resulting decrease in Psys as blood is transferred from the venous
side into the arterial side. The solid line represents the baseline simulation signal
and the dotted line represents the resulting decrease in Psys.
Combining these relationships in Equations 4.22-4.24 yields (Mehler & Som-
payrac, 2001):
CV P ↑→ CO ↑→ CV P ↓→ CO ↓ (4.25)
From Equation 4.25 it can be seen how CVP and CO modulate each other and
thus stabilize the circulatory system. It is important to ensure that these funda-
mental relationships are correctly captured and simulated with the CVS model
to guarantee results that are physiologically expected, relevant and consistent, as
shown in Figures 4.9-4.14.
4.4 Limitations
All of the volume calculations serve the primary purpose of keeping the volume
distributions within the model as physiologically correct as possible during a
variety of scenarios, including different levels of normo-, hypo- and hypervolemia,
other disease states, and/or variable hemodynamic conditions. Because this CVS
model is a relatively minimal model, not all relevant physiological aspects can be
strictly accounted for in this research. More specifically, internal blood volume
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shifts, which are for example caused by reflex mechanisms, are only minimally
accounted and not necessarily specifically or accurately captured.
4.5 Summary
This chapter illustrated the interactions between the heart (cardiovascular) and
lung (cardiopulmonary) systems for spontaneous and mechanically aided venti-
lation, commonly observed in critically ill patients. Transient and steady-state
effects were investigated and the observed physiological behaviours modelled in
the CVS system.
Additionally, all volume-based calculations were presented and details given
for the modelling of the stressed and unstressed blood volumes, taking the effects
of hyper- and hypovolemia, as well as vasodilation and -constriction into account.
Finally, basic circulatory simulations were performed to validate the CVS model
and its structure and components. This chapter thus finalizes the description of
the CVS model.
Appendix B summarizes the equations for the cardiopulmonary and circula-
tory parts of the CVS model. The volume calculations are given in Equations
B.1-B.16.
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Chapter 5
Parameter Identification
This chapter explains the methods used to identify the patient-specific parameters
from the CVS model. A previously described integral-based method (Hann et al.,
2006) forms the basis for the identification process. The integral method has been
extended to allow identification for the new model parameters and adjustments
have been made to improve the identification process. For details about this
method and its advantages compared to traditional identification methods, the
interested reader is referred to (Hann et al., 2006; Starfinger et al., 2007b).
5.1 Overview of Identification Approaches and
Methods
In contrast to the many CVS models available in literature, which mainly concen-
trate on simulating the entire cardiovascular/circulatory system or parts thereof,
there are only very few approaches and methods published that are concerned
with the system identification of such models. There are even less methods avail-
able for predicting therapy effects as based on a CVS model and parameter iden-
tification.
An example for a CVS model identification and therapy prediction is available
in (Heldt et al., 2006; Samar et al., 2005), where subset selection-based optimiza-
tion algorithms are used to overcome the ill-conditioned parameter estimation
problem as caused by a model built at a resolution too high to allow for accurate
estimation of all model parameters from the available input signals.
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A second example can be found in (Sun et al., 2000), where a CVS model con-
sisting of 28 differential equations with over 100 circulatory parameters is tried
to be identified. However, as a nonlinear optimization algorithm is used, this
algorithm may fail to find the global minimum if it attempts to adjust too many
model parameters at the same time.
Another example is available in (Long et al., 1994). This research is based
on known physiological relationships between parameters such as MAP, CO and
LVEDP. Disease states such as mitral and aortic stenosis are represented by an
altered relationship between the physiologic parameters. For example, mitral
stenosis is characterized as causing a pressure gradient in diastole between left
atrium and ventricle. Other diseases and/or treatments are modelled in a similar
way. However, this approach has several weaknesses, as it is neither patient-
specific nor does it describe the whole circulatory system of a particular patient
with all the possible underlying dysfunctions. Therefore, if a pathological state,
such as heart failure, has not yet been adequately covered by the model, unreliable
predictions are made and the model is difficult to adjust to a particular patient
and condition as it needs constant alterations in the relationships between the
parameters.
The identification process as presented in the following chapter, however uses
the optimized patient-specific parameters, which are obtained during the course of
the ICU stay and thus characterize the evolution of any underlying dysfunctions
and diseases the patient may have. Hence, these parameter trends can be used
to diagnose the hemodynamic condition of each individual patient and point the
clinical staff in the right direction, for example showing if the volume status or
ventricle contractility are improving or worsening.
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5.2 Integral Identification Problem Formulation
Consider the CVS model as defined in Equations 3.28 to 3.43. Assume that
all flows, pressures and volumes are measured or estimated and note, that the
following equations apply during ejection (systole) and filling (diastole):
Vlv(eb : ef)− Vlv(eb) = −
∫ ef
eb
Qav dt (5.1)
Vlv(fb : ff)− Vlv(fb) =
∫ ff
fb
Qmt dt (5.2)
Vrv(eb2 : ef2)− Vrv(eb2) = −
∫ ef2
eb2
Qpv dt (5.3)
Vrv(fb2 : ff2)− Vrv(fb2) =
∫ ff2
fb2
Qtc dt (5.4)
where eb,eb2=ejection begin for the LV,RV; ef ,ef2=ejection finish for the LV,RV;
fb,fb2= filling begin for the LV,RV and ff ,ff2=filling finish for the LV,RV.
These volumes are for example measured by using a conductance catheter. Sim-
ilar substitutions can be made for the other volumes and flows, for example Vao
is given by:
Vao(t)− Vao0 =
∫ t
0
(Qav −Qsys) dt (5.5)
Using Equation 5.5, the Equation defining the pressure in the aorta, Pao, can
be rewritten as:
Pao(t) = Pao0 + Eao ·
∫ t
0
(Qav −Qsys) dt (5.6)
which after substituting Equation 3.40 into Equation 5.6 and reordering yields
the following matrix for determining the parameter Eao:
( ∫
Qav
∫
Pao
∫
Psys
) ·
 EaoA1
A2
 = ( Pao − Pao0 ) (5.7)
with A1 =
−Eao
Rsys
and A2 =
Eao
Rsys
. Similarly, the following matrices are obtained
for Epa, Evc, Epu, Ecap, Esys, Rsys, Rpulin, Rvr and Rpulout. Note, that for reasons
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of simplicity and clarity, the differential dt and the upper and lower limits of
the integration symbol
∫
are omitted. Usually and if not stated otherwise, the
integration is done over one heart beat. In cases where matrices are constructed
separately for ejection and filling periods, the integrals are only calculated during
these periods.
( ∫
Qpv
∫
Ppa
∫
Pcap
) ·
 EpaA3
A4
 = ( Ppa − Ppa0 ) (5.8)
with A3 =
−Epa
Rpulin
and A4 =
Epa
Rpulin
.
( ∫
Qav
∫
Vsys,eff Pao − Pao0
) ·
 RsysEsys
A5
 = ( ∫ Pao ) (5.9)
with A5 =
−Rsys
Eao
.
( ∫
Qpv
∫
Vcap,eff Ppa − Ppa0
) ·
 RpulinEcap
A6
 = ( ∫ Ppa ) (5.10)
with A6 =
−Rpulin
Epa
.
( ∫
Qtc
∫
Vvc Pvc − Pvc0
) ·
 RvrEvc
A7
 = ( ∫ Psys − ∫ Pth ) (5.11)
with A7 =
Rvr
Evc
.
( ∫
Qmt
∫
Vpv Ppu − Ppu0
) ·
 RpuloutEpu
A8
 = ( ∫ Pcap − ∫ Pth ) (5.12)
with A8 =
Rpulout
Epu
. Note that the flow integrals
∫
Qmt,
∫
Qav,
∫
Qtc and
∫
Qpv
in Equations 5.7 - 5.12 are substituted by their corresponding volumes as given by
Equations 5.1 - 5.4. This has the advantage that the volumes in the ventricles are
measured or at least estimated signals whereas the flows are usually not measured
or estimated.
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For the remaining model parameters the following calculations, using Equations
5.1 to 5.4 during filling and ejection periods, are performed:
A ·

Lav
Lmt
Ltc
Lpv
Eeslvf
P0lvf
Eesrvf
P0rvf
Rav
Rmt
Rtc
Rpv
P0pcd

= ~b (5.13)
where matrix A and vector ~b are given by:
A =

Alv,eject
Alv,fill
Arv,eject
Arv,fill
 (5.14)
~b =

~blv,eject
~blv,fill
~brv,eject
~brv,fill
 (5.15)
and the matrix for the left ventricle during ejection, Alv,eject, is given by:
Alv,eject =(
Qav(eb : ef) ~0 ~0 ~0 −Ie1 −Ie2 ~0 ~0 Vlv(eb : ef)− Vlv(eb) ~0 ~0 ~0 −Ie5
)
(5.16)
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with Ie1, Ie2 and Ie5 defined as:
Ie1 =
∫ ef
eb
((Vlvf − Vdlvf ) · driL) (5.17)
Ie2 =
∫ ef
eb
((1− driL) · (e(λlvf ·(Vlvf−Volvf )) − 1)) (5.18)
Ie5 =
∫ ef
eb
(e(λpcd·(Vlv+Vrv−Vopcd) − 1) (5.19)
The matrix for the left ventricle during filling, Alv,fill, is given by:
Alv,fill =(
~0 Qmt(fb : ff) ~0 ~0 If1 If2 ~0 ~0 ~0 Vlv(fb : ff)− Vlv(fb) ~0 ~0 If5
)
(5.20)
with If1, If2 and If5 defined as:
If1 =
∫ ff
fb
((Vlvf − Vdlvf ) · driL) (5.21)
If2 =
∫ ff
fb
((1− driL) · (e(λlvf ·(Vlvf−Volvf )) − 1)) (5.22)
If5 =
∫ ff
fb
(−e(λpcd·(Vlv+Vrv−Vopcd) − 1) (5.23)
Vector ~blv,eject for the left ventricle during ejection is given by:
~blv,eject = Pth · (tnew(eb : ef)− tnew(eb))−
∫
Pao (5.24)
Vector ~blv,fill for the left ventricle during filling is given by:
~blv,fill =
∫
Ppu − Pth · (tnew(fb : ff)− tnew(fb)) (5.25)
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where tnew is defined as:
tnew = t− t(1) (5.26)
and t is the time period over which the identification takes place. Similar equa-
tions are obtained for the right ventricle during filling and ejection.
5.2.1 New Formulation for Arterial Elastances Eao and Epa
Arterial compliance is defined as the change in volume following a change in pres-
sure. Arterial elastance is given as the reciprocal of the compliance and thus by a
pressure change (4P ) following a volume change (4V ). Many researchers have
concluded, that arterial elastance can consequently be calculated by substitut-
ing the pulse pressure (PP) for 4P and stroke volume SV for 4V as given by
following equations (Chemla et al., 1998; Zhu et al., 1995):
Eao =
PPao
SV
(5.27)
Epa =
PPpa
SV
(5.28)
Hence, Eao and Epa are not identified anymore, but are directly given by
the measured arterial and pulmonary artery pulse pressure (PPao, PPpa) and the
stroke volume. Note, that if Ppa is not measured, than at least Eao is given as it
can be assumed that Pao and SV are measured signals.
In this research, Equations 5.27 and 5.28 are adjusted by a multiplying factor
of 1.25 as it was found that adding this factor improves the estimate for Eao
and Epa. Otherwise, both elastances would have been slightly underestimated
compared to what was clinically observed; resulting in poor matches for the arte-
rial pulse pressures PPao and PPpa when the identified model was re-simulated.
This multiplying factor was found by observing the relationship between stroke
volume and change in volume in Vao and Vpa. The arterial elastances in the CVS
model are defined (assuming zero unstressed volumes Vdao and Vdpa):
Eao =
Pao
Vao
(5.29)
Epa =
Ppa − Pth
Vpa
(5.30)
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which can be rewritten as:
Eao,max =
∆Pao
∆Vao
(5.31)
=
PPao
∆Vao
(5.32)
Epa,max =
∆(Ppa − Pth)
∆Vpa
(5.33)
=
PPpa
∆Vpa
(5.34)
As the maximum changes in Vao and Vpa (∆Vao, ∆Vpa) are usually hard to
measure or estimate, the maximum changes in Vlv (LVSV) and Vrv (RVSV) are
used, respectively. These maximum changes are the stroke volumes from the
left and right ventricles. However, the stroke volumes are not identical to the
maximum changes in Vao and Vpa, but are highly correlated as shown in Figures
5.1 and 5.2. The following Equations are derived linking ∆Vao and ∆Vpa to the
stroke volumes LVSV and RVSV:
LV SV = 1.25 ·∆Vao (5.35)
RV SV = 1.25 ·∆Vpa (5.36)
Hence, Equations 5.27 and 5.28 are multiplied by the factor 1.25. Importantly,
the effect of a slightly inaccurate value for Eao and Epa will cancel as the trends
over time of these arterial elastances are what is clinically important, rather than
their absolute values.
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Figure 5.1: Relationship between ∆Vao and SV.
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Figure 5.2: Relationship between ∆Vpa and SV.
Furthermore, as Eao is given, Equation 5.9 can now directly be solved for Rsys
and Esys:
Rsys =
Eao · (
∫
Psys −
∫
Pao)
(Pao − Pao0 −
∫
Qav · Eao) (5.37)
Esys =
∫
Pao −Rsys · (
∫
Qav − 1/Eao · (Pao − Pao0))∫
Vsyseff
(5.38)
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Similarly, Equation 5.10 can be solved for Rpulin and Ecap:
Rpulin =
Epa · (
∫
Pcap −
∫
Ppa)
(Ppa − Ppa0 −
∫
Qpv · Epa) (5.39)
Ecap =
∫
Ppa −Rpulin · (
∫
Qpv − 1/Epa · (Ppa − Ppa0))∫
Vcapeff
(5.40)
5.2.2 New Matrix Formulation
Given the new formulation for Eao and Epa (Equations 5.27 and 5.28) and the
resulting simplified calculation ofRsys, Esys, Rpulin and Ecap as given by Equations
5.37-5.40, the new matrix system can be defined as:
Aall =
(
Aapp θ
θ A
)
(5.41)
~ball =
(
~bapp
~b
)
(5.42)
where matrix A and vector ~b have already been defined in Equation 5.14, θ is
a zero matrix with the corresponding number of rows and columns and matrix
Aapp is given by:
Aapp =
(
Avr θ
θ Apulout
)
(5.43)
~bapp =
(
~bvr
~bpulout
)
(5.44)
with Avr and Apulout defined:
Avr · ~xvr = ~bvr (5.45)( ∫
Qtc Pvc − Pvc0
) · ( Rvr
A7
)
=
( ∫
Psys −
∫
Pvc
)
(5.46)
Apulout · ~xpulout = ~bpulout (5.47)( ∫
Qmt Ppu − Ppu0
) · ( Rpulout
A8
)
=
( ∫
Pcap −
∫
Ppu
)
(5.48)
where A7 and A8 are already given in Equations 5.11 and 5.12, respectively.
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5.3 Identification Process
The previous section gave an overview of the integral formulation and the equa-
tions involved in identifying the patient-specific parameters. This section de-
scribes the process of identifying the parameters.
5.3.1 Identification Inputs
In order to work reliably, the more measured input signals are available the better.
The more input signals have to be estimated, the less reliable the identification
will be, as more uncertainty is included. Table 5.1 gives the input signals, which
are either continuously measured or available in discrete time steps or only esti-
mated.
Input signals for Identification Process
Signal [Unit] Comments
Arterial Pressure Obtained from PiCCO monitor
Pao [mmHg] or directly measured from catheter
(discrete or continuous waveform)
Pulmonary Artery Pressure Directly measured from catheter or estimated
Ppa [mmHg] (continuous waveform if measured)
Central venous pressure Obtained from PiCCO monitor
CV P [mmHg] (discrete waveform)
Ventricle volumes Directly measured from conductance catheter
Vlv, Vrv [ml] or estimated (continuous waveform if measured)
Stroke volume Directly measured from conductance catheter
SV [ml] or obtained from PiCCO monitor
(continuous or discrete waveform)
Heart Rate Measured from ECG
HR [s−1] or obtained from PiCCO monitor
(discrete waveform)
Global end-diastolic volume Obtained from PiCCO monitor
discrete waveform, only needed when Vlv, Vrv
GEDV [ml] are not measured directly
Table 5.1: Input signals for parameter identification
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5.3.2 Scaling Model Outputs - Discrete Data
For discrete data, the waveforms are not known, therefore the integral method
of (Hann et al., 2006) cannot be directly applied. However, waveforms can be
artificially generated by scaling a set of previously calculated model outputs to
best fit the maximum and minimum measured data values for the pressures and
volumes. The assumption is that these validated model waveforms are reasonably
conformable with the actual clinical case. In return, significantly less measure-
ment and potentially fewer invasive catheters are required.
The scaled signal, Signew, is obtained from a previously calculated signal,
Sigold, as follows:
Signew = a · Sigold + b (5.49)
a =
(Sigm,max − Sigm,min)
(Sigs,max − Sigs,min) (5.50)
b =
(Sigs,max · Sigm,min − Sigm,max · Sigs,min)
(Sigs,max − Sigs,min) (5.51)
where the subscript s refers to simulated output and the subscript m refers to
measured data.
5.3.3 Scaling Model Outputs - Continuous Data
For some of the porcine experiments, continuous waveforms are measured in Vlv,
Vrv, Pao and Ppa. However, the same scaling approach can be used to simplify
the parameter identification. In particular, scaling effectively filters noise and
unmodelled dynamics from the data. The identification problem is thus restricted
to dynamics in the model. Note that the final comparison is still made to the
original data and this approach is only done to minimize computational effort and
complexity in the identification process. An example of scaling in this clinical
porcine case is shown in Figure 5.3, for the pressure in the aorta (Pao) before
and after scaling, with a = 0.5871 and b = 6.7166. However, matching only the
maximum and minimum values has the limitation that the waveform shape may
not be precisely captured.
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Figure 5.3: Porcine Pulmonary Embolism: Pressure in aorta (Pao) before and
after scaling with a = 0.5871 and b = 6.7166. The dotted line represents the
measured, clinical porcine data. The solid line represents the model data before
(upper panel) and after (lower panel) scaling.
5.3.4 Substitution of Flow Integrals During the Scaling
Process
Another adjustment has been made to better calculate the parameters that are
determined by the flows in and out of the ventricles. Previously, these flows have
been used in the identification process and thus significant error was introduced
during the scaling process, where only the pressure and volume signals are scaled,
however not the flows as they are unknown. The flow integrals
∫
Qmt,
∫
Qav,∫
Qtc and
∫
Qpv are now substituted by their corresponding volumes as given in
Equations 5.1 - 5.4 and shown in Figure 5.4. This change has the advantage that
the volumes in the ventricles are measured, or at least estimated signals whereas
the flows themselves are not usually directly measured or estimated. Hence,
significantly less error is introduced during the scaling part of the parameter
identification process.
Figure 5.5 shows in the upper panel the flow integral and corresponding vol-
ume signal for the flow across the aortic valve (Qav) from simulated data. The
lower panel shows the difference between both signals, which is negligible (< 1%)
relative to the signal.
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filling begin
ef: 
ejection finish
ff: 
filling finish
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ejection begin
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ff
filling: Qmt ejection: Qav
Cardiac cycle: Pressure-Volume loop: Volume Vlv:
Flows:
Figure 5.4: Overview of cardiac cycle with filling (fb:ff) and ejection (eb:ef)
periods, which produces the volume in the left ventricle (Vlv) and the two flows
in (across mitral valve: Qmt) and out (across aortic valve: Qav) of the ventricle.
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Figure 5.5: Substitution of flow signal with volume signal during identification
process (upper panel) and difference between these two signals (lower panel).
5.3.5 Simulation Using Optimized Parameters
Figure 5.6 shows the overall process of the simulation and parameter identifica-
tion algorithm. After the patient-specific parameters have been identified for a
respective point in time, these parameters are then used to rerun the model sim-
ulation. The simulated output is then compared to the clinical data. However,
due to errors in the initial parameter approximations and the process of scal-
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ing output signals, parameter identification should be iterated to ensure optimal
convergence. Fast convergence consistently occurred within 5-10 iterations and is
stopped when the relative error between model output and clinical data reaches
a set tolerance.
Choose initial set of parameters
Simulation
Scale output signals to 
measured data
Identify patient specific 
parameters
Simulation output acceptable?
End
Start
Simulation
Measured data
yes
no
Figure 5.6: Parameter identification algorithm: 1.) a set of parameters is used
for an initial simulation, 2.) data is then scaled to match the measured data and
3.) identified. This process is iterated until the simulation output is acceptable.
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5.3.5.1 Summary of the Identification Process
Figure 5.6 gives an overview of the identification process, which is based on
previous work (Hann et al., 2006; Starfinger et al., 2007b). The following steps
are performed:
1. Obtain clinical measurements and signals as shown in Table 5.1
2. Use volume calculations to estimate the initial volume conditions for the
CVS model
3. Use initial set of parameters to obtain first simulation output (Starfinger
et al., 2007b)
4. Scale simulation output signals (Ppa, Pao, Vlv, Vrv) to match the clinical,
porcine data (Starfinger et al., 2007b)
5. Identify the animal-specific parameters for the scaled signals using the
integral-based methods based on (Hann et al., 2006)
6. Re-scale the simulation output signals to better match the porcine data
7. Repeat steps 4 to 6
8. Stop the iterative process when a set error tolerance is reached
5.3.5.2 Example
The following Figures show how the left and right ventricle signals improve with
each iteration starting with the initial first simulation in Figures 5.7 and 5.8 and
ending with Figures 5.13 and 5.14. Each Figure shows the pressure in left/right
ventricle (Plv/Prv), pressure in aorta/pulmonary artery (Pao/Ppa) and volume in
left/right ventricle (Vlv/Vrv). The solid lines represent the clinical data (simu-
lated) which are tried to identify the model parameters for. After re-simulation
the model output signals are matched to the true clinical signals. The dotted lines
are the model simulation output signals. Figures 5.7 and 5.8 show the true signals
and CVS model output signals before the first iteration, as obtained for the ini-
tially chosen parameter set. Figures 5.9 and 5.10 show the true signals and CVS
model output signals after the first parameter identification and re-simulation
with the identified parameters has taken place.
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Figure 5.7: Left ventricle (LV): True (solid) pressure and volume signals vs. sim-
ulated CVS model output signals (dotted) before first parameter identification.
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Figure 5.8: Right ventricle (RV): True (solid) pressure and volume signals vs.
simulated CVS model output signals (dotted) before first parameter identifica-
tion.
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Figure 5.9: Left ventricle (LV): True (solid) pressure and volume signals vs.
simulated CVS model output signals (dotted) after first parameter identification.
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Figure 5.10: Right ventricle (RV): True (solid) pressure and volume signals vs.
simulated CVS model output signals (dotted) after first parameter identification.
Figures 5.11, 5.12 and Figures 5.13, 5.14 show the true signals and CVS
model output signals after subsequent iterations of the parameter identification
process and following re-simulation with the identified parameters. In Figures
5.7 to 5.14, it can clearly be seen how the model output signals slowly converge
with the true signals and the minimum and maximum values move closer to the
true signal values. Note that the scaling used for creating these Figures is a
simple minimum/maximum scaling, explaining why the waveforms slightly differ
between the model output and true signal.
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Figure 5.11: Left ventricle (LV): True (solid) pressure and volume signals vs.
simulated CVS model output signals (dotted) after second parameter identifica-
tion.
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Figure 5.12: Right ventricle (RV): True (solid) pressure and volume signals vs.
simulated CVS model output signals (dotted) after second parameter identifica-
tion.
93
5. PARAMETER IDENTIFICATION
11.5 12 12.5 13 13.5
0
10
20
30
40
50
time in s
Pr
es
su
re
s 
(m
mH
g) 
an
d V
olu
me
 (m
l)
 
 
Plvp
Vlvp
Paop
Plvs
Vlvs
Paos
Ppus
Figure 5.13: Left ventricle (LV): True (solid) pressure and volume signals vs. sim-
ulated CVS model output signals (dotted) after third parameter identification.
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Figure 5.14: Right ventricle (RV): True (solid) pressure and volume signals vs.
simulated CVS model output signals (dotted) after third parameter identifica-
tion.
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5.4 Structural Identifiability
The conventional identifiability theory only holds for either linear differential
equations or polynomial differential equations e.g. with saturation. This theory
cannot be easily applied in this full non-linear model including ventricular in-
teraction. However, by making Ppu and Pvc constant in the full model, setting
Vspt = 0ml and Pperi = 0mmHg, the left ventricle systemic system is separated
from the right ventricle pulmonary system. The theory can now be applied, but
only on the separate stages of filling and ejection, as across a complete heart beat
there are nonlinear Heaviside functions due to the open on pressure, close on flow
valve law. From these equations it can be shown that the model is structurally
identifiable. A more useful theory would be to take into account modelling error
and noise, but no identifiability theory currently exists to handle this case.
5.5 Summary
This chapter presented the integral-based methods for the CVS model parameter
identification process. More details and the derivation of Equations 5.7-5.12
can be found in (Hann et al., 2006). The parameter identification process was
further explained as illustrated in Figure 5.6 and Section 5.3.5.1, summarizing
the iterative steps of the process.
The scaling method was presented in Section 5.3.2 and an example given in
Figures 5.7-5.14. Table 5.1 summarized the input signals for the identification
process. These signals are commonly monitored and measured in a clinical en-
vironment. Finally, the structural identifiability was mentioned, ensuring the
identification of unique parameter values.
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Chapter 6
Application to Clinical Data:
Model and Identification Process
Validation
This chapter clarifies and details the primary physiological and computational
reasons for modifying and extending the original CVS model, as well as the
associated adjustments to the parameter identification process. The extended
CVS model and all newly developed methods are justified with regard to their
intended purpose of patient-specific model-based parameter identification using
a physiological cardiovascular and circulatory model. The application to a real-
time clinical environment with critical care patients also adds focus to some of
the modelling decisions made.
6.1 Introduction
Model validation is the most important part of developing a model for clinical use.
A model will only be accepted and used when it has passed rigorous validation
tests that convince clinicians of its safety and efficacy. However, every simulation
model can only be an approximation of the actual system and will never fully
represent the true system. A model is thus only accurate for the special purpose
for which it was developed.
More specifically, the CVS model presented in Chapters 3 and 4, is an accu-
rate representation of the macro-dynamics of the cardiovascular and circulatory
system as typically seen in ICU patients. It is not intended to use the CVS model,
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or any extensions to it, for micro-analysis, such as analyzing flow rates or shear
stresses at the arterial wall. These analyses would require for more localized or
detailed models, or some form of multi-scale modelling approach.
Reality Conceptual model
Computer model
Analysis
Com
puter Sim
ulation
Pr
og
ra
m
m
in
g
Model qualification
Model 
Validation
Model 
Verification
Figure 6.1: Validation process for simulation models, source: (Schlesinger, 1980).
Figure 6.1 shows a general framework of validating simulation models (Schlesinger,
1980). As can be seen in Figure 6.1, a conceptual model is generated by analysis
of the real world. Subsequently, the model is programmed and the correctness
of the programming needs to be verified. Once this task has been achieved, the
model needs to be validated for its purpose.
6.2 Model Qualification
This part of the model validation process is concerned with whether the model is
an accurate representation of the real system with regard to its intended purpose.
More specifically, it has to be clarified if the CVS model is a correct represen-
tation of the true circulatory system and an appropriate balance between model
complexity and accuracy has to be found. Thus, the model has to be a reasonable
representation for the intended purpose of its use, in this case as a diagnostic and
therapy decision support tool.
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The CVS model has been validated in several simulation studies (Smith et al.,
2004, 2006, 2007) and in porcine experiments of Pulmonary Embolism, Septic
shock and PEEP titrations at different volemic levels (Desaive et al., 2007, 2008;
Starfinger et al., 2007b, 2008d,e). In all studies, the model and developed methods
were able to identify the main hemodynamic trends during healthy and diseased
states. In addition, it was able to identify specific parameter changes and trends
at the onset of diseases and/or treatments that were clinically and physiologically
expected. These validation studies thus increase the confidence in the CVS model
and parameter identification process and the model seems to be a legitimate
description of the real circulatory system.
6.3 Model Verification
Model verification is used to determine if the computer model (programmed in
Matlab) properly represents the conceptual description of the model, as illus-
trated in the overview given in Figure 3.4. After extensively testing the Matlab
program and provided that there are no internal coding or source program errors,
it can be assumed that the computer program works within the tested range. It
should be noted that no computer program can ever realistically be fully verified
to guarantee a 100% error-free implementation.
6.4 Model Validation
Model validation is defined as determining that the model output signals have
sufficient accuracy for the model’s intended purpose and over the domain of the
model’s intended applicability (Martis, 2006; Sargent, 1998). In this case, the
goal of the CVS model validation is to increase the model’s credibility. Increased
credibility would make it a useful tool that, clinically, addresses the right problems
and provides accurate information about the circulatory system being modelled
to attending clinical staff.
The following paragraphs highlight the problems encountered during the model
and parameter identification validation process. As a result, the original CVS
model (Smith, 2004) and identification method (Hann et al., 2006) have been
extended in this research. The new and modified form is presented in Chapters
3, 4 and 5, respectively.
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This chapter therefore summarizes the modifications that were developed to
solve problems encountered during the validation process using the original model
of Smith (2004); Smith et al. (2004). The problems are briefly discussed here and
solutions are provided that resolved the problems. Note that all problems men-
tioned in this chapter are problems of the original CVS model and identification
process and have been resolved for the extended model and methods. The overall
goal is to use these issues to further highlight the extended model presented in a
clinically relevant and physiological fashion.
6.4.1 Problems of the Original Identification Process
If the CVS model is uniquely identifiable then there is always only one set of
parameters that satisfies the integrals in the identification equations. Naturally,
this state can only be achieved when the simulated model output matches all true
clinical signals, such as all flows, volumes and pressures. However, this scenario
is very unlikely in a real world application with noise and sensor error. Thus,
estimations have to be performed, which will introduce error.
Introducing error by not providing all possible signals during the identification
process will result in a non-unique parameter set. In other words, there will be
different sets of parameters, which may all produce a subset of similar output
signals from the model to those that were measured. When subsequently used
as model parameters for forward simulations erroneous predictions and trends
may result. These different output signals may only vary slightly with negligible
small differences in the signals that are used to identify the data. However, there
will most likely be differences in certain volumes, such as the volume in the aorta
(Vao). Hence, there have to be some restrictions and pre-assumptions about these
not readily available signals to guarantee that the best parameter set is found,
which also satisfies these additional physiological or clinical constraints.
Furthermore, there are parameters that compensate for each other. Thus, if
one parameter is low the other one is typically high, but taken together produce
the same output yielded if the first parameter is high and the second low. There
are some obvious compensation mechanisms. For example, Rsys usually trades
off with Evc, as both parameters share integral equations and thus one integral
matrix in the identification process.
However, there seems to be no simple way of characterizing all the possible
compensation mechanisms, as all main parameters compensate each other in a
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more or less obvious way. These trade-offs are the reason for obtaining non-unique
parameter sets. Hence, restrictions on certain parameters have to be introduced
to not allow all parameters to freely change. This need for added constraints is
especially true for the valve resistances (Rav, Rmt, Rtc and Rpv), which should
remain largely fixed during the identification process, especially when no stenosis
or regurgitation are expected to develop.
Note, that these constraints should not hinder the identification of the best or
true parameter set. An initial parameter set is chosen to start, and all subsequent
identifications are based on these parameters and change relative to them. Thus
for example, if a stenosis is present, the first identified resistance value serves
as the baseline value and it can be assumed that the stenotic condition will not
change significantly during the course of time (assumed to relatively short) where
identifications are performed. It can further be assumed that the respective
resistance remains largely constant during the identification process, justifying
the process of keeping the valve resistance parameters fixed.
However, to use the identification process for real clinical data, one has to
guarantee that all estimations and initial parameter guesses are valid. Further-
more, it has to be determined, which parameters have to be identified and which
can be kept at fixed values.
The questions that are raised are obvious: How does one know which set of
parameters is the correct one? How can false parameter changes be prevented?
What parameters should remain constant? The overall question is one of adding
constraints or bounds to the identification process to enhance and ensure identi-
fiability of the model in the presence of limited, noisy clinical data.
The following paragraphs explain how these problems were resolved and pro-
vide explanations for adjustments made to the CVS model and identification
process presented in Chapters 3, 4 and 5. This description is thus provided to
further highlight the capability and structure of the model and as an added source
or form of model validation.
6.4.2 Solution 1: Improving the Identification Process
6.4.2.1 Predetermining Model Parameters
To overcome identification trade off problems, it is vital to carefully examine
the CVS model to get an idea of how and why the parameters change, and how
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they interact with each other. After running several simulations and identify-
ing different output signals with different volumes, certain mechanisms that link
parameters to model output signal changes become obvious. These parameter -
output signal mechanisms can be described by equations. For example, from the
CVS model structure it can be directly derived that Rsys has to correlate with
(Pao − Psys)/SV , which is also clinically and physiologically expected.
Further correlations can be found within the CVS model and good correlations
are found between left ventricle elastance Eeslvf and the ratio of SAP/LV ESV .
This relationship is expected because Eeslvf is derived from the end-systolic pres-
sure and volume relationship (ESPVR), and characterizes the ventricle contrac-
tility. The same applies for Eesrvf and SPAP/RV ESV . The overall idea is to
use these clinically and physiologically expected model correlations to constrain
some of the parameter values.
Parameter values can be fixed at pre-determined values, which can either be
well known population values found in the literature or, as in this case, pre-
calculated values. This approach has the advantage of making the model more
identifiable as less parameters need to be optimized. Keeping model parameters
at constant values will introduce some error, but this error is consistent over all
identifications. Hence, this scenario is likely to be preferred over an identification
where the parameters are less likely to be uniquely identifiable or consistently
identified over time. Note that in the latter case, inconsistent identification due
to poor identifiability would likely result in missing trends in parameter values
as CVS dysfunction occurs - i.e. missed or poor diagnosis.
6.4.2.2 Example: Pre-determining Eesrvf and Eeslvf
Approach 1, Ees = SAP/ESV: The left and right ventricular end-systolic
elastances are defined as the slope of the ESPVR and can be obtained from the
PV-loop. Theoretically, one needs at least two PV-loops to measure the slope of
the ESPVR. However, the first and simplest assumption might be that the x-axis
intercept Vd is zero, which gives the approximate Ees value defined:
Ees =
systolic arterial pressure
ESV − V d (6.1)
=
systolic arterial pressure
ESV
(6.2)
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Because Vd is only used in the ESPVR equation (see Equation 3.44) in the
entire CVS model, one can see that Vd directly trades off with Ees. Thus, a higher
Vd value will cause a higher Ees value and vice versa. It therefore follows that
there will be no effect on the other model signals using this approach and that a
Vd = 0 value will only change the absolute value of Ees, but will have no effect
on its trends or on the other parameters.
Further, each Ees value obtained can later be adjusted to the true absolute
value by correcting the Vd value to a more realistic value, such as for example
Vd = 20ml. Several simulations were performed to confirm this assumption and
no difference in the signals and subsequently identified parameters was found.
Approach 2, Single-beat ESPVR estimation: To improve the initial Ees
parameter value estimate used, a second approach has been studied. This ap-
proach calculates Ees based on a previously published single-beat estimation
method (Brimioulle et al., 2003). Briefly, this method uses an isovolumetric ven-
tricular pressure (Prv, Plv) for a single heart beat to determine the end-systolic
pressure-volume relationship (ESPVR). Figure 6.2 shows this method schemati-
cally, where A→ B is the isovolumetric contraction, B → C the ejection period,
C → D represents the isovolumetric relaxation phase and D → A the filling. The
end-systolic pressure volume relationship is given by the Vd−C line and ESPVR
is assumed to be linear and afterload independent.
In particular, trace ABCD is the P-V loop for a normal beat, where A is the
end-diastolic point at the end of the filling period, B is the point after isovolumet-
ric contraction just before ejection, C is the point after ejection (end-systolic) and
D is the point after isovolumetric relaxation, shortly before filling starts again.
Traditionally, the ESPVR is determined by progressively increasing the afterload
at the same preload (for example by using a pulmonary artery constriction) and
recording several P-V loops as shown in Figure 6.2. The end-systolic points of
the recorded P-V loops will then all lie on one line, forming the ESPVR.
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Figure 6.2: Principle of single-beat ESPVR estimation, adapted from (Brimioulle
et al., 2003). The line through C for a single beat that intersects Vd and the AB
isovolumetric line at point E is used to estimate ESPVR and Ees.
In contrast, in the single-beat approach, only one P-V loop is needed and the point
E is the calculated maximal pressure of an isovolumetric beat (Pmax,iso). The line
E-C will then define the ESPVR. The value of Vd is given as the x-axis intercept.
To determine Pmax,iso, a pressure reading (Plv, Prv) of one heart beat is used and
the isovolumetric pressures are defined as the pressure values before the maximum
first derivative dP
dt
and after minimal dP
dt
. The maximum pressure (Pmax,iso) is
obtained by fitting the following equation to the isovolumetric pressure values
(Brimioulle et al., 2003):
P = a+ b · sin(c · t+ d) (6.3)
where t equals time. Pmax,iso is obtained as the maximum of the fitted pressure
curve as can be seen in the left panel of Figure 6.3. The right panel of Figure 6.3
shows how this Pmax,iso is then used to obtain the ESPVR in the P-V loop. The
end-systolic point C is calculated as the intercepting point of the ventricular and
arterial pressure. Note that due to noise in the pressure signals, one additional
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P-V value before and after the end-systolic P-V value is calculated and finally,
Ees and Vd are determined as the mean over these 3 values.
However, when this new approach of calculating ESPVR with the correspond-
ing Ees and Vd values was validated using simulated model output data with
various Vd and Ees values, problems in the identification of Vd and thus ESPVR
became obvious, as can be seen in the examples shown in Figures 6.4 and 6.5.
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Figure 6.3: Determination of Eesrvf and Vd from the maximum isovolumetric
pressure Prvmax,iso, adapted from (Brimioulle et al., 2003).
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Figure 6.4: Determination of Eesrvf and Vd from simulated data with Vdsim =
12ml and Vdcalc = −50ml.
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Figure 6.5: Determination of Eesrvf and Vd from simulated data with Vdsim =
20ml and Vdcalc = 0ml.
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Figures 6.4 and 6.5 show the results obtained using the single-beat ESPVR
estimation method for simulated model outputs with no added noise. Figure
6.4 shows the results for a simulated Vd = 12ml and Figure 6.5 for a simulated
Vd = 20ml. It can clearly be seen how the single-beat method obtains an incorrect
ESPVR and thus a very different Vd value compared with the true (simulated)
value. The correct determination of the end-systolic point (Ves, Pes) is especially
sensitive, which is crucial in determining the correct slope of ESPVR. In this
case, only simulated data was used, thus providing a very clear, defined end-
systolic point. However, the results obtained are poor and will likely become
even worse using real clinical data where measurement noise will complicate the
correct determination of the (Ves, Pes) values used.
Nevertheless, it should be mentioned that this single-beat method might well
be suitable for determining the correct ESPVR slope directly from clinical data.
However, it is not suitable for use with our model data. This difference occurs
because the model output signals yield different waveform shapes compared to
clinical data because only a minimal model that does not perfectly capture all
the dynamics seen in clinical measurements is used in this study.
Therefore, in the CVS model simulations presented, Eeslvf and Eesrvf are
calculated as described in Approach 1 (Section 6.4.2.2) and Vdlvf and Vdrvf are
set to be zero.
6.4.2.3 Example: Pre-determining Eao and Epa
This approach of pre-calculating model parameters can similarly be applied to
other parameters in the CVS model. Thus, suitable approximations for the arte-
rial elastances Eao and Epa are described in Section 5.2.1, in Equations 5.27 and
5.28.
6.4.2.4 Example: Pre-determining Esys, Ecap, Evc and Epu
Similarly to the arterial elastances Eao and Epa, the remaining CVS model elas-
tances can be estimated using known or estimated pressures and volumes. For
example, the initial Esys value can be estimated:
Esys =
Psys
Vsyseff
(6.4)
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where Psys is either measured or estimated and Vsyseff results from the volume
calculations described in Section 4.2. The other elastances are estimated in a
similar way.
Importantly, these estimations are only used for the initial parameter set. The
estimated elastance parameters are then used to obtain the first simulation output
signals to start the identification process. During this process these elastances
are more specifically identified.
6.4.2.5 Improving the Scaling Process
Scaling naturally introduces error. In particular, it is important to remember
that the true signals are not used for identification. Instead model output signals
are used and then scaled to match the true signal peak values. This approach
assumes that the waveforms are not too different between the true and simulated
signals. However, this assumption only holds true when sufficient effort has been
spent to pre-match the signals and thus guarantee a good initial parameter set
before the real identification process takes place.
To improve the results and decrease the likelihood for errors introduced in
the scaling process, the scaling has been improved. The typically unknown flow
signals (Qmt, Qav, Qtc, Qpv) are replaced by the measured or estimated volume
signals, as first illustrated in Section 5.3.4. This approach has the advantage
that a scaled, and thus new and changed volume signal, does not only affect
the parameter identifications for parameters that are directly obtained from the
volumes (such as Eeslvf , Eesrvf and the four valve resistances), but also parameters
that are calculated using the flow signals (such as Rsys and Rpulin). Hence, with
this approach it is guaranteed that a new and updated volume signal affects all
possible parameters.
6.4.2.6 Volume Restrictions
As has been mentioned before in Section 6.4.1, the more input signals that are
measured or estimated, the better the model parameter identification should be
and the more likely it is that unique model parameters are found. For example,
it might well be that two different sets of CVS model parameters can be used to
simulate the same (or very similar) Vlv and Pao model output signals. However,
the Vpv and Vcap signals could be quite different, thus distinguishing the 2 pa-
rameter sets. However, if these signals are not known and/or ignored during the
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identification process, the correct parameters may not be found. It is thus much
better if as many signals as possible are included in the identification process,
and using physiologically or clinically validated estimates aids this process.
Therefore, the identification process also includes the CVS model compart-
ment volumes Vvc, Vpv, Vcap and Vsys. This inclusion means that the identification
process uses additional input information and tries to match the CVS model out-
put signals to these 4 additional volume signals. As these volume signals are
estimated (see Section 4.2 in Chapter 4), it has to be kept in mind that these
signals could also hinder the correct parameter set being found.
In particular, the CVS model may no be able to simulate these exact signals
correctly. However, slight differences in the target and simulated model output
signals can be incorporated into the identification process to prevent this issue
from arising. Hence, it is always ensured that the identified parameters, when
re-run in the CVS model simulation, not only produce good matches to the main
input signals, such as Vlv, Vrv, Pao and Ppa, but also good matches to the other
estimated CVS model volumes and pressures Psys, Pcap, Vsys, Vcap, Vvc, Vpv, Vao
and Vpa.
6.4.3 Solution 2: Improving the CVS Model
It is obvious, that a more realistic and physiologically correct CVS model will
allow simulations that produce realistic results. It also means that parameters can
be identified, whose values can be directly explained by physiology, and, generally
speaking, all observed parameter changes are expected or clinically explainable.
However, a less correct model or a model missing important dynamics will make
it more difficult to obtain parameter values that can be similarly explained, or
that can be used to make useful predictions about future parameter values or
changes. An insufficient model structure where essential parameters are missing
will also lead to other model parameters being misused to produce the expected
output. The ID process will therefore identify parameter values that cannot be
explained clinically or physiologically and behave different than expected.
As the CVS model does not have its own compartment for the atrium, the
atrial properties are lumped together with the adjacent pressure-volume compart-
ment, which is for the left ventricle the pulmonary vein (P, Vpu). For the right
ventricle it is the vena cava (P, Vvc) compartment. In cases where the atrial pres-
sure becomes negative, it would be advisable to also allow a negative Pvc and Ppu
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pressure to capture this behavior. However, in the original CVS model (Smith,
2004) a negative Pvc pressure is not possible unless the volume Vvc becomes neg-
ative, as well. The modified and extended CVS model solves this problem by
adding the intrathoracic pressure, as can be seen in Figure 3.4 and Equations
3.28 - 3.30, allowing these effects to be captured.
Other modifications included adding two additional P,V- compartments, one
for the systemic capillaries (body) and one for the lung capillaries. P, Vsys and
P, Vcap are added, as depicted in Figure 3.4, to enable more realistic model be-
havior in situations where arterial and venous resistances behave in opposite
directions. For example, during the application of PPV and PEEP, LV afterload
and RV preload decrease, resulting in an drop in Rsys, but an increase in Rvr, as
explained in more detail in Section 4.1.2.1.
Another advantage of adding Rvr (resistance to venous return) into the CVS
model is that a change in RV preload can now easily be simulated by adjusting
Rvr. For example, in the original CVS model, vena cava constriction (VCC) is
simulated by increasing the resistance Rtc (Smith et al., 2006). However, this
resistance is really the tricuspid valve resistance and not the resistance for con-
trolling all of or the majority of venous return. The new modified CVS model
allows Rtc and Rvr to change separately from each other, one resistance con-
trolling venous return while the other characterizes the valve mechanics, such as
stenosis or regurgitation.
6.5 Summary
This chapter investigated the model qualification, verification and validation.
Necessary adjustments to the model structure and components, and to the iden-
tification process were included to allow the optimal model parameters to be
identified in a consistent way. These adjustments included the pre-calculation of
model parameters, such as Eeslvf , Eesrvf , Eao and Epa. By pre-calculating these
parameters, less model parameters have to be identified and the identifiability of
the remaining model parameters increases. Thus, a more optimal and consistent
set of parameters can be found.
Further adjustments include the estimation of the initial model compartment
volumes (Vsys, Vcap, Vvc, Vpv, Vao and Vpa). Using these volumes in the identifi-
cation process guarantees consistency over all identifications and subjects as the
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CVS model output signals are not only matched to the main pressure and volume
signals, but also to these compartment volumes. Note, that by using these esti-
mated volumes, the initial estimation of the CVS model elastances Esys, Ecap, Evc
and Epu is possible. These elastances are then used to produce the first simula-
tion output signals to start the identification process, and are then subsequently
identified and optimized.
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Chapter 7
Application to Porcine
Experiments of Pulmonary
Embolism (PE)
This chapter1 gives initial results obtained when combining the CVS model with
the extended integral based parameter identification method to track drug in-
duced pulmonary embolism in porcine data from an initial healthy state to the
fully developed disease state.
7.1 Introduction
7.1.1 Epidemiology and Pathophysiology of PE
Pulmonary Embolism usually develops from thrombi that form in the deep veins
of the legs, pelvis or arms and dislodge and embolize to the pulmonary arteries.
Pulmonary embolism is a serious condition that can cause permanent damage to
the affected lung, low oxygen levels and damage to other organs as caused by the
decrease in oxygen supply. If a clot is large, or if there are many clots, pulmonary
embolism can cause death.
Pulmonary arterial obstruction and the release of vasoactive agents such as
serotonin by platelets elevate pulmonary vascular resistance. Alveolar dead space
increases which impedes gas exchange and reflex bronchoconstriction increases
airway resistance and lung edema decrease pulmonary compliance resulting in an
1This chapter is based on (Starfinger et al., 2007b).
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increased right ventricular afterload and subsequently dilatation, ischemia and
dysfunction of the right heart (Goldhaber, 1998).
Figure 7.1: Schematic illustration of Pulmonary Embolism with an embolus
formed in the femoral vein and travelling to the infarction site in the lung, ob-
tained from the website of the Society of Vascular Surgery (SVS).
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7.1.2 Incidence of PE and Diagnostic Methods
Diagnosing Pulmonary Embolism accurately and in a timely manner is challeng-
ing as the clinical signs and symptoms are heterogenous and non-specific and thus
a wide range of symptoms is possible. The mortality rate of acute PE patients
is higher than in patients with acute myocardial infarction, exceeding 10% at 30
days and 16% at 3 months (Goldhaber et al., 1999). Thus, as PE is potentially
lethal, a fast and accurate diagnosis is essential.
Clinical suspicion of PE exist, when the patient complains about acute dysp-
nea without an apparent cause (Nijkeuter & Huisman, 2005). Other symptoms
include acute chest pain, cough, hemoptysis (coughing up of blood or blood-
stained sputum), cyanosis and fainting. Clinical signs present are acute right
ventricular dysfunction, including tachycardia, low arterial blood pressure, neck
vein distention and an accentuated pulmonary component of the second heart
sound or a tricuspid regurgitation murmur. However, these signs are non-specific
and inconsistently found in PE patients. Hence, further diagnostic tests are nec-
essary, which usually include clinical prediction rules (for example Well’s score
and Geneva score), D-dimer testing (D-dimers are degradation products of fibrin
which are released when a thrombus is degraded by fibrinolysis) and/or imaging
techniques (such as lung scintigraphy and helical CT). However, these diagnostic
tests are often very costly and consume a considerable amount of resources.
Thus, having a diagnostic tool which can accurately identify pulmonary em-
bolism would be beneficial and help provide a better and more consistent patient
care. The goal of this research is to demonstrate the applicability of the CVS
model for identifying the varying PE disease states from the healthy state to the
onset of the disease and fully diseased state.
In this research, the full range of hemodynamic responses was captured with
mean identification errors of 4.1% in the pressures and 3.1% in the volumes for 6
sets of clinical data. Pulmonary resistance increased significantly with the onset
of embolism in all cases, as expected, with the percentage increase ranging from
89.98% to 261.44% of the initial state. The model also predicted an increase in
the right ventricle expansion index and a decrease in septum volume consistent
with known physiological response to pulmonary embolism. These results are a
first clinical validation of this model-based cardiac diagnostic approach.
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7.2 Methods
Under the control of the Ethics committee of the Medical Faculty of the University
of Lie`ge, pulmonary embolization was induced in pigs with autologous blood
clots (Desaive et al., 2005; Ghuysen et al., 2008). The clots were injected every
two hours with decreasing concentrations. Aortic pressure and pulmonary artery
pressure are measured using micromanometer-tipped catheters (Sentron pressure-
measuring catheter; Cordis, Miami, FL) while right and left ventricle pressures
are measured using 7F, 12 electrodes (8-mm interelectrode distance) conductance
micromanometer tipped catheters (CD Leycom, Zoetermeer, The Netherlands).
The conductance catheter technique is based on measuring time varying con-
ductance of the blood in the ventricle. This conductance is approximately linearly
proportional to the blood volume in the ventricle. To improve the accuracy, the
ventricle is divided in several segments and the conductance of each segment is
obtained by measuring the voltage between two adjacent electrodes of the conduc-
tance catheter. The ventricular volume is obtained as the sum of the segmental
volumes (Baan et al., 1984).
The pigs were bled during the experiment. However, the exact blood loss
was not measured. In order to account for the blood loss, the volume available
in the circulation is approximately linearly reduced. The initial start volume is
estimated using a total blood volume of 65− 70ml/kg (Morton et al., 1993) and
the distribution of blood volume in heart, pulmonary system, aorta and vena cava
(Klabunde, 2004). The blood loss is then approximated using the reduction in
left ventricular end-diastolic volume (LVEDV) as obtained from (Preisman et al.,
2002). It is worth noting that the total volume is, despite not being part of the
parameter set, also identifiable as the volume which allows the best fit to the given
clinical data. Additionally it should be mentioned, that to maintain simplicity
the minimal CVS model ignores the unstressed volume, thus the volumes at zero
pressure (Vd and Vo) are set to zero for all chambers, except for the septum
volume.
7.3 Results
The parameter identification method is applied to the pig data. The identified
parameters are used to rerun the CVS model and produce pressure and volume
curves, which are then compared to the clinical data. This process is repeated in
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all the measured periods during the pulmonary embolism experiment using the
pig’s steady state response data. The results are shown for two of the pigs in
detail followed by a summary of the results in all pigs.
7.3.1 Pig 1
7.3.1.1 Beginning of Experiment - “Healthy” Status at 30 mins
Figure 7.2 shows the simulated model output for the pressure in the left and
right ventricles (Plvs, Prvs), the volume in the left and right ventricles (Vlvs, Vrvs)
and the pressure in the aorta, pulmonary artery (Paos, Ppas) overlaid with the
corresponding clinical data (Plvp/Prvp, Vlvp/Vrvp, Paop/Ppap) at 30 mins into the
pulmonary embolism experiment. The simulation data matches the measured
porcine data very well with errors within 4.2 mmHg and 4.4 ml for maximum
and minimum pressures and volumes respectively.
Figure 7.3 shows the Volume-Pressure waveforms for the left and right ven-
tricles in more detail. The upper panel in Figure 7.3 is the simulated ventricle
volume and the dotted line is the measured porcine volume for 2 heartbeats. The
lower panel shows the same results obtained for the ventricle pressure. Finally,
Figure 7.4 shows the resulting Pressure-Volume relationships (P-V loops) for the
left and right ventricles. Errors in all cases are in the range of 0.15% to 4.76%.
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Figure 7.2: Pig 1, Model output vs clinical data
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Figure 7.3: Pig 1, Model output vs clinical data for Pressure and Volume
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Figure 7.4: Pig 1, Pressure-Volume Relationship
7.3.1.2 During the Experiment - at 120 mins
Figure 7.5 shows the P-V loops for the left and right ventricle 120 minutes into the
pulmonary embolism experiment. Although the model didn’t exactly capture all
the volume shapes in the left and right ventricles, the pressure waveform shapes
were accurately captured, as well as the maximum and minimum pressures and
volumes. Overall, the errors in the maximum pressures and volumes that are
typically used to define trends in different disease states are within 0.17% to
4.95%, respectively.
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Figure 7.5: Pig 1, Pressure-Volume Relationship
7.3.1.3 End of Experiment - at 180 mins
Figure 7.6 displays the P-V loops at 180 minutes, which was the end of the
experiment. Again the results show a very close match. Errors in the maximum
pressures and volumes are all within 0.20% and 6.59% respectively.
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7.3.1.4 Summary of Identified Parameters
The identified subject (pig) specific parameters systemic and pulmonary vascular
resistance, Rsys and Rpul, differ significantly between healthy and disease state
as Figure 7.7 shows with Rpul increasing by 261.44%.
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Figure 7.7: Pig 1: Pulmonary and vascular systemic resistance during pulmonary
embolism experiment
7.3.2 Pig 2
Figure 7.8 thumbnails the P-V loops for pig 2 at 0, 120 and 180 mins. Similar
accuracy in capturing the clinically observed dynamics is evidenced. The errors in
the maximum pressures and volumes are all within 0.01% and 9.86% respectively.
Figure 7.9 shows that the identified pulmonary and systemic vascular resistance
(Rpul, Rsys) differ significantly between healthy and diseased state, as expected,
with Rpul increasing by 89.98%.
The model also captures the specific hemodynamic changes resulting from
pulmonary embolism. The volume in the right ventricle (Vrv) increases during
pulmonary embolism due to the increased afterload, which causes right ventricle
dilation. Figure 7.10 shows the time evolution of the left and right end-diastolic
volume ratio (RVEDV/LVEDV) as an index for the expansion of the right ven-
tricle during the experiment. As expected, this index increases.
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Ventricular interaction changes are also captured, where Figure 7.11 shows
the time evolution of the mean value of the septum volume (Vspt) over a cardiac
cycle, decreasing from the beginning to the end of the experiment. This result
agrees with the physiological fact that the overfilled right ventricle compresses the
underfilled left ventricle during the embolization. Hence, Vspt decreases because
it is defined as being part of the right ventricle volume (Chung et al., 1997; Smith,
2004). Finally, it’s worth nothing that as the embolism grows and left ventricle
volume decreases the systemic resistance, Rsys, increases in Figure 7.9, in the
reflexive attempt to divert more blood to the heart. However, Rsys drops at the
end likely due to the near death of the pig and very low blood volume.
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Figure 7.8: Pig 2: P-V Loops for left and right ventricle at 30, 120 and 180 mins
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Figure 7.9: Pig 2: Pulmonary and vascular systemic resistance during pulmonary
embolism experiment
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Figure 7.10: Pig 2: RVEDV/LVEDV, simulated vs porcine data
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Figure 7.11: Pig 2: Mean septum volume Vspt during pulmonary embolism ex-
periment
7.3.3 Summary of Results in All 6 Pigs
Table 7.1 gives the mean and standard deviation of the absolute errors for the
maximum and minimum pressures and volumes. The values are shown for the
pressure in aorta (Pao), pulmonary artery (Ppa) and left and right ventricle
(Plv,Prv). Table 7.2 gives the mean error and standard deviation for the volumes
in both ventricles (Vlv,Vrv). Table 7.3 shows the maximum percentage increase
for pulmonary vascular resistance (Rpul) and maximum percentage changes in
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systemic vascular resistance (Rsys) and the contractilities (Eeslvf , Eesrvf ) in the
left and right ventricle during the pulmonary embolism experiment. The number
of heart beat periods that are captured as well as the different points in time
are shown. The primary goal is to capture rising pulmonary vascular resistance,
Rpul, in this clinical case. Figure 7.12 shows Rpul over time for all 6 pigs.
Pressures (mmHg)
Pig Pao Ppa Plv Prv Total Error
Pig 1 3.501±3.247 2.313±1.939 2.313±2.392 1.377±1.651 2.367±2.487
Pig 2 2.693±1.545 2.666±1.445 1.894±0.880 1.308±1.172 2.210±1.404
Pig 3 2.831±2.572 2.885±1.562 1.163±1.000 1.306±1.784 2.035±1.972
Pig 4 2.567±2.130 2.305±1.796 2.414±2.607 0.571±0.708 1.956±2.097
Pig 5 5.042±3.161 2.394±1.827 1.604±1.179 1.264±1.337 2.576±2.505
Pig 6 2.753±2.048 2.542±2.177 2.102±2.457 1.701±2.587 2.275±2.3411
All Pigs 3.207±2.638 2.472±1.788 2.022±2.007 1.186±1.525 2.223±2.173
Table 7.1: Mean model response errors and standard deviation for maximum and
minimum Pressures combined.
Volumes (ml)
Pig Vlv Vrv Total Error
Pig 1 1.666±1.682 1.273±1.187 1.477±1.473
Pig 2 2.073±1.369 1.296±1.168 1.693±1.328
Pig 3 1.150±1.042 4.182±2.055 2.642±2.218
Pig 4 3.316±2.315 2.294±2.156 2.802±2.288
Pig 5 3.468±0.870 3.007±1.609 3.242±1.300
Pig 6 3.505±3.148 2.900±2.192 2.275±2.241
All Pigs 2.537±2.063 2.202±1.944 2.372±2.011
Table 7.2: Mean model response errors and standard deviation for maximum and
minimum Volumes combined
1Note the standard deviation as caused by outliers.
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Pig # fitted Time %increase %increase %increase %increase %decrease
periods in min Rpul Rsys Eeslvf Eesrvf Vspt
Pig 1 44 0-240 261.44 40.66 29.10 154.60 9.13
Pig 2 43 0-180 89.98 49.34 74.78 20.56 40.15
Pig 32 18 0-120 24.23 27.16 0.81 9.74 8.37
Pig 4 45 0-265 166.85 39.21 19.06 56.44 19.84
Pig 5 29 0-180 103.63 21.16 71.51 80.07 27.64
Pig 6 20 0-210 99.52 53.90 11.00 14.64 14.00
Table 7.3: CVS porcine specific parameters
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Figure 7.12: Pulmonary vascular resistance (Rpul) for all 6 pigs during the exper-
iment
2This pig only had limited data and insufficient time for the parameters to change signifi-
cantly.
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7.4 Discussion
The results presented show that the minimal CVS model is capable of capturing
the essential dynamics of porcine CVS response to induced pulmonary embolism.
More specifically, the clinical and physiological changes expected in pulmonary
embolism include:
 Pulmonary vascular resistance (Rpul) increases (Goldhaber, 1998)
 Systemic vascular resistance (Rsys) increases as a reflex response (Klabunde,
2004)
 Contractilities in the left and right ventricles (Eeslvf , Eesrvf ) increase as a
reflex response, but are expected to drop at the end of the experiment,
where the pig is in a near death state and is no longer able to regulate its
circulation (Burkhoff & Tyberg, 1993; Klabunde, 2004)
 Right ventricle expansion index (RV EDV/LV EDV ) increases during the
experiment as the overfilled right ventricle compresses the underfilled left
ventricle (Gan et al., 2006; Lualdi & Goldhaber, 1995)
 Septum volume (Vspt) decreases as the septum is shifted towards the left
ventricle (Desaive et al., 2005; Gan et al., 2006)
 Total blood volume in the circulation decreases in this case as the pigs were
bled during the experiment (Desaive et al., 2005)
 Other model parameters would be expected to remain largely constant evi-
dencing the ability to distinguish this clinical case without non-physiological
parameter values elsewhere in the model.
The parameter identification method correctly identifies the physiologically
expected changes in porcine hemodynamics during the pulmonary embolism ex-
periment. Figures 7.9 and 7.12 show the increase in pulmonary and systemic
vascular resistance (Rpul,Rsys), as expected. The pulmonary vascular resistance
(Rpul) increases significantly from the initial healthy state to the disease state
in all pigs with a range of percentage increases of 89.98% to 261.44%. Thus, it
matches common physiological signs seen in pulmonary embolism as pulmonary
arterial obstruction and the release of vasoactive substances increase pulmonary
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vascular resistance (Goldhaber, 1998). Figure 7.12 shows the time evolution of
Rpul for all six pigs during the experiment.
Figures 7.7 and 7.9 show the ability of the model to pick up reflex response,
where the pig increases systemic resistance to help restore blood pressure. How-
ever, near the end, when the pig is near death, systemic resistance (Rsys) drops
off. This last result is potentially a sign that the pig can no longer regulate
hemodynamics effectively.
The left and right ventricle contractilities (Eeslvf , Eesrvf ) also increased during
the pulmonary embolization experiment as shown by Table 7.3. These contrac-
tilities are known to be part of reflex response (Burkhoff & Tyberg, 1993) and
could be used as an index of ventricular inotropic state. An increased heart
rate for example also stimulates inotropy which is known as the Bowditch effect
(Klabunde, 2004). Thus, the observed increase in left and right ventricle con-
tractility together with the observed increase in heart rate also agree well with
known physiological principles.
The right ventricle expansion towards the left ventricle is captured and shown
in Figure 7.13. The model simulates blood backing up in the right ventricle due
to increased afterload causing an expansion of the right ventricle. This effect is
captured by the index RVEDV/LVEDV, matching known physiological response
(Lualdi & Goldhaber, 1995).
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Figure 7.13: RVEDV/LVEDV index for all 6 pigs during the experiment
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Table 7.3 displays the percentage decrease in the septum volume from the be-
ginning to the end of the experiment. This decrease agrees with the fact that
the right ventricle compresses the left ventricle as the level of embolization grows
(Gan et al., 2006). Similarly, Figure 7.11 shows the time evolution of the mean
septum volume, (Vspt), during the experiment for pig 2.
The blood loss in these clinical experiments was accounted for by approxi-
mately linearly reducing the volume available in the circulation during the sim-
ulations. The blood loss for the six pigs ranges from 84ml to 515ml, 9% to 44%
of the total blood volume respectively. These values seem reasonable when com-
pared to the values in (Preisman et al., 2002) but cannot be fully validated as
this data was not explicitly collected in the tests (Desaive et al., 2005).
Finally, Table 7.3 summarizes the percentage increases in the parameters asso-
ciated with pulmonary embolism. It is worth noting that the remaining model pa-
rameters stayed relatively constant throughout the experiment. Specific changes
in these parameters over all time frames and pigs was < 15%.
7.5 Conclusions
This research demonstrates the potential of using a minimal CVS model (Hann
et al., 2005; Smith et al., 2004) and integral-based parameter identification method
(Hann et al., 2006) for real time patient specific modelling and diagnosis. A wide
range of clinically measured porcine hemodynamics in pulmonary embolism were
successfully captured over time. The integral method identified all model pa-
rameters with less than 5% error in clinical pressure and volume outputs. More
importantly, critical measures and expected physiological responses to pulmonary
embolism were all successfully captured in the presence of noise and using real
clinical data.
The accurate diagnosis and treatment of pulmonary embolism requires an
interdisciplinary approach and remains a difficult and expensive task due to non-
specific and challenging clinical signs, which sometimes do not coincide with
clinical suspicion (Goldhaber, 1998; Nijkeuter & Huisman, 2005). A real-time
patient specific CVS model as demonstrated here could thus potentially assist
clinical staff in diagnosing pulmonary embolism using data and catheters typically
available in the ICU.
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Chapter 8
Application to Porcine
Experiments of PEEP Titrations
This chapter presents the results of a further porcine validation study during
PEEP titrations at different volemic levels. The first part1 describes the identifi-
cation process of different PEEP levels, whereas the second part2 concentrates on
the prediction of future patient responses towards changes in PEEP. Both parts
of this chapter have also been presented to the 37th annual SCCM congress.3
8.1 Clinical Importance of PEEP
Positive end-expiratory pressure (PEEP) is an operator-controlled variable that
can be set during mechanical ventilation. The application of PEEP can be ben-
eficial or detrimental for the patient dependent on how much the applied value
differs from the optimal value with the greatest benefit. More specifically, in
patients with lung injury, high PEEP levels may be necessary to maintain or re-
store oxygenation and for each individual patient the right balance between too
much and too little PEEP has to be found. Too little PEEP may result in airway
or alveolar collapse, whereas too much PEEP can cause alveolar overdistention
and hemodynamic problems as caused by changes in intrathoracic pressure and
consequently reductions in SV and CO, as already discussed in 4.1.2.1.
Thus, an important goal during mechanical ventilation is finding the optimal
PEEP for each individual patient. This PEEP value will provide the best oxy-
1The first section is based on (Starfinger et al., 2008d).
2The second section is based on (Starfinger et al., 2008e).
3Abstract published in (Starfinger et al., 2007a).
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genation with the least detrimental impact on cardiopulmonary function. Figure
8.1 summarizes the effects too little or too much PEEP has.
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Figure 8.1: Determining optimal PEEP, source: (Courtney & Asselin, 2006).
The goal of this part of the research is to validate the CVS model using
a porcine experiment of PEEP titrations at different volemic levels. The CVS
model and methods are used to identify the patient-specific parameters during the
experiment. These model parameters are then furthermore used to predict the
patient’s response towards a change in PEEP and/or volume status. The long-
term goal is to use the CVS model and methods as a device assisting clinical staff
in choosing the appropriate therapy for each individual patient, as for example
determining the optimal PEEP.
8.2 Part I: Identifying Different PEEP Levels
8.2.1 Introduction
The CVS model can be formulated in terms of equations and its parameters iden-
tify the model making it patient-specific. Therefore, when the patient-specific pa-
rameters can be identified from measured clinical data so that the model matches
the clinical measurements, then a model of the patient with their fundamental
dynamic (Pressure-Volume, PV) behavior can be created. These parameters can
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then be used to assist clinical staff with diagnosis, as for example the contractility
index of the left ventricle can be elevated or depressed, thus giving an idea about
the performance of the ventricle. A similar example would be the parameter rep-
resenting the pulmonary vascular resistance, and thus giving information about
the pressures in the pulmonary arteries - for example if an embolus is developing.
Therefore, by observing the trends, how the parameters change over time
(new identifications can be performed for any few heartbeats of data) valuable
information about the patient’s hemodynamic condition can be tracked, diag-
nosed and overall monitored for more effective treatment. This use of the model
has already been validated on clinical data from animal trials (pigs) in induced
pulmonary embolism (Starfinger et al., 2007b). This research presents a further
validation of the model and methods by identifying the different hemodynamic
conditions as caused by changing PEEP and volemic levels.
Spontaneous breathing and ventilation can have extensive effects on cardio-
vascular function. These effects are usually well tolerated in healthy subjects
but may cause detrimental hemodynamic effects in critically ill patients, where
pulmonary and or cardiovascular diseases and dysfunctions are present. It is thus
important to understand the cardiopulmonary interactions and account for them
when modelling the cardiovascular system. In this research, the CVS model
is extended to capture more realistically different hemodynamic conditions as
caused by the application of different PEEP values and levels of normo-, hypo-
and hypervolemia. The amount of necessary data for the parameter identifica-
tion process has, compared to previous work, further been reduced, to make the
whole approach even more applicable for a clinical environment. Instead of using
the left and right ventricle end-systolic and end-diastolic volumes, now only the
global end-diastolic volume (GEDV) and an estimated total blood volume (TBV)
are needed to identify the different PEEP and volemic levels correctly. The iden-
tification process has also been modified to allow for a more robust identification.
8.2.2 Methods
8.2.2.1 CVS Model
The CVS model is a simple, yet clinically validated model for the heart and cir-
culation (Smith et al., 2004, 2006) as previously presented in Section 3.2. This
model comprises a series of connected pressure-volume chambers with greater
detail for the active ventricular portions of the heart and their interaction. More
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specifically, the left/right ventricle, aorta, pulmonary artery/vein and vena cava
are captured as explicit physiological regions with independent fundamental cir-
culatory (PV) dynamics. A more detailed description of the CVS model can be
found in (Hann et al., 2005; Smith, 2004; Smith et al., 2004, 2006; Starfinger
et al., 2007b).
In this research, the original CVS model has been extended to include one
compartment for the lung capillaries and a second for the body capillaries as
described in Section 3.2 and Chapter 4, thus separating the venous and arterial
systems and resistances. This is important when heart-lung interactions during
positive pressure ventilation (PPV) and more specifically during the application
of different PEEP levels have to be simulated. Increases in intrathoracic pressure
(Pth) cause right ventricular preload to decrease by increasing the resistance to
venous return (Rvr), and left ventricular afterload to decrease (Fessler, 1997; Miro
& Pinsky, 2005). This afterload reduction is achieved by a decrease in systemic
resistance (Rsys). One can see, that two resistances on either side, the arterial
and venous side, are necessary to correctly simulate the complex behaviors during
mechanical or spontaneous breathing.
8.2.2.2 Integral-Based Parameter Identification
The parameter identification method used in this research has previously been
shown to rapidly and accurately identify virtually the entire parameter set in the
presence of significant measurement noise (Hann et al., 2006; Starfinger et al.,
2007b). The identification method is slightly adjusted in this research to allow
a more robust parameter identification. Details of the adjustments are given
in Chapter 5. For clarity, a short summary of the main identification steps is
provided in the following paragraph.
As for discrete measurements the waveforms are not known, the integral
method of (Hann et al., 2006) cannot be directly applied. However, waveforms can
be artificially generated by scaling a set of previously calculated model outputs
to best fit the maximum and minimum measured data values for the pressures
and volumes. The assumption is that these validated model waveforms are rea-
sonably conformable with the actual clinical case. The scaled signals are then
re-identified and a new CVS forward simulation is performed with the previously
identified parameters producing a much closer match to the clinical data than
the first initial parameter set. The simulated output is then compared to the
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clinical data. Subsequently, the output signals are re-scaled and new parameters
are identified which are then again used to run another simulation. This iterative
process is stopped when the relative error between model output and clinical data
reaches a set tolerance. This identification process is also illustrated in Figure
5.6.
8.2.2.3 Volume Calculations
All volume calculations performed for the CVS model compartments during the
identification process are described in detail in Section 4.2. The following para-
graph provides a short summary of the volume estimations as specifically per-
formed for the PEEP titration experiment.
The parameter identification process needs the two ventricle volumes as input
signals to accurately determine some of the parameters. More specifically, the
end-diastolic and end-systolic volumes (EDV, ESV) are needed. However, these
volume measurements are usually not available in a clinical environment and thus
need to be estimated. Currently, the LVEDV and RVEDV are estimated based on
an estimated total blood volume (TBV) and the measured global end-diastolic
volume (GEDV). As the stroke volume (SV) is a measured variable too, ESV
can be calculated by subtracting SV from EDV. The remaining model volumes
are estimated based on known blood distributions. Importantly, the volume in
the pulmonary capillary and vein compartments (Vcap, Vpv) are given by the
pulmonary blood volume (PBV) which is obtained as GEDV/4. The volumes in
aorta and pulmonary artery are also directly given, as the pressures Pao and Ppa
are given and the elastances Eao and Epa are calculated.
Note that as a result of these estimations, specific detailed questions cannot
be answered, as information is lost on how one ventricle expands relative to the
other (e.g. RVEDV/LVEDV expansion index). However, in this research we are
not so much interested in identifying specific ventricular volumes, but we are
rather interested in identifying the change in SV, which is directly given as a
measured signal.
8.2.2.4 PEEP Experiment Study Protocol
Instrumentation and Monitoring The experiment was approved by the Na-
tional animal ethics committee and data of seven 20-22kg pigs was analyzed for
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this research. A detailed description of the anesthesia, ventilation, instrumen-
tation and monitoring procedure has been published in (Lambert et al., 2007).
Here, only a limited and brief discussion of the study protocol is given where it
is relevant for this analysis. Measurements were obtained from the right femoral
artery, right carotid artery and the right internal jugular vein for monitoring
the intravascular pressures and cardiac output. Pulmonary artery pressure was
recorded using a PAC (Swan-Ganz, CCO mbo CCO/SvO2 7.5F, Edwards Life-
sciences, Irvine, CA) and esophageal pressure was measured via a latex balloon
catheter (Viasys Healthcare, Hochberg, Germany). The esophageal catheters
were connected to transducers (T450545A, Edwards Lifesciences, Irvine, CA)
and the signals were transferred to a monitor (CM4008, Cardiomed, Ontario,
Canada). Data was continuously measured and stored on a computer using Mat-
lab (The MathWorks, MA). Analysis was performed using Matlab.
Interventions The measurements were performed at three different PEEP lev-
els of 0, 10 and 20cmH2O and at 5 different volemic levels: baseline (normov-
olemia, N), 10% volume loss (hypovolemia, H), re-transfusion of blood (normo-
volemia, I1), infusion of a volume equal to 10% of the estimated blood volume
(10% hypervolemia, I2) and infusion of a volume equal to 20% of the estimated
blood volume (20% hypervolemia, I3). Each blood infusion or removal was done
over a period of 5 minutes, followed by a 10 minutes stabilization period with
5cmH2O PEEP to guarantee steady-state measurements.
8.2.3 Results
8.2.3.1 PEEP Titration Experiment at Different Volemic Levels
The integral-based parameter identification is applied to clinical porcine data for
a true clinical validation. Detailed results for three of the seven pigs are presented
and a summary of all seven pigs is given in Table 8.1. Figure 8.2 shows in the
upper panel the simulated model output for the systolic and diastolic pressures
in the aorta (SAP and DAP, solid line). The circles are the measured systolic
and diastolic pressures. Note, that the x-axis shows the interventions performed
during the PEEP titration protocol, where 0 − 20 represent the beginning of a
PEEP sequence of 0, 10 and 20cmH2O. The symbols N, H, I1, I2 and I3 stand for
baseline normovolemia (N), hypovolemia (H), re-transfusion normovolemia (I1),
10%- and 20% hypervolemia (I2 and I3), respectively. The middle panel shows
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the systolic and diastolic pulmonary artery pressures (SPAP and DPAP) and
the lower panel shows the central venous pressure (CVP). The simulation data
matches the measured porcine data very well with errors well below 5% for the
maximum and minimum pressures.
Difference in % for measured and simulated pressures and volumes
SAP DAP SPAP DPAP CVP SV
µ 3.57 5.51 3.79 4.98 3.55 5.35
σ 2.22 3.34 2.36 3.35 2.36 3.38
Table 8.1: Mean error and standard deviation in % for measured and simulated
pressures and volumes over all 96 identified segments. SAP = systolic arterial
pressure, DAP = diastolic arterial pressure, SPAP = systolic pulmonary artery
pressure, DPAP = diastolic pulmonary artery pressure, CVP = central venous
pressure, SV = stroke volume.
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Figure 8.2: Model output (solid lines) vs clinical (circles) pressures for pig 1. The
upper panel shows the systolic and diastolic arterial pressures (SAP, DAP), the
middle panel shows the systolic and diastolic pulmonary artery pressures (SPAP,
DPAP) and the lower panel shows the central venous pressure (CVP).
Figure 8.3 displays in the upper panel the measured GEDV (one measur-
ment/circle per intervention) and the simulated ventricle end-diastolic volume
VEDV (VEDV=LVEDV+RVEDV, upper solid line). Note that as the atria vol-
umes are not simulated, VEDV is multiplied by a factor of 1.5 to enable a direct
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comparison between the two volumes. The second line in the upper panel rep-
resents measured PBV (one measurment/circle per intervention) and the solid
line represents the simulated pulmonary venous and capillary blood volume. The
lower panel shows the measured (circles) and simulated SV (solid line). Again,
the simulation data matches the measured porcine data very well with errors well
below 10% for the maximum and minimum volumes.
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Figure 8.3: Model output (solid lines) vs clinical (circles) volumes for pig 1. The
upper panel shows the GEDV and PBV and the lower panel shows the stroke
volume (SV).
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Figures 8.4 and 8.5 show the simulated vs clinally measured pressure and vol-
ume signals for a second pig and Figures 8.6 and 8.7 show the same results for
a third pig. Similar good results were obtained for all other pigs as can be seen
in Table 8.1. Figures 8.8 and 8.9 clearly show that the identified subject (pig)
specific parameters venous return resistance (Rvr) and pulmonary vascular resis-
tance (Rpulin), differ significantly between PEEP 0cmH2O and PEEP 20cmH2O
states. For all seven pigs, Rvr increases when PEEP is applied, this is particularly
significant during the volemic levels of hypo- and normovolemia (H, N and I1).
Less significant changes are observed during hypervolemia (I2 and I3). Likewise,
Rpulin increases with increasing levels of PEEP.
N−0 20 H−0 20 I1−0 20 I2−0 20 I3−0 20
0
100
200
SA
P/
DA
P 
 
in
 m
m
Hg
N−0 20 H−0 20 I1−0 20 I2−0 20 I3−0 20
0
50
SP
AP
/D
PA
P 
in
 m
m
Hg
   
N−0 20 H−0 20 I1−0 20 I2−0 20 I3−0 20
10
20
30
interventions
CV
P 
   
in
 m
m
Hg
Figure 8.4: Model output (solid lines) vs clinical (circles) pressures for pig 3. The
upper panel shows the systolic and diastolic arterial pressures (SAP, DAP), the
middle panel shows the systolic and diastolic pulmonary artery pressures (SPAP,
DPAP) and the lower panel shows the central venous pressure (CVP).
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Figure 8.5: Model output (solid lines) vs clinical (circles) volumes for pig 3. The
upper panel shows the GEDV and PBV and the lower panel shows the stroke
volume (SV).
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Figure 8.6: Model output (solid lines) vs clinical (circles) pressures for pig 5. The
upper panel shows the systolic and diastolic arterial pressures (SAP, DAP), the
middle panel shows the systolic and diastolic pulmonary artery pressures (SPAP,
DPAP) and the lower panel shows the central venous pressure (CVP).
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Figure 8.7: Model output (solid lines) vs clinical (circles) volumes for pig 5. The
upper panel shows the GEDV and PBV and the lower panel shows the stroke
volume (SV).
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Figure 8.8: Identified Rvr for all 7 pigs and all PEEP/volume interventions.
Figure 8.10 shows how Rvr directly correlates with Psys/SV and Figures 8.11
and 8.12 show the good correlations obtained for systemic vascular resistance
(Rsys) and (SAP − Psys)/SV and Rpulin and (SPAP − Pcap/SV ), respectively.
Finally, Figures 8.13 and 8.14 show the correlations for the ventricle contractilities
Eeslvf , Eesrvf and the ratio of systolic arterial pressure and end-systolic volume.
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Figure 8.9: Identified Rpulin for all 7 pigs and all PEEP/volume interventions.
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Figure 8.10: Correlation for Psys/SV and Rvr for all 96 identified segments for
all 7 pigs and all PEEP/volume interventions.
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Figure 8.11: Correlation for (SAP − Psys)/SV and Rsys for all 96 identified
segments for all 7 pigs and all PEEP/volume interventions.
0 0.5 1 1.5 2
0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1
(SPAP−Pcap)/SV
R
pu
l in
r = 0.9660
Figure 8.12: Correlation for (SPAP − Pcap)/SV and Rpulin for all 96 identified
segments for all 7 pigs and all PEEP/volume interventions.
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Figure 8.13: Correlation for SAP/LV ESV and Eeslvf for all 96 identified seg-
ments for all 7 pigs and all PEEP/volume interventions.
0 0.5 1 1.5 2 2.5 3 3.5 4
0
0.5
1
1.5
2
2.5
3
3.5
SPAP/RVESV
Ee
sr
vf
r = 0.9003
Figure 8.14: Correlation for SPAP/RV ESV and Eesrvf for all 96 identified
segments for all 7 pigs and all PEEP/volume interventions.
8.2.4 Discussion
Mechanical ventilation, for example PPV with additional PEEP, can cause pro-
found steady-state effects in critically ill patients. As respiratory-induced changes
in Pth are transmitted directly to all vessels in the thoracic cavity, the pressure
in the right atrium increases during PPV. It is known that PEEP often reduces
venous return (VR) and thus cardiac output (CO) (Cassidy et al., 1948; Fessler,
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1997; Miro & Pinsky, 2005; Shekerdemian & Bohn, 1990). Over the years there
has been some controversy how exactly PEEP alters VR. Some investigators have
concluded that PEEP decreases VR by reducing the pressure gradient (Psys−Pra)
(Johnston et al., 1989; Wise et al., 1981). Note, that Psys is the mean systemic
pressure, which is also known as mean circulatory filling pressure (MCFP). Note
furthermore, that as the CVS model does not explicitly model the right atrium,
but lumps it together with the vena cava, Pra is in the model represented by Pvc.
However, other researchers have demonstrated that Psys and Pra change equally
during positive airway pressure and thus a change in the driving pressure gradient
cannot be the reason for decreases in VR during PEEP (Fessler, 1997; Jellinek
et al., 2000; Peters et al., 1997). Recent publications suggest that the main effect
by which PEEP decreases venous return is by increasing the resistance to venous
return (Fessler, 1997; Miro & Pinsky, 2005; Shekerdemian & Bohn, 1990).
Thus, during PEEP, VR is decreased not by altering the pressure gradient
(Psys−Pra) but by increasing the resistance to venous return Rvr. Hence, different
PEEP levels should result in different values for Rvr or more specifically, Rvr
should increase during elevated PEEP levels, which is shown in Figure 8.8 and
matches physiological expectations. Furthermore, it is also known that right
ventricular afterload increases during PPV, so one would expect Rpulin to increase
with increasing levels of PEEP. Figure 8.9 shows this result, as expected.
Additionally, reflex response mechanisms of the body decrease unstressed sys-
temic volume (Vdsys) and thus rise stressed systemic volume (Vsys) which in turn
leads to a rise in Psys and helps to sustain the pressure gradient for VR (Jacob-
sohn et al., 1997; Peters et al., 2001). The CVS model successfully simulates this
behavior, as can be seen in Figure 8.15. Figure 8.15 displays, how the effective
systemic volume Vsyseff (with Vsyseff = Vsys − Vdsys) rises during PEEP levels
from 0 to 20cmH2O. Figure 8.15 shows the systemic volume Vsys normalized
by the baseline value for PEEP 0cmH2O. The increase in Vsys is more accentu-
ated during hypo- and normovolemia, as expected as the central venous pressure
and intrathoracic pressure are both higher during these states compared to 10%-
and 20% hypervolemia. Note, that PBV decreases with rising PEEP levels, as
the volume is shifted form the pulmonary circulation centrally to help raise Vsys
(Peters et al., 2001) as seen in Figures 8.3 - 8.7.
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Figure 8.15: Effective normalized systemic volume for all 15 identified segments
for pigs 1,3 and 5 over all PEEP/volume interventions.
In Figures 8.2 - 8.6 it can be seen how well the increase in CVP is matched by
simulated data from the CVS model for the different PEEP levels. Furthermore,
Figure 8.10 shows that Rvr correlates directly with the ratio of Psys and stroke
volume, this is as expected, as the pressure gradient (Psys − Pvc) divided by SV
gives the mean resistance to venous return. Note, that as the pressure gradient
remains relatively equal and both pressures change similarly, it does not matter
if (Psys − Pvc)/SV or Psys/SV is calculated.
Similar good correlations for Rsys and Rpulin are obtained and shown in Fig-
ures 8.11 and 8.12. Note, that these correlations further validate the CVS model
and identification method as the identified parameters behave as physiologically
expected. Likewise, good correlations for the two ventricle contractilities (Eeslvf ,
Eesrvf ) are given in Figures 8.13 and 8.14 and are as expected. As in our model,
Vd (ESPVR and x-axis intercept) is set to zero for simplicity reasons, one can see
that ESPVR is approximately given by the ratio of systolic arterial pressure to
end-systolic volume.
Finally, Table 8.1 summarizes all results for all seven pigs and a total of 96
separate identifications. Note, that 9 measurements had to be omitted from final
analysis as they contained corrupted data, such as produced by disconnected
catheters. These results show that the minimal CVS model is able to capture
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the essential dynamics of the porcine CVS response to increasing levels of PEEP
over a variety of volemic conditions and over a selection of subjects.
8.2.5 Conclusions
The integral-based optimization successively identified pig-specific parameters
for the minimal cardiac model. This further validation shows the ability of the
model to adequately and realistically capture (with unique values) the impact
of pressure-volume changes with PEEP and fluid therapy. This research thus
increases our confidence in the clinical applicability and validity of this overall
diagnostic monitoring approach.
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8.3 Part II: Predicting Future Response Towards
Different PEEP Levels
8.3.1 Introduction
Circulatory dysfunctions and disease account for a significant number of ICU
admissions. For example, a recent study found that 58% of ICU admissions for
patients aged 65-74 years in Olmsted County, Minnesota were due to cardio-
vascular dysfunction, with a further 17% due to respiratory disease (Seferian &
Afessa, 2006). The treatment and management of this large group of patients
is significantly affected by the difficulty in monitoring and managing circulatory
status and efficiency.
However, cardiac disease states are highly patient-specific, such that every
patient has a unique expression of the disease or dysfunction. They are thus dif-
ficult to accurately diagnose given the sometimes limited measurements available
and the body’s natural reflex responses to restore circulatory equilibrium, both of
which can mask the underlying symptoms. Clinical staff must therefore consider
many combinations of different disease scenarios based on frequently conflicting
patient data, including clinical history and non-invasive and/or invasive studies
(Grenvik et al., 1989). Hence, successful diagnosis and treatment often rely on
the experience and intuition of clinical staff, increasing the likelihood for clinical
error, which is common with rates up to 50% (Abramson et al., 1980; Donchin
et al., 1995; Morris, 2001; Suresh et al., 2004).
Tools for diagnosis and guiding therapy can help reduce variation and pro-
vide a more consistent care. Computerized protocols have thus become more
widespread as they can be applied to complex clinical problems to create patient-
specific therapy instructions (Kortgen et al., 2006; Leibovici et al., 2007; Rees
et al., 2002). A cardiovascular (CVS) model could be integrated into the clinical
decision making process by offering clinicians the possibility of not only assisting
in diagnosing, but also providing a model-based means to test different therapeu-
tic procedures and their likely effect on the patient. Hence, treatment could be
optimized for each patient and unnecessary interventions avoided.
A previously published integral-based parameter identification method (Hann
et al., 2006) has been shown to successively identify pig-specific parameters for
a minimal cardiac model (Starfinger et al., 2007b). These models and methods
were further validated using a porcine experiment of PEEP titrations at different
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volemic levels (Starfinger et al., 2008d), where the model’s ability to capture the
impact of pressure-volume changes with PEEP and fluid therapy was shown.
This research is a further clinical validation of the overall diagnostic monitor-
ing approach and extends the previously described methods. It illustrates one
method for using this CVS model and integral-based parameter identification
for therapy guidance and decision support by forward simulating the expected
patient response to different interventions. Thus, this research provides a predic-
tive validation of the model’s capability and efficiency in a decision support role,
rather than a physiological data matching validation. More specifically, general
rules are developed relating PEEP to specific model parameters such that the
model can then be used to predict the general patient response to increases in
PEEP from 0 to 10cmH2O and from 10 to 20cmH2O during different volemic
states.
8.3.2 Methods
8.3.2.1 Prediction Process and PEEP-Specific Model Parameters
As shown previously, the CVS model parameters can be obtained accurately
and repeatedly for the porcine experiment of PEEP titrations (Starfinger et al.,
2008d). Furthermore, very good correlations were found between specific model
parameters and specific output signals (Starfinger et al., 2008d). These initial
good results allow the assumption that an overall rule can be created that links
changes in PEEP to corresponding changes in specific CVS model parameters.
A general rule that is true for all studied pigs would allow the implementation of
PEEP-specific parameters that change according to the currently applied PEEP.
Such PEEP-varying parameters would enable more realistic and physiologically
correct simulation of the cardiovascular system with the potential for using such
forward simulations for diagnosis and therapy decision support.
The rules for PEEP-specific parameters are obtained by examining the per-
centage changes in the CVS model parameters for pig 1 during the different PEEP
settings and volemic levels. As it is assumed, that the CVS model parameters are
identified reliably, it can be expected that the rules obtained from only one pig
also hold true for predicting the response of the remaining pigs. These parameter
changes can however also be explained by reflecting on the known physiological
effects of mechanical ventilation and especially PEEP on the circulation. Specif-
ically, during the application of positive pressure ventilation (PPV) with PEEP,
149
8. APPLICATION TO PORCINE EXPERIMENTS OF PEEP
TITRATIONS
intrathoracic pressure increases and venous return is decreased. This decrease
occurs not by altering the pressure gradient (Psys − Pra), but by increasing the
resistance to venous returnRvr (Fessler, 1997; Miro & Pinsky, 2005; Shekerdemian
& Bohn, 1990). Hence, different PEEP levels should result in different values for
Rvr. More specifically, Rvr should increase during elevated PEEP levels. Fur-
thermore, it is also known that right ventricular afterload increases during PPV
(Fessler, 1997; Miro & Pinsky, 2005), so one would expect Rpulin to also increase
with increasing levels of PEEP.
8.3.3 Results
8.3.3.1 PEEP-Specific Changes in Resistances and Volumes
Table 8.2 shows how the CVS model identified parameters are affected by changes
in PEEP from 0 to 10cmH2O and from 10 to 20cmH2O. The percentage changes
represent values obtained from pig 1 as studied as detailed in (Starfinger et al.,
2008d). The CVS model volumes are calculated for PEEP 0cmH2O as described
previously (Starfinger et al., 2008d). Table 8.3 shows how the volumes are then
adjusted for predicting the volume changes for PEEP of 10 and 20cmH2O, re-
spectively. These values were obtained by observing the model identified volume
changes, but could also be explained by expected physiological PEEP-induced
changes (Jacobsohn et al., 1997; Peters et al., 2001; Rothe, 1979) and direct
examination of the data.
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PEEP-specific parameter changes
Parameter 0cmH2O ⇒ 10cmH2O 10cmH2O ⇒ 20cmH2O
Eao plus 10% plus 20%
Epa plus 10% plus 60%
Evc plus 10% plus 10%
Epu plus 5% plus 5%
Rsys minus 10% minus 10%
Rvr plus 30% plus 50%
Rpulin plus 40% plus 60%
Rpulout plus 15% plus 30%
Ecap plus 40% plus 50%
Popcd plus 10% plus 10%
Table 8.2: Parameter changes for forward simulating changes in PEEP from 0 to
10cmH2O and from 10 to 20cmH2O.
PEEP-specific volume changes
Volume 0cmH2O ⇒ 10cmH2O 10cmH2O ⇒ 20cmH2O
Vlv minus 25% minus 25%
Vrv minus 20% minus 20%
Vpv minus 30% minus 30%
Vvc minus 30% minus 50%
Vpa minus 10% minus 35%
Vao minus 25% minus 50%
Vsys plus 2% plus 2%
Vcap minus 2% minus 2%
Table 8.3: Volume changes for forward simulating changes in PEEP from 0 to
10cmH2O and from 10 to 20cmH2O.
8.3.3.2 Prediction of Arterial Pressures and Stroke Volume
Predictions are made using data identified at PEEP of 0cmH2O for each of the
remaining 6 pigs. Note that data of pig 1 used for identification, is not used in the
prediction process. The estimated PEEP-specific parameter and volume changes
in Tables 8.2 and 8.3 are used to predict changes in a given pigs model parameters
and initial volume conditions. The modified PEEP-specific parameters are then
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used to simulate the therapy intervention with results compared to the clinical
data.
Figure 8.16 shows the prediction results obtained for Pig 2. In the upper
panel, the predicted stroke volume (SV) is displayed with a cross, whereas the
measured clinical values are shown as a dotted line. Predictions were made for
PEEP values of 10 and 20cmH2O for the different volemic levels of normovolemia
(N and I1), hypovolemia (H) and the two infusion-induced hypervolemic states
(I2 and I3). Note that the values for PEEP of 0cmH2O are not shown as no
predictions were performed for these PEEP values. The middle panel shows
the predicted (cross) versus clinical (dotted line) systolic arterial pressure values
(SAP) and the lower panel shows the results for predicting systolic pulmonary
artery pressure (SPAP). Figures 8.17 to 8.21 show the same results as obtained for
Pigs 3-7 respectively. Table 8.4 summarizes the prediction results for all 6 pigs and
gives the median and maximum absolute percentage errors and the interquartile
range (IQR) for predicting stroke volume (SV), systolic arterial pressure (SAP)
and systolic pulmonary artery pressure (SPAP).
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Figure 8.16: Model prediction (cross) vs clinical (dotted line) pressures and vol-
umes for pig 2 for PEEP 10 and 20cmH2O. The upper panel shows the stroke
volume (SV), the middle panel shows the systolic arterial pressure (SAP) and the
lower panel shows the systolic pulmonary artery pressure (SPAP).
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Figure 8.17: Model prediction (cross) vs clinical (dotted line) pressures and vol-
umes for pig 3 for PEEP 10 and 20cmH2O. The upper panel shows the stroke
volume (SV), the middle panel shows the systolic arterial pressure (SAP) and the
lower panel shows the systolic pulmonary artery pressure (SPAP).
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Figure 8.18: Model prediction (cross) vs clinical (dotted line) pressures and vol-
umes for pig 4 for PEEP 10 and 20cmH2O. The upper panel shows the stroke
volume (SV), the middle panel shows the systolic arterial pressure (SAP) and the
lower panel shows the systolic pulmonary artery pressure (SPAP).
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Figure 8.19: Model prediction (cross) vs clinical (dotted line) pressures and vol-
umes for pig 5 for PEEP 10 and 20cmH2O. The upper panel shows the stroke
volume (SV), the middle panel shows the systolic arterial pressure (SAP) and the
lower panel shows the systolic pulmonary artery pressure (SPAP).
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Figure 8.20: Model prediction (cross) vs clinical (dotted line) pressures and vol-
umes for pig 6 for PEEP 10 and 20cmH2O. The upper panel shows the stroke
volume (SV), the middle panel shows the systolic arterial pressure (SAP) and the
lower panel shows the systolic pulmonary artery pressure (SPAP).
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Figure 8.21: Model prediction (cross) vs clinical (dotted line) pressures and vol-
umes for pig 7 for PEEP 10 and 20cmH2O. The upper panel shows the stroke
volume (SV), the middle panel shows the systolic arterial pressure (SAP) and the
lower panel shows the systolic pulmonary artery pressure (SPAP).
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Prediction of PEEP-induced hemodynamic changes
All pigs, PEEP 10 SAP DAP SPAP DPAP SV
median 6.65 9.80 4.24 5.94 12.24
max 22.62 31.89 12.92 18.71 38.95
iqr 7.64 11.14 3.78 5.52 13.05
All pigs, PEEP 20 SAP DAP SPAP DPAP SV
median 10.47 12.99 6.51 7.14 16.86
max 30.69 33.82 12.82 18.24 33.61
iqr 13.26 14.03 6.98 5.25 13.08
All pigs, all predictions SAP DAP SPAP DPAP SV
median 7.93 11.52 4.62 7.02 14.49
max 30.69 33.82 12.92 18.71 38.95
iqr 8.10 13.86 5.54 8.40 12.58
Table 8.4: Absolute median and maximum percentage error and interquartile
range for predicted values of SAP/DAP = systolic/diastolic arterial pressure,
SPAP/DPAP = systolic/diastolic pulmonary artery pressure and SV = stroke
volume.
8.3.4 Discussion
It is well known that PEEP often reduces venous return (VR) and thus cardiac
output (CO). Recent publications suggest that the main effect by which PEEP
decreases venous return is by increasing the resistance to venous return (Rvr)
(Fessler, 1997; Miro & Pinsky, 2005; Shekerdemian & Bohn, 1990). Hence, differ-
ent PEEP levels should result in different values for Rvr or more specifically, Rvr
should increase during elevated PEEP. Table 8.2 shows how Rvr is increased with
increasing PEEP values, matching physiological expectations. Furthermore, it is
also known that right ventricular afterload increases during PPV (Fessler, 1997;
Miro & Pinsky, 2005), so one would expect Rpulin to also increase with increasing
levels of PEEP. Analogously, the parameter changes for LV afterload (Rsys) and
LV preload (Rpulout) can be derived.
All other parameter changes can be explained similarly. Thus, for example,
increasing arterial elastance values (Eao and Epa) are observed during the PEEP
titration experiment and are expected because the pulse pressure/stroke volume
ratio (PP/SV) determines the arterial elastances and during PEEP, stroke volume
decreases more than pulse pressure does. Venous elastances (Evc and Epu) are
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assumed to increase as well because positive end-expiratory pressure elevates the
transpulmonary pressure which compresses the large intrathoracic veins and right
atrium. Note however that the systemic elastance (Esys) remains constant as it
has been shown that increases in PEEP decrease unstressed volume and thereby
increase stressed volume with no change in compliance (Nanas & Madger, 1992).
It can also be expected, that the pericardium becomes stiffer (diastolic elas-
tance P0pcd increases) with increasing levels of PEEP, as the heart becomes more
and more compressed by the expanding lung and pressurized thoracic cavity.
Similarly, Ecap, the lung capillaries elastance is expected to increase with falling
pulmonary blood volume (PBV) values and thus decreases in compliance. Note,
that Rsys remains constant during hypovolemia, assuming a compensation caused
by an increased sympathetic activity in response to the blood loss. Table 8.2
shows these parameter variations matching clinical observations in their general
trends.
Changes in the volumes can be similarly explained. As GEDV decreases
with increasing PEEP levels, it can be followed that LVEDV and RVEDV have
to decrease, as well. Vpv and Vcap are expected to decrease as given by the
drop in pulmonary blood volume. Note, that Vsys remains constant as blood is
shifted centrally to help maintain CVP. However, Vsys is simulated to slightly
decrease during hypovolemia, as hypovolemia inhibits fluid reabsorption due to
high capillary pressures (Peters et al., 2001). Table 8.3 shows the general trend
of these volume variations.
Figures 8.16 to 8.21 and Table 8.4 show how the CVS model and these PEEP-
specific variable changes were able to predict the main trends in the clinically
relevant systolic and diastolic arterial pressures (SAP, DAP), systolic and dias-
tolic pulmonary artery pressures (SPAP, DPAP) and stroke volume (SV). Note,
that starting from only one pig it has been shown that a general population rule,
valid over all studied pigs, can be formulated and used to predict hemodynamic
changes, thus showing that all pigs react along similar trends. This assumption
makes sense as the pigs were healthy and no other diseases or hemodynamic in-
stabilities were induced. Overall, the prediction error results are within clinical
variation and close to measurement error in some cases. These results thus show
the general applicability of this CVS model and methods to predictively cap-
ture the main hemodynamic trends due to this often applied intervention over a
number of different pigs.
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8.3.4.1 Study Limitations
It has to be mentioned that for this research all model volumes had to be es-
timated, based only on an estimated TBV and measured GEDV. This approx-
imation naturally introduces a potentially significant degree of uncertainty and
possible source of model error. As can be seen in Figures 8.16 to 8.21, the pre-
diction results during normo- and hypovolemia are relatively good with median
absolute percentage errors less than 6% for the arterial pressures and less than
10% for the stroke volume. However, the prediction results are not that good
for the hypervolemia states, suggesting a model error. In particular, the approx-
imated volumes and any error they contain may well be exacerbated in this case.
Further research will thus need to be conducted to better model or estimate the
different volume compartments, especially during hypervolemic states.
8.3.5 Conclusions
The integral-based optimization led to the successful definition of PEEP-specific
population parameters for a minimal cardiac model. These PEEP-specific pop-
ulation values were used to validate the predictive ability of the model for use
in guiding this often used therapy. This further validation shows the ability of
the model to adequately and realistically simulate the impact of pressure-volume
changes with PEEP and fluid therapy. Moreover, such rules can be similarly
derived and used to predict the response towards a variety of interventions, while
errors or deviations from can point out developing disease states or hemodynamic
instabilities.
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Chapter 9
Application to Porcine
Experiments of Septic Shock
This chapter presents the results of a porcine validation study during induced
endotoxic shock. The first section analyzes right ventricular (RV)-vascular cou-
pling during hemofiltration and compares the model-based identified RV-vascular
coupling to previously reported results in (Lambermont et al., 2006).1
The second part of this chapter analyzes and identifies the different effects
on the hemodynamic status of the pigs during induced endotoxic shock with and
without hemofiltration (HF). Results of the identified RV-vascular coupling are
also compared to the results available in (Lambermont et al., 2006).2
9.1 Pathophysiology of Septic Shock
Sepsis is a very complex and serious systemic response to infection that also
has a significant impact on cardiovascular and circulatory performance. Sepsis
results in as many deaths in the USA as out-of-hospital cardiac arrests, and four
times the number for breast cancer (Angus & Crowther, 2003). More specifically,
mortality rates have ranged from 25% to 80% over the last few decades (Angus
et al., 2001). In the USA, the annualized increase in the incidence of sepsis is
estimated to be about 9% and its associated mortality rate 18% (Martin et al.,
2003). Septic shock, the most severe form of sepsis, accounts for about 9% of
admissions to ICUs and its short-term mortality ranges between 40% and 60%
1The first section is based on (Desaive et al., 2008; Starfinger et al., 2008b).
2The second section is based on (Starfinger et al., 2008c).
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(Annane et al., 2003). Figure 9.1 shows the trend and improvement of mortality
rates over the last decades (Dellinger, 2003; Friedman et al., 1998).
Figure 9.1: Septic shock mortality rates. Source: (Dellinger, 2003; Friedman
et al., 1998)
Septic shock or severe sepsis and multiple organ failure are thus one of the
leading causes for morbidity and mortality in the critical care setting. The current
definition of septic shock as defined by the ACCP/SCCM Consensus Conference
Meeting in 1992 is: “ ... sepsis-induced hypotension (systolic blood pressure
< 90mmHg or a reduction of ≤ 40mmHg from baseline) despite adequate fluid
resuscitation along with the presence of perfusion abnormalities that may include,
but are not limited to, lactic acidosis, oliguria, or an acute alteration in mental
status. Patients who are receiving inotropic or vasopressor agents may have a
normalized blood pressure at the time that perfusion abnormalities are identified
... ” (ACCP/SCCM, 1992; Dellinger, 2003).
Figure 9.2 shows the normal circulation whereas Figure 9.3 shows the circula-
tory system during septic shock, but before fluid resuscitation. Figure 9.4 shows
the circulatory status after fluid resuscitation. In septic shock, as seen in Figure
9.3, venous return to the right heart is decreased as caused by the combinatory
effects of capillary leaks, less stressed systemic volume and loss of circulatory tone
leading to systemic arterial resistance. Moreover, venous capacitance and pul-
monary resistance are usually increased, which together with a reduced ventricle
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contractility lead to impaired stroke volume and cardiac output. A decreased
systemic arterial resistance therefore leads to a low blood pressure and conse-
quently hypotension. Fluid resuscitation can compensate for the capillary leak
and result in increased venous return. Most patients in septic shock after fluid
resuscitation thus have a high cardiac output, but a low systemic vascular resis-
tance state (Dellinger, 2003), indicating the key clinically important diagnostic
characteristics and treatments.
Figure 9.2: Normal, baseline circulatory status. Source: (Dellinger, 2003)
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Figure 9.3: Circulatory status in septic shock before fluid resuscitation. Source:
(Dellinger, 2003)
Figure 9.4: Circulatory status in septic shock after fluid resuscitation. Source:
(Dellinger, 2003)
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The hemodynamic profile of septic shock can therefore be summarized with
the causative physiological effects as follows (Dellinger, 2003):
 Hypovolemia (loss of cardiac filling and volume)
– Capillary leak
– Venous dilation
 Cardiogenic effects:
– Decrease in contractility of the ventricles
 Obstructive effects:
– Increase in pulmonary vascular resistance
 Distributive (hypoperfusion despite normal or increased CO) effects:
– Decreased splanchnic blood flow
– Shunting
 Cytotoxic effects:
– Inability of tissues to utilize O2 (despite adequate supply)
9.2 Part I: Model-Based Analysis of RV-Vascular
Coupling During Endotoxic Shock
9.2.1 Introduction
Since continuous hemofiltration (HF) was first described as a new form of re-
nal replacement therapy (Kramer et al., 1977), a lot of experimental research
has shown that hemofiltration can also improve hemodynamics and survival in
septic shock. This research identifies parameters using the previously described
CVS model and parameter identification process (Hann et al., 2006; Starfinger
et al., 2007b, 2008d), using data from a porcine experiment of induced endotoxic
shock, combined with continuous veno-venous hemofiltration (CVVH) (Lamber-
mont et al., 2006). Measurements used to identify the model parameters are
the: minimum and maximum volumes in the ventricles (Vlv, Vrv), pressures in
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aorta, pulmonary artery (Pao, Ppa) and heart rate (HR). All of these are reason-
ably measured or estimated in a critical care setting. Every 30 minutes into the
experiment new parameters are identified that uniquely represent the pig’s hemo-
dynamic condition at that time. It is shown that the model is able to accurately
capture all the pressures and volumes when compared to measured clinical data.
RV-vascular coupling has been widely studied during septic shock as right
heart failure is one of the numerous and more severe complications seen in septic
shock. Impaired RV function results from an inappropriate matching between the
ventricular inotropic or activation state and pulmonary vascular impedance, with
secondary altered ventricular-vascular coupling (D’Orio et al., 1998). RV-vascular
coupling can be used to analyze how effectively right myocardial performance is
transmitted to the pulmonary circulation. The wave pattern of flows and pres-
sures in the main pulmonary artery represent a result of a collision between a
forward wave from the RV with a backward wave from the more peripheral parts
of the pulmonary arterial tree. Such a wave reflection has a negative effect as a
phase shift between pressure and flow waves is produced, which in turn reduces
the hydraulic power output of the RV delivered into the main pulmonary artery
(D’Orio et al., 1998). As a result, there is not enough RV output compared to
the resistance of the pulmonary circulation, leading to an impeded power trans-
fer to the pulmonary circulation and therefore consequently to inadequate left
ventricle (LV) inflow and reduced cardiac output (CO). The CVS model param-
eters produce similar results in identifying RV-vascular coupling, as published
earlier (Lambermont et al., 2006), and thus show the potential to use this type
of model-based physiological monitoring to diagnose developing disease states.
9.2.2 Methods
9.2.2.1 CVS Model
The CVS model is a lumped parameter model which was previously developed
by (Smith, 2004) and is based on earlier work of (Chung et al., 1997; Olansen
et al., 2000). The new and extended model is presented in Section 3.2.
9.2.2.2 Integral-Based Parameter Identification
The parameter identification methods are presented in Chapter 5 and Section
8.2.2.2. The parameters given in Table 9.1 are identified based on the previously
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published integral-based identification process (Hann et al., 2006; Starfinger et al.,
2007b).
Parameters used in CVS model
Taken from literature or measured
Pth, period, λlvf , λrvf , λspt, λpcd, Eesspt, V dspt, V ospt, P0spt,
V olvf , V orvf , V dlvf , V drvf , V dvc, V dao, V dpa, V dpv
Optimized
Lav, Lmt, Ltc, Lpv, Eeslvf , P0lvf , Eesrvf , P0rvf , Rav, Rmt, Rtc, Rpv,
Pao0, Ppu0, Ppa0, Pvc0, P0pcd, Esys, Ecap, Eao, Epa, Evc, Epu, Rsys,
Rpulin, Rpulout, Rvr
Table 9.1: Parameters used in CVS model.
9.2.2.3 Experimental Protocol
All experimental procedures for this experiment were reviewed and approved by
the Ethics Committee of the Medical Faculty of the University of Lie`ge. They
were performed in accordance with the Guide for the Care and Use of Laboratory
Animals, as adopted and promulgated by the U.S. National Institutes of Health
(NIH Publication No. 85-23, revised 1996). The experiments were performed on
7 healthy pigs weighing 25-30 kg. Data from 6 pigs was analyzed and identified
for this research. The animals were premedicated and anesthetized, as described
previously (Lambermont et al., 2003). Measurements were obtained for systemic
arterial pressure (Pao), pulmonary arterial pressure (Ppa) and the left and right
ventricle pressures and volumes (Plv, Vlv, Prv, Vrv) as described in (Lamber-
mont et al., 2003). In particular, the volume measurements that provide data
for Equations 5.1-5.4 are made by a 7F, 12-electrode (8mm interelectrode dis-
tance) conductance micromanometer-tipped catheter (CD Leycom, Zoetermeer,
The Netherlands).
After a 30 min stabilization period, the animals received a 0.5 mg/kg en-
dotoxin infusion (lipopolysaccharide from Escheria coli serotype 0127:B8; Sigma
Chemical, St. Louis, MO, USA) over a 30 min period (T000 - T030). From
60 minutes (T060) into the experiment onwards, the animals underwent a zero-
balance continuous veno-venous hemofiltration (CVVH) at a rate of 45 ml/kg/h.
A 0.7 m2 large-pore (78 A˚) membrane with a cutoff of 80 kDa (Sureflux FH 70,
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Nipro, Osaka, Japan) and a Baxter BM 25- BM 14 hemofiltration device (Bax-
ter Health Care, Munich, Germany) were used. Ultrafiltrate was replaced in the
postdilution mode by a bicarbonate-buffered hemofiltration fluid (Na+: 150mM;
K+: 3mM; bicarbonate: 30mM) at a temperature of 37.
9.2.3 Results
9.2.3.1 Identification of Endotoxic Shock
Figure 9.5 shows the clinically measured end-diastolic (EDV) and end-systolic
(ESV) left ventricle volumes for all identified segments over all pigs (solid lines).
The crosses and boxes represent the CVS model simulation output when re-run
using the identified model parameters. As can be seen, the model output values
match the true clinical values very well with mean absolute percentage errors less
than 3%, which is well within measurement or estimate errors (Baan et al., 1984;
Burkhoff et al., 1985). Figure 9.6 shows the same results for the right ventricle
volumes, respectively.
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Figure 9.5: Model output (cross) vs clinical (circle, solid line) left ventricle vol-
umes for all identified segments over all pigs. The upper line shows the clinical
vs. identified end-diastolic volume (LVEDV) and the lower line shows clinical vs.
identified end-systolic volume (LVESV).
Figure 9.7 shows the matched systemic arterial systolic and arterial diastolic
pressure values (SAP, DAP). Solid lines represent the clinical measurements and
the crosses and boxes the CVS model outputs. Again, very good matches are
obtained with mean absolute percentage errors less than 7%.
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Figure 9.6: Model output (cross) vs clinical (circle, solid line) right ventricle
volumes for all identified segments over all pigs. The upper line shows the clinical
vs. identified end-diastolic volume (RVEDV) and the lower line shows clinical vs.
identified end-systolic volume (RVESV).
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Figure 9.7: Model output (cross) vs clinical (circle, solid line) arterial pressure
for all identified segments over all pigs. The upper line shows the clinical vs.
identified systolic arterial pressure (SAP) and the lower line shows clinical vs.
identified diastolic arterial pressure (DAP).
Figure 9.8 shows the same results for the systolic and diastolic pulmonary artery
pressures (SPAP, DPAP), respectively. Note, that the match between the two sig-
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nals shows larger errors for measurements 34-38, because the clinically measured
Ppa signal went below zero, a non-physiological value that is almost certainly a
measurement error rather than a true measurement. These measurements were
thus ignored during the identification process, but represent the kinds of errors
that can occasionally occur.
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Figure 9.8: Model output (cross) vs clinical (circle, solid line) pulmonary artery
pressure for all identified segments over all pigs. The upper line shows the clinical
vs. identified systolic pulmonary artery pressure (SPAP) and the lower line shows
clinical vs. identified diastolic pulmonary artery pressure (DPAP).
Figure 9.9 illustrates the very good matches achieved for one typical pig in
greater detail. The first two subfigures show the left and right ventricle signals
at the beginning of the experiment (T000). The upper panel of the left subfigure
(LV) shows the clinical (Vlvp) vs. simulated left ventricle volume (Vlvs) and in
the lower panel the clinical (Plvp) vs. simulated left ventricle pressure (Plvs) and
arterial pressure (Paop, Paos), respectively.
It has to be noted, that during the identification process only the systolic
(maximum) and diastolic (minimum) values of the measured ventricle volume
(EDV, ESV) and arterial pressure (SAP, DAP) are used. The left ventricle pres-
sure (Plv) is not used as this measurement is rarely obtained in a clinical setting.
However, it can clearly be seen that relatively good matches are nevertheless ob-
tained for the ventricle pressures, further validating the model and identification
process.
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If desired, the ventricle pressures could easily be matched more accurately by
adjusting the simple activation functions used in the CVS model (Smith et al.,
2004). However, this level of accuracy and added modification was not intended
in this study and is not necessary given the good match between re-simulated
model and clinical data.
The right subfigure (RV) illustrates the same results for the right ventricle
volume (Vrv, upper panel) and the right ventricle pressure and pulmonary artery
pressure (Prv, Ppa, lower panel). The following 4 subfigures show the same signals
at 120 minutes into the experiment and at 240 minutes. In each case, the matches
between pig-specific, identified model and clinical data are qualitatively very
good.
Importantly, this study did not intend to accurately match the pressure and
volume waveform shapes, but only the minimum (diastolic) and maximum (sys-
tolic) values. This goal was adopted because the main focus is to identify the
overall macro-hemodynamic condition, and less interest is thus placed on ex-
actly matching specific waveforms. For example, exactly matching the dicrotic
notch in the arterial pressure signals was not a goal. These smaller, less clini-
cally relevant dynamics are often a function of small unmodelled non-linearities
or small non-linearities in patient-specific cardiac activation function. In addi-
tion, a patient-specific activation function would eliminate most of these clinically
insignificant differences.
Table 9.2 shows the mean absolute percentage errors for the identified mini-
mum and maximum pressure and volume signals (SAP, SPAP, LVESV, LVEDV,
RVEDV, RVESV) for the identified re-simulated model over all pigs. Generally,
the errors are well below 10%, which is within measurement noise. However, as
mentioned before, there are a few larger errors for the pulmonary artery pressure
Ppa, as seen in Figure 9.7, that are caused by a suspiciously low non-physiological
pressure signal that was ignored.
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Figure 9.9: Model output (dotted) vs clinical (solid line) volume and pressure
signals for left and right ventricle (LV, RV). The upper panel shows the clinical
(p) vs. simulated ventricle volume (s). The lower panel shows the clinical (p) vs.
simulated (s) ventricle and arterial pressure. The results are shown for 0 (begin),
120 (middle) and 240 (end) minutes into the experiment.
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Difference in % for measured and simulated pressures and volumes
SAP SPAP LVEDV LVESV RVEDV RVESV
µ 3.19 7.01 1.36 2.12 1.18 1.90
σ 2.70 5.27 1.00 1.62 1.07 1.53
IQR 3.93 4.54 1.64 2.10 1.19 1.97
Table 9.2: Mean absolute percentage error (µ), standard deviation (σ) and inter-
quartile range (IQR) in % for measured and simulated pressures and volumes over
all 38 identified segments. SAP = systolic arterial pressure, SPAP = systolic pul-
monary artery pressure, LVEDV = left ventricle end-diastolic volume, LVESV =
left ventricle end-systolic volume, RVEDV = right ventricle end-diastolic volume,
RVESV = right ventricle end-systolic volume .
9.2.3.2 Analysis of Right Ventricular-Vascular Coupling
RV-vascular coupling is a significant clinical indicator of serious circulatory and
cardiac dysfunction in sepsis (D’Orio et al., 1998; Lambermont et al., 2003).
Figure 9.10 shows the mean cardiac output (CO) for all analyzed pigs during the
endotoxic shock experiment, separated for the left and right ventricle outputs. It
can be seen that the identified model-based CO (crosses) matches the measured
clinical data (solid/dashed line) very well. Note that the right ventricle CO
remains relatively constant during the whole experiment. The lower panel of
Figure 9.11 shows the mean right ventricle end-systolic elastance (Eesrvf ) over all
pigs during the experiment. This elastance is identified during the identification
process. Note that the absolute values do not match the clinically estimated
values in the upper panel (Lambermont et al., 2006) as the value of the model-
based Eesrvf depends on the unstressed ventricle volume (Vd). For reasons of
simplicity, this value is assumed to be zero (Vd=0 ml) during the identification
process. However, Eesrvf can easily be adjusted for a different and probably
more realistic Vd. More importantly for clinical diagnosis, the identified Eesrvf
trend matches very well with recently reported values obtained for the same
experimental data (Lambermont et al., 2006) as shown in the upper panel of
Figure 9.11.
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Figure 9.10: Mean measured cardiac output (CO) for all 5 analyzed pigs during
the endotoxic shock experiment.
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Figure 9.11: Mean identified right ventricle elastance (Eesrvf ) for all 5 analyzed
pigs during the endotoxic shock experiment.
Figure 9.12 shows in the upper panel the mean pulmonary artery elastance
as obtained and published previously (Lambermont et al., 2006). In the lower
panel the identified mean pulmonary arterial elastance (Epa) is shown during the
experiment. Qualitatively the same trends are observed, validating the model.
Note, the absolute values are not expected to match because Epa in the CVS
model is calculated based on the pulmonary artery pulse pressure and stroke
volume as compared to the calculated Epa values from (Lambermont et al., 2006),
using a four element Windkessel model as described in more detail in (Fourie
176
9.2 Part I: Model-Based Analysis of RV-Vascular Coupling During
Endotoxic Shock
et al., 1992).
Figure 9.13 shows a similar result obtained for the mean pulmonary inflow
resistance (Rpulin), which is likewise representing right-ventricular afterload in the
CVS model. Both figures match closely with recently reported trends obtained
for the same experimental data (Lambermont et al., 2006). Note again that the
absolute values do not match perfectly, as in the CVS model the arterial elastances
are estimated and not optimized during the identification process. However, the
trends are what is clinically important for diagnosis and determining the efficiency
of any therapy given.
Figure 9.14 shows in the upper panel the RV-coupling reported previously
(Lambermont et al., 2006) and in the middle panel the coupling (Eesrvf/Rpulin)
obtained from the identified CVS model parameters during the endotoxic shock
experiment. The lower panel shows the difference between the two. The ratio
Eesrvf/Rpulin describes the coupling efficiency of the right ventricle to the pul-
monary vascular tree. If this ratio decreases and RV-vascular uncoupling occurs,
less power is transferred to the pulmonary circulation and as a result, right car-
diovascular performance is impaired. Again, the trends match very well. Note
that the coupling in the CVS model is best represented by the ratio Eesrvf/Rpulin
as both parameters, Eesrvf and Rpulin are identified directly from the clinical data
during the identification process.
Figure 9.15 shows the mean identified systemic vascular resistance (Rsys) over
all pigs during the endotoxic shock experiment. This value is clinically important
due to impact of sepsis on blood pressure, where increasing sepsis and septic
shock decrease blood pressure via loss of control over systemic vascular tome and
reduced resistance. This loss of resistance is clearly evident in Figure 9.15 as the
endotoxin experiment proceeds.
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Figure 9.12: Mean identified pulmonary arterial elastance (Epa), representing
right ventricular afterload, for all 5 analyzed pigs during the endotoxic shock
experiment.
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Figure 9.13: Mean identified pulmonary input resistance (Rpulin), representing
right ventricular afterload, for all 5 analyzed pigs during the endotoxic shock
experiment.
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Figure 9.14: Mean identified right ventricular-vascular coupling (Eesrvf/Rpulin)
for all 5 analyzed pigs during the endotoxic shock experiment.
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Figure 9.15: Mean identified systemic vascular resistance (Rsys) for all 5 analyzed
pigs during the endotoxic shock experiment.
9.2.4 Discussion
The major findings of this research are twofold. Firstly, the clinical experimental
results obtained previously (Lambermont et al., 2006) are matched using the
extended CVS model and parameter identification process. Figure 9.14 displays
in the middle panel the identified RV-vascular coupling which is represented by
the ratio of RV end-systolic elastance (Eesrvf ) and pulmonary vascular resistance
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(Rpulin). It can clearly be seen how hemofiltration (which starts at 60 min into
the experiment) is able to prevent RV-vascular uncoupling that is commonly
observed during the late phases of endotoxic shock (Lambermont et al., 2003).
The data shows that in the early phases of endotoxic shock, RV-vascular coupling
is preserved by an increase in RV contractility (Eesrvf ) as seen in Figure 9.11.
During the later stages and with CVVH, RV-vascular coupling is preserved where
a decrease in pulmonary vascular resistance (Rpulin), as seen in Figure 9.13, is
suggested to be the main reason for this effect (Lambermont et al., 2006). These
results allow for a better understanding of the mechanisms of RV dysfunction
during septic shock and thus have the potential to lead to more effective diagnosis
and choice of therapies for myocardial depression in septic shock.
Secondly, the CVS model and identification process are also further validated
by correctly identifying similar trends to those observed during clinical endotoxic
shock experiments. Additionally, systemic vascular resistance (Rsys) is identified
during the experiment and the mean resistance for all pigs is shown in Figure
9.15. These results match physiological expectations as low peripheral vascular
resistance is a common sign in sepsis and decreases left ventricular afterload, as
also seen in Figure 9.7 in reduced arterial pressures.
Table 9.2 summarizes all results for all five pigs and a total of 38 identification
periods. Note, that all measurements for one pig and 8 measurements of the
remaining five pigs had to be omitted from this final analysis as they contained
corrupted data, such as those produced by disconnected catheters. These results
show that the extended CVS model is able to capture the essential dynamics
of the porcine CVS response to endotoxic shock and CVVH over a selection of
subjects.
9.2.5 Conclusions
The integral-based optimization successfully identified pig-specific parameters for
the extended CVS model. This further validation shows the ability of the model
to adequately and realistically capture the impact of pressure-volume changes
during endotoxic shock and with CVVH. Comparable results to previously re-
ported studies are obtained when analyzing the RV-vascular coupling, further
validating the methods and approach presented here. In particular, the model is
able to aggregate diverse measured data into a clear, clinically and physiologically
relevant diagnostic picture as the condition develops. As discussed, the results
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thus offer patient-specific monitoring of otherwise unmeasurable, but clinically
very significant, physiological parameters that can lead to improved therapy of
care. This research thus increases confidence in the clinical applicability and va-
lidity of this overall diagnostic monitoring approach preparatory to initial studies
with human subjects.
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9.3 Part II: Model-Based Analysis and Compar-
ison of Endotoxic Shock With and Without
Hemofiltration
9.3.1 Introduction
The CVS model and identification process have previously been validated in the
identification and model-based analysis of induced endotoxic shock with continu-
ous veno-venous hemofiltration (CVVH) therapy (Starfinger et al., 2008b). Simi-
lar RV-coupling results were obtained for a patient-specific identified CVS model
compared to previously measured clinically data (Lambermont et al., 2006), fur-
ther validating the developed model and the identification procedure. In this
research, a porcine model of induced endotoxic shock without hemofiltration is
analyzed and the CVS model parameters are identified using only right heart
measurements.
The novelty of this identification is that for the first time the identification
process is applied to strictly right heart signals and no left ventricle signals were
measured. This reduced data set is of particular clinical importance as often only
data from one of the ventricles is available. The CVS model and identification
process are therefore applied here to only the measured right ventricle signals.
However, similar contractility, afterload and RV-coupling trends are obtained
when compared to previously reported results (Lambermont et al., 2006).
This research is therefore intended to show the robustness of the methods de-
veloped and the potential to use this type of model-based physiological monitoring
to diagnose developing disease states. It also shows the extended clinical potential
for those cases where significantly less measured data is available. Hence, this re-
search showcases model-based monitoring and diagnosis of untreated sepsis using
further reduced clinical data.
9.3.2 Methods
9.3.2.1 Experimental Protocol
All experimental procedures and protocols used in this investigation were re-
viewed and approved by the Ethics Committee of the Medical Faculty of the
University of Lie`ge. The investigation conforms with the Guide for the Care and
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Use of Laboratory Animals published by the US National Institutes of Health
(NIH Publication No. 85-23, revised 1996).
Experiments were performed on 12 healthy pure pietran pigs of either sex
weighing from 20 to 30 kg. The animals were premedicated with intramuscular
administration of ketamine (20 mg/kg) and diazepam (1 mg/kg). Anesthesia was
then induced and maintained by a continuous infusion of sufentanil (0.5 mg/kg/h)
and pentobarbital (5 mg/kg/h). Spontaneous movements were prevented by pan-
curonium bromide (0.2 mg/kg). After endotracheal intubation through a cervical
tracheostomy, the pigs were connected to a volume cycled ventilator (Evita 2,
Dra¨ger, Lu¨beck, Germany) set to deliver a tidal volume of 10 ml/kg with a FiO
of 0.4 and at a respiratory rate of 20 breaths /min. End-tidal CO (PETCO )
measurements (Capnomac, Datex, Helsinki, Finland) were used to monitor the
adequacy of ventilation. Respiratory settings were adjusted to maintain PETCO
between 30 and 35 mmHg.
In both groups, the animals received a 0.5-mg/kg endotoxin infusion (lipopoly-
saccharide from Escherichia coli serotype 0127:B8; Sigma Chemical, St. Louis,
MO, U.S.A.) over 30 mins (from T0 to T30). They were then randomized into two
groups. In the Endo group ( n = 6), they received no further intervention while
in the EndoHF group ( n = 7), they underwent, from T60 onward, a zero-balance
CVVH at a rate of 45 mL/kg/h (7). A 0.7-m 2 large-pore (78 A˚) membrane
with a cutoff of 80 kDa (Sureflux FH 70, Nipro, Osaka, Japan) and a Baxter
BM 25- BM 14 hemofiltration device (Baxter Health Care, Munich, Germany)
were used. Ultrafiltrate was replaced in the postdilution mode by a bicarbonate
buffered hemofiltration fluid (Na+: 150 mM;K+: 3 mM; bicarbonate: 30 mM) at
a temperature of 37. Anticoagulation of the extracorporeal circuit was achieved
using a loading dose of 5000 IU of heparin followed by an anticoagulation regimen
based on the activated clotting time (100200 s).
Measurements were obtained for systemic arterial pressure (Pao), pulmonary
arterial pressure (Ppa) and right ventricle pressure and volume (Prv, Vrv) as de-
scribed previously in (Lambermont et al., 2003).
9.3.2.2 CVS Model
The CVS model is a lumped parameter model which was previously developed
by (Smith, 2004) and is based on earlier work of (Chung et al., 1997; Olansen
et al., 2000). The new and extended model is presented in Section 3.2.
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9.3.2.3 Integral-Based Parameter Identification
The parameter identification methods are presented in Chapter 5 and Section
8.2.2.2.
9.3.2.4 Estimations for Left Ventricle Signals
As the left ventricle signals are not measured in this reduced data study, they
must be estimated for the identification process. The left ventricular volume
(Vlv) is assumed to be the same as the measured right ventricular volume (Vrv),
for reasons of simplicity. Thus, the left ventricle stroke volume (LVSV) is also
assumed to be the same as the measured right ventricle stroke volume (RVESV).
The left ventricular pressure (Plv) is not required during the identification process
and is thus not specifically estimated. These approximations are not necessarily
accurate in a dynamic, septic patient, but provide an initial starting point.
9.3.2.5 Volume Calculations
The central venous pressure (CVP) or systemic pressure Psys plays a central
role in the CVS model and identification process. The CVP provides insight
into the venous system function and, more specifically, gives information about
the effective systemic volume Vsys,eff . However, CVP is not measured in this
experiment and there is also no directly measured information available about the
volume status of the pigs. Therefore, certain assumptions about the volumes and
pressures in the CVS model have to be made. These assumptions help guarantee
that the best and optimal parameters, relative to these assumed volumes, are
identified. In all cases, the identified model parameters are then used to re-
simulate the model and produce output signals that not only match the measured
signals, but also all other estimated volumes and pressures. The overall approach
thus provides consistent means of identification and validation, given clinical data.
It is known that during septic shock the effective systemic volume decreases
as a result of capillary leak (absolute hypovolemia) or venodilation (relative hy-
povolemia) (Bridges & Dukes, 2005; Dellinger, 2003). Therefore, the evolution
of septic shock was simulated in this research by a stepwise reduction of 5% of
the effective systemic volume Vsys,eff every 30 minutes. This stepwise reduction
is a rather conservative estimate of the reduction in volume (Task Force of the
American College of Critical Care Medicine, Society of Critical Care Medicine,
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19). If necessary, the CVS model can easily be run with more severe reductions
simulating more severe forms of septic shock.
Note, that all initial CVS model volumes are estimated based on the known
distribution of blood, as previously described in (Starfinger et al., 2008d,e) and
in Section 4.2.
9.3.2.6 Summary of Methods
In this research, the main goal is to identify the CVS model parameters based only
on measured input data from the right side of the heart, using only estimated
left ventricle signals. The measured signals for this research that are used for
identification are the pressures in the aorta and pulmonary artery (Pao, Ppa),
and the volume in the right ventricle (Vrv). The results obtained show that the
CVS model and identification methods are able to correctly identify parameters
from this significantly reduced set of data. The identified parameters are then
used to re-run a pig-specific CVS model simulation producing output signals that
match the measured clinical data. Output values that match the clinical data also
serve to validate the left ventricle and other assumptions made in the iterative
identification process.
Parameter values are presented as mean normalized values over all analyzed
pigs. Previously reported values for the same experimental data of induced sep-
tic shock with (EndoHF group, (Lambermont et al., 2006)) and without (Endo
group, (Lambermont et al., 2003)) hemofiltration are normalized for comparison.
Data values are normalized with regard to the baseline (time=0 min) value to
guarantee the correct representation of the parameter trends, rather than show-
ing the absolute values where extreme low or high values for one pig can easily
influence the mean value over all pigs. All the data is thus self-normalized before
comparison across pigs or treatment method.
9.3.3 Results
9.3.3.1 Identification Results
Figure 9.16 shows the clinically measured right ventricular stroke volumes (RVSV)
for all identified segments over all pigs (solid line). The crosses represent the CVS
model simulation output when re-run using the patient-specific identified model
parameters. As can be seen, the model output values match the true clinical
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values very well, with median absolute percentage errors less than 5%, which is
well within measurement or estimate errors (Baan et al., 1984; Burkhoff et al.,
1985).
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Figure 9.16: Clinical (solid line) vs simulated identified patient-specific model
(cross) right ventricular stroke volume (RVSV) over all analyzed pigs.
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Figure 9.17 shows the systemic arterial systolic and diastolic pressure values
(SAP, DAP). The solid lines represent the clinical measurement and the +,
markers represent the identified patient-specific CVS model output for SAP and
DAP respectively. Again, very good matches are obtained with median absolute
percentage errors less than 3%.
0 10 20 30 40 50
20
40
60
80
100
120
140
160
180
nr of measurements
SA
P 
an
d 
DA
P 
in
 m
m
HG
 
 
model − SAP
clinical SAP
model − DAP
clinical DAPPig 1
Pig 2 Pig 3 Pig 4 Pig 5 Pig 6
Figure 9.17: Clinical (solid lines) vs simulated systolic (cross) and diastolic (box)
arterial pressures (SAP, DAP) over all analyzed pigs.
187
9. APPLICATION TO PORCINE EXPERIMENTS OF SEPTIC
SHOCK
Figure 9.18 shows the pulmonary arterial systolic and diastolic pressure values
(SPAP, DPAP). The solid lines represent the clinical measurement and the +,
markers represent the identified, patient-specific CVS model output for SPAP
and DPAP respectively. Similarly, very good matches are obtained, with median
absolute percentage errors less than 7%.
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Figure 9.18: Clinical (solid lines) vs simulated systolic (cross) and diastolic (box)
pulmonary artery pressures (SAP, DAP) over all analyzed pigs.
Figure 9.19 illustrates the very good matches achieved for one specific pig in
greater detail. The first subfigure shows the right ventricle signals at the begin-
ning of the experiment (T0). The upper panel shows the clinical vs. simulated
right ventricular pressure and the pressure in pulmonary artery. In the lower
panel, the clinical vs. simulated right ventricular volume is shown. It should be
noted, that during the identification process only the systolic (maximum) and
diastolic (minimum) values of the measured ventricle volume (EDV, ESV) and
arterial pressure (SPAP, DPAP) are used. The right ventricular pressure is not
used as this measurement is rarely obtained in a clinical setting. However, it can
clearly be seen that relatively good matches are nevertheless obtained for the ven-
tricle pressures, even where that measurement was not used in the identification
process, further validating the model and identification process.
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If desired, the ventricle pressures could easily be matched more accurately by
adjusting the activation functions in the CVS model (Smith, 2004; Smith et al.,
2004). However, this level of accuracy and added modification was not intended
in this study. The following subfigures illustrate the same results as in the first
part of Figure 9.19, but at 90 and 120 minutes into the experiment.
It was never intended for this study to perfectly match the pressure and vol-
ume waveform shapes, but only the minimum (diastolic) and maximum (systolic)
clinically measurable values. This goal was adopted because the main focus is
to identify the overall macro-hemodynamic condition, and less interest is placed
on exactly matching the specific waveforms. For example, exactly matching the
dicrotic notch in the arterial pressure signals was not a goal. These smaller,
less clinically relevant dynamics are often a function of small unmodelled non-
linearities or small non-linearities in patient-specific cardiac activation function.
In addition, a patient-specific activation function would eliminate most of these
clinically insignificant differences.
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Figure 9.19: Model output (dotted) vs clinical (solid line) volume and pressure
signals for right ventricle (RV). The upper panel shows the clinical vs. simulated
ventricle and arterial pressure. The lower panel shows the clinical vs. simulated
ventricle volume. The results are shown for 0, 90 and 120 minutes into the
experiment.
Table 9.3 shows the median absolute percentage errors for the identified min-
imum and maximum pressure and volume signals (SAP, DAP, SPAP, DPAP,
RVESV, RVEDV, RVSV) for the identified re-simulated model over all pigs. Gen-
erally, the errors are well below 10%, which is within typical measurement noise
levels.
190
9.3 Part II: Model-Based Analysis and Comparison of Endotoxic
Shock With and Without Hemofiltration
Difference in % for measured and simulated pressures and volumes
SAP DAP SPAP DPAP RVEDV RVESV RVSV
median 2.87 4.33 3.02 6.40 1.37 1.55 4.71
IQR 2.89 5.82 3.99 7.98 1.43 2.09 5.11
Table 9.3: Median absolute percentage error and interquartile range (IQR) in
% for measured and simulated pressures and volumes over all 38 identified seg-
ments. SAP/DAP = systolic/diastolic arterial pressure, SPAP/DPAP = sys-
tolic/diastolic pulmonary artery pressure, RVEDV = right ventricle end-diastolic
volume, RVESV = right ventricle end-systolic volume, RVSV = right ventricle
stroke volume.
Figure 9.20 shows the mean normalized systemic stressed volume (Vsyseff ),
and the identified mean normalized systemic vascular (Rsys) and pulmonary re-
sistance (Rpulin), as well as the resistance to venous return (Rvr) over all pigs
during the endotoxic shock experiment for the Endo group. Thus this data does
not include the effect of hemofiltration.
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Figure 9.20: Mean normalized values for estimated systemic volume Vsys,eff and
the identified model parameters systemic vascular resistance Rsys, pulmonary
vascular resistance Rpulin and resistance to venous return Rvr over all analyzed
pigs during the septic shock experiment in the Endo group.
9.3.3.2 Analysis of RV-Coupling
The upper panel in Figure 9.21 shows the clinically measured right ventricular
end-systolic elastance (Eesrvf ) during the endotoxic shock experiment, as previ-
ously reported (Lambermont et al., 2003, 2006). The solid line represents the
obtained mean normalized Eesrvf value in the endotoxic group (Endo), whereas
the dashed line represents the mean normalized Eesrvf value in the hemofiltration
group (EndoHF), respectively. The lower panel of Figure 9.21 shows the similar
results obtained from the CVS model and identification process. The solid line
again represents the mean normalized Eesrvf value for the Endo group and the
dashed line the mean normalized Eesrvf in the EndoHF group. Note that the
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analysis of the EndoHF group was not part of this research and has been pub-
lished previously (Desaive et al., 2008; Starfinger et al., 2008b). This elastance,
as with all the other model parameters, is identified during the identification
process.
Note that the absolute values obtained for Eesrvf depend on the unstressed
ventricle volume (Vd). For reasons of simplicity, this value is assumed to be
zero (Vd=0 ml) during the identification process. However, Eesrvf can easily be
adjusted for a different, and probably more realistic, Vd, as these adjustments have
no effect on the other identified model parameters. The identified Eesrvf trends
match very well with recently reported values obtained for the same experimental
data (Lambermont et al., 2006), as shown in comparing the upper and lower
panels of Figure 9.21.
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Figure 9.21: Mean normalized right ventricular end-systolic elastance Eesrvf over
all analyzed pigs during the septic shock experiment with (EndoHF) and without
(Endo) hemofiltration. Upper panel: results as obtained by (Lambermont et al.,
2006), lower panel: results obtained with CVS model and identification process.
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The upper panel of Figure 9.22 shows the clinically estimated pulmonary arte-
rial elastance (Ea) during the endotoxic shock experiment, as previously reported
by (Lambermont et al., 2003, 2006). The solid line represents the mean normal-
ized Ea value obtained in the endotoxic group (Endo), whereas the dashed line
represents the mean normalized Ea value clinically obtained in the hemofiltration
group (EndoHF), respectively. The lower panel shows the similar results obtained
for the CVS model and identification process. However, instead of showing the
pre-calculated, fixed and thus not identified (optimized) Epa value, the pulmonary
vascular resistance Rpulin is shown. The value of Rpulin, like the value of Ea, rep-
resents right ventricular afterload, but in this case, it is identified. The solid line
represents the mean normalized Rpulin value for the Endo group and the dashed
line the mean normalized value in the EndoHF group. The analysis of the En-
doHF group was not part of this research and has been published previously in
(Desaive et al., 2008; Starfinger et al., 2008b). Comparing the upper and lower
panels the trends are (qualitatively) similar.
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Figure 9.22: Upper panel: Mean normalized pulmonary arterial elastance Ea
over all analyzed pigs during the septic shock experiment with (EndoHF) and
without (Endo) hemofiltration as obtained by (Lambermont et al., 2006). Lower
panel: Mean normalized pulmonary vascular resistance Rpulin over all analyzed
pigs during the septic shock experiment with (EndoHF) and without (Endo)
hemofiltration as obtained with CVS model and identification process.
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Figure 9.23 shows in the upper panel the RV- vascular coupling as clinically
obtained by the ratio of Eesrvf to Ea, and how the RV-coupling evolves over time
as previously reported by (Lambermont et al., 2003, 2006). The solid line rep-
resents the obtained mean normalized RV-coupling value in the endotoxic group
(Endo), whereas the dashed line represents the mean normalized RV-coupling
value in the hemofiltration group (EndoHF), respectively. The lower panel shows
the same results obtained from the CVS model and identification process. How-
ever, in this model-based case, the ratio of Eesrvf to Rpulin is shown, as it uses
values identified with this limited data set.
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Figure 9.23: Mean normalized RV-coupling over all analyzed pigs during the sep-
tic shock experiment with (EndoHF) and without (Endo) hemofiltration. Upper
panel: results as obtained by (Lambermont et al., 2006), lower panel: results
obtained with CVS model and identification process.
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9.3.4 Discussion
One of the major goals of this research is to show the applicability of the CVS
model and identification process for a severely reduced data set. In this research,
only the right heart signals (Vrv, Ppa) and the arterial pressure (Pao) are available
for identifying the induced endotoxic shock. Despite this restricted data set
and the additional assumptions made regarding the other model volumes and
pressures, the CVS model parameters are consistently identified. This accurate
level of identification is validated by re-simulation and comparison to clinical data
including measured data not used in the identification process. Importantly, it
holds true not only for the right part of the model, but for the entire parameter
set.
When re-simulating the model with the identified parameters, the output
signals produced match the observed clinical data very well, as shown in Figures
9.16, 9.17 and 9.18. Median absolute percentage errors are less than 5% for the
volumes and less than 7% for the pressures, as shown in Table 9.3. These errors
are well within typical clinical measurement errors (Baan et al., 1984; Burkhoff
et al., 1985).
A second important finding of this research is that, despite the reduced data
set and necessary assumptions made, the CVS model is able to accurately iden-
tify and re-simulate endotoxic shock. Clinically, and importantly, the identified
parameter trends match physiological expectations. For example, Figure 9.20
shows the model simulated normalized systemic volume and how it decreases
during the time course of the experiment, accounting for the loss of circulatory
control and hypovolemia seen in septic shock (Bridges & Dukes, 2005; Dellinger,
2003). The data and results obtained from the pig-specific identified models thus
match clinical measurements and expectations.
Figure 9.20 also shows the mean normalized identified trends for the CVS
model parameters Rsys, Rpulin and Rvr over all analyzed pigs during the experi-
ment. The value of Rsys is perhaps (unexpectedly) identified to initially increase
at the beginning of the experiment. However, after 30mins and with the ongoing
endotoxin infusion, Rsys is decreasing, with a further two relatively small increases
at the end of the experiment. Overall, this trend indicates an initial physiological
compensation followed by a failure of circulatory control that is typical of septic
shock (Dellinger, 2003). From a model-based diagnostics perspective, this result
accurately tracks disease onset, initial (successful) compensation and (eventual)
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physiologic failure, all of which are clinically significant in determining appropri-
ate therapies and dosing.
The mean normalized Rpulin values over all pigs increase during the experi-
ment, as expected (Bridges & Dukes, 2005; Dellinger, 2003). There is a sharp
drop at 60 mins into the experiment. However, this decrease is consistent with
previously published results (Lambermont et al., 2003), where a similar drop can
be observed at 60 mins. Clinically, the model is thus capturing the known effects
of sepsis in this portion of the circulation, as well. It is important to note that
differences in systemic (Rsys) and pulmonary (Rpulin) behaviours and resistances
can help dictate the clinical therapeutic balance between vasopressor and fluid
resuscitation therapy if they are known. Hence, this model and identification
method can provide this level of clinical advice and guidance.
The mean normalized resistance to venous return, Rvr, decreases consistently
during the experiment. This result is expected, as the venous return is already
impeded by a low blood volume caused by fluid losses into the tissue, as well as by
the effects of veno- and vasodilation. In septic shock, proinflammatory cytokines
cause an increase in endothelial-derived nitric oxide, which in turn is a major
mediator for vasodilation and hypotension (Bridges & Dukes, 2005). Therefore,
the body tries to restore venous return and the model identifies this behaviour
as a lowered resistance to venous return that is needed to compensate for the
lower venous volume, pressure and flow back to the heart. Again, this capability
to very specifically capture the circulatory dysfunction due to sepsis has clinical
significance and importance in balancing therapy selection and dosing.
A third finding of this research is the identification and analysis of right ven-
tricular (RV)-vascular coupling in the endotoxic (Endo) group compared to the
hemofiltration (EndoHF) group. Previously, these results were reported in (Lam-
bermont et al., 2006) and the results shown in this research confirm these results
as similar coupling values and trends are obtained for the Endo and EndoHF
groups, as shown in Figure 9.23. More specifically, in the upper panel the previ-
ously reported coupling values are shown as normalized mean values over all pigs
and the lower panel shows the coupling as obtained using the CVS model and
methods presented in this research. The data shows that in the early phases of
endotoxic shock, RV-vascular coupling is preserved by an increase in RV contrac-
tility (Eesrvf ), as seen in Figure 9.21. However, during the later stages and with
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CVVH, RV-vascular coupling is preserved where a decrease in pulmonary vascu-
lar resistance (Rpulin), as seen in Figure 9.22, is suggested to be the main reason
for this effect (Lambermont et al., 2006). These results allow for a better under-
standing of the mechanisms of RV dysfunction during septic shock. Clinically,
the crossover point in Figure 9.23 between Endo and EndoHF groups clearly
delineates the time and efficiency of HF therapy selection, which is unique in
model-based monitoring.
Overall, using a significantly reduced data set for identification is shown to
have a very good potential for these methods to be used clinically. Such reduced
sets of measurements are commonly seen clinically and obviate the need for special
or costly sensors or equipment beyond what is currently used. Hence, the last
result is one of validating the overall concept’s potential practicality for clinical
implementation.
Table 9.3 summarizes the results for all six pigs and a total of 50 identification
periods. These results show that the extended CVS model is able to capture the
essential dynamics of the porcine CVS response to endotoxic shock over a selection
of subjects.
9.3.5 Conclusions
The integral-based optimization successively identified pig-specific parameters for
the extended CVS model. This further validation shows the ability of the model
to adequately and realistically capture the impact of pressure-volume changes
during endotoxic shock and to do so in the presence of a significantly reduced
data set for identification. Comparable results to previously reported studies are
obtained when analyzing the clinically important RV-vascular coupling, further
validating the methods and approach presented here. In particular, the model
is able to aggregate diverse measured data into a clear, clinically and physiolog-
ically relevant diagnostic picture as the condition develops. This research thus
increases confidence in the clinical applicability and validity of this overall diag-
nostic monitoring approach preparatory to initial studies with human subjects.
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Chapter 10
Adrenaline Simulation Study
This chapter1 describes the results obtained for simulating the effects of Adrenaline
in the CVS model. These results are compared to data from literature and the
predictive capability of the CVS model and methods developed are tested and
the model and methods are thereby further validated.
10.1 Introduction
Drugs for supporting the cardiovascular system are selected to either improve
heart rate (chronotropic effects), myocardial contractility (inotropic effects), ar-
terial blood pressure (vasoconstrictive effects), a reduction in afterload (vasodila-
tor effects), or a multiple combination of these effects. Many of these drugs also
increase electrical conduction (dromotropy) within the heart and augment relax-
ation (lusitropy). However, most of these drugs are non selective and may also
increase or decrease heart rate and afterload. These added changes carry the po-
tential risk of causing cardiac arrhythmias and increasing myocardial ischemia by
creating a mismatch between myocardial oxygen demand and supply (American
Heart Association, 2005). Additionally, some agents have also metabolic effects
that increase blood glucose, lactate and metabolic rate, and these effects should
also be taken into account when prescribing such drugs.
10.1.1 Drugs in Heart Failure and Cardiogenic Shock
The main problem in heart failure and hypotension (as caused by an acute heart
failure) is a loss of cardiac contractile function with a subsequently reduced or-
1This chapter is based on (Starfinger et al., 2008a).
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gan perfusion and hypotension. Drugs used in this case aim to improve cardiac
output, as it will lead to improved organ perfusion and normalization of arte-
rial blood pressure. Cardiac function and output can be improved by reducing
afterload and/or increasing preload by increasing fluid volume (for example in
hypovolemic and circulatory shock), and enhancing contractility of the heart.
10.1.2 Drugs in Circulatory Shock
This form of hypotensive shock is usually caused by an inadequate blood volume
as might be caused by hemorrhage. It can also be due to a loss of vascular tone
caused by infection and inflammation, as in septic shock for example. The main
goal in this case is to improve arterial blood pressure and vasoconstrictor drugs are
thus typically administered, often in the combination with fluid administration.
10.1.3 Drug Dosing and Infusion Rates
Specific drug infusion rates are typically not recommended in critically ill pa-
tients, mostly due to inter-patient variations in pharmacokinetics (drug dose -
concentration relation) and pharmacodynamics (drug concentration - effect rela-
tion) (Kellum & Pinsky, 2002; Zaritsky, 1994). Such drugs are thus dosed based
on an initial dose within a known therapeutic range. This dose is then varied
(titrated) at the bedside to achieve the desired effect, while limiting side effects.
There are a number of broad guidelines available for the appropriate use
of these drug therapies in critical care. However, sometimes it is not possible
to implement these algorithms because of patient-specific conditions, resident
learning curves and individual physician medication preferences (Bobek et al.,
2001). Hence, dosing regimes depend mainly on the intuition and experience of
the clinical staff and it cannot necessarily be guaranteed that the optimal dose
for each individual patient is chosen or maintained as patient condition evolves.
Therefore, a clinically validated computerized cardiovascular system (CVS)
model that provides accurate and patient-specific simulations of the cardiovas-
cular and circulatory system in response to various doses would be desirable.
Such a model can then be identified for each specific patient, creating a unique
representation of the patient’s condition within the model, as represented by
patient-specific parameters. A patient-specific model could be used to forward
simulate the likely response towards a change in dose. Noting response to initial
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doses, a drug sensitivity could be determined to optimize further dosing. Overall,
model-based estimation of drug effect and its patient sensitivity to enable dose
optimization would create unique clinical opportunity and advantages.
10.1.4 Adrenaline (Epinephrine)
Adrenaline (European Pharmacopoeia and BAN) or Epinephrine (INN) functions
as a hormone in the bloodstream and as a neurotransmitter when released across
a neuronal synapse. Adrenaline is released by the adrenal medulla upon activa-
tion of preganglionic sympathetic nerves innervating this tissue. This activation
occurs during times of stress, such as during exercise, heart failure, hemorrhage,
excitement or pain. Circulating adrenaline causes (Klabunde, 2004):
 Increased heart rate and inotropy (β1-adrenoceptor mediated)
 Vasoconstriction in most systemic arteries and veins (postjunctional α1-
and α2-adrenoceptors mediated)
 Vasodilation in muscle and liver vasculatures at low concentrations (β2-
adrenoceptor mediated)
 Vasoconstriction at high concentrations (α1-adrenoceptor mediated)
10.1.4.1 Adrenaline Usage in Critically Ill Patients
An observational study, which enrolled 84 patients in an ICU between February
and March 2005, showed that between 35% and 45% of patients were treated
with inotropes (Biswal et al., 2006). Adrenaline is used in patients who are
in cardiac arrest or who require inotropic or vasopressor support. Adrenaline
may additionally be used in cases of anaphylaxis associated with hemodynamic
instability or respiratory distress (American Heart Association, 2005; Ellis & Day,
2003). Furthermore, it improves myocardial and cerebral hemodynamics during
cardiopulmonary resuscitation (CPR).
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10.1.5 Goals for this Research
The goals for this research are twofold. The first aim is to validate the CVS
model for the first time in drug therapy scenarios and by doing so to provide a
basis for future clinical trials. Ultimately, the goal is to use the CVS model and
methods developed to predict the patient’s response towards different drugs and
doses over time to individualize and customize this aspect of patient care.
Pharmaceuticals represent 4% to 7% of the yearly operating expense of most
hospitals (Pierpaoli, 1993) and in ICUs this value ranges from 32.6% to 41.5%
of a hospital’s total drug costs (Weber et al., 2003). Hence, there is a growing
financial demand for optimizing the amount of drugs prescribed and avoiding
unnecessary prescriptions. Use of this CVS model, or similar, could help reduce
these costs by allowing the appropriate patient-specific dose to be found more
efficiently.
It should be pointed out that this CVS model so far has only been clinically
validated using data from porcine experiments (Desaive et al., 2007; Starfinger
et al., 2007b, 2008b,d,e) within a very controlled environment. In these cases,
desired effects are induced purposefully and usually not treated. However, data
obtained from clinical trials on critically ill patients, adds the challenge of a mul-
tivariate environment, where a variety of therapeutic treatments are performed
and drugs are administered combined with different ventilatory support options
and fluid administrations. Therefore, it is important to know the effect each in-
dividual treatment option is likely to have and how the parameters in the CVS
model may need to be adjusted to correctly represent these changes.
This study uses human clinical data from 3 adrenaline dose response studies
found in literature (Heringlake et al., 2007; Levy et al., 1997; White & Leenen,
1997). These studies present hemodynamic data, such as arterial pressures and
the cardiac index, at the level of detail needed for the model identification process.
Thus, this research is a first validation of the CVS model and methods in a more
realistic clinical environment.
The goal is to be able to identify the underlying patient-specific parameters
that allow the representation of the patient’s hemodynamic status and adrenaline
dose response within this CVS model. More specifically, the CVS model is iden-
tified for each data set and therefore represents the unique hemodynamic con-
dition, expressed in the different parameter values and trends over time. These
patient-specific parameter values and trends are then used to predict the patient’s
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response towards a change in dose of adrenaline and over time. These predictions
are then compared to the clinical data given in the studies (Heringlake et al., 2007;
Levy et al., 1997; White & Leenen, 1997). Results are presented in the form of
absolute percentage errors between predicted and clinically observed data.
10.2 Methods
10.2.1 CVS Model
The CVS model is a lumped parameter model which was previously developed
by (Smith, 2004) and is based on earlier work of (Chung et al., 1997; Olansen
et al., 2000). The new and extended model is presented in Section 3.2.
10.2.2 Integral-Based Parameter Identification
The parameter identification method used in this research has previously been
shown to rapidly and accurately identify almost the entire parameter set in the
presence of significant measurement noise (Hann et al., 2006; Starfinger et al.,
2007b). As the identification process has been extensively described (Desaive
et al., 2007; Starfinger et al., 2008d,e), and in Chapter 5 and Section 8.2.2.2, only
a brief summary of the individual steps is provided here.
10.2.3 Summary of the Identification Process
Figure 5.6 gives an overview of the identification process based on previous work
(Hann et al., 2006; Starfinger et al., 2007b, 2008d,e). The following steps are
performed:
1. Obtain clinical measurements and signals
2. Use volume calculations to estimate the initial volume conditions for the
CVS model (Starfinger et al., 2008d)
3. Use initial set of parameters to obtain first simulation output (Starfinger
et al., 2007b, 2008d,e)
4. Scale simulation output signals (Ppa, Pao, Vlv, Vrv) to match the clinical
data (Starfinger et al., 2007b, 2008d,e)
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5. Identify the patient-specific parameters for the scaled signals using the
integral-based methods based on (Hann et al., 2006)
6. Re-scale the simulation output signals to better match the clinical data
7. Repeat steps 4 to 6
8. Stop the iterative process when a set error tolerance is reached
10.2.4 Experimental Protocols
Three clinical studies reported in the literature were used in this research (Her-
inglake et al., 2007; Levy et al., 1997; White & Leenen, 1997). Results from each
are employed here to identify and validate the CVS model. As cited, the clinical
data is thus not the work of the authors and only published results are used here.
10.2.4.1 Study 1: Effects of Age on Cardiovascular Responses to
Adrenaline in Man
In this study (White & Leenen, 1997), Adrenaline was administered to 14 young
normotensive subjects (age 21-40 years, mean 30± 2 years; 8 male, 6 female) and
18 older normotensive subjects (age 50-73 years, mean 60± 2 years; 6 male, 12
female). All subjects had weight within 20% of the ideal body weight. They
all had normal history, physical examination and biochemistry. The subjects
were instructed to refrain from caffeine and alcohol 24 hours prior to each study
morning and they did not take any other medication for the duration of the study.
The study was approved by the Human Ethics Committee of the University of
Ottawa and written informed consent was obtained.
Arterial blood pressure (ABP) was measured using a blood pressure cuff
applied to the arm that was not used for the infusion. Blood pressure was
recorded using a Roche Arteriosonde (Roche Medical Electronics Inc., Cran-
bury, NJ, USA). ECG electrodes were applied to measure heart rate (HR) by
a Tektronic 414 monitor (Tektronic Inc., Beaverton, OR, USA). On the study
morning, following a rest period of at least 60 minutes, adrenaline was started at
20 ng/kg/min and increased to 40, 80, 120 and 160 ng/kg/min or until the heart
rate had increased by 20-25 beats/min or the diastolic blood pressure decreased
by 15 mmHg. Each dose was infused for 8 mins. Heart rate and blood pressure
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were measured every 2 mins for 10 minute periods prior to the start of an infu-
sion and twice during the last 2-3 mins at each rate of infusion. Mean values and
standard deviation were used for statistical analysis.
Table 10.1 summarizes the data obtained from this study for the different
adrenaline doses and populations (young/older and male/female). The following
measurements are used for the parameter identification process:
 heart rate (HR)
 systolic and diastolic arterial pressures (SAP, DAP)
 left ventricular end-systolic and end-diastolic volume indexes (LVESVI,
LVEDVI)
 left ventricular stroke volume (LVSV, as calculated from LVEDVI and
LVESVI)
Overall, this study provides 24 unique data sets that may be used.
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Study 1: Adrenaline doses, populations and hemodynamic measurements
Adrenaline dose number of SAP DAP MAP LVEDVI LVESVI
(ng/kg/min) participants (mmHg) (mmHg) (mmHg) (ml/m2) (ml/m2)
Young (Y)
Baseline 14 111 75 87 81 21
20 14 112 69 83.3 82 18
40 14 114 66 82 83 15
80 14 124 62 82.6 84 12
120 13 132 61 84.6 85 11
160 13 139 61 87 88 11
Older (O)
Baseline 18 115 76 89 65 14
20 18 115 72 86.3 64 12
40 18 119 69 85.6 65 8
80 18 126 67 86.6 67 8
120 16 132 68 89.3 69 8
160 10 136 68 90.6 67 6
Young Male (YM)
Baseline 8 114 79 90.6 86 23
40 8 117 68 84.3 86 18
Max (150) 8 143 62 89 90 12
Young Female (YF)
Baseline 6 107 69 81.6 75 18
40 6 110 62 78 80 13
Max (160) 6 132 58 82.6 82 10
Older Male (OM)
Baseline 6 117 74 88.3 64 16
40 6 121 67 85 66 11
Max (133) 6 140 65 90 68 8
Older Female (OF)
Baseline 12 114 77 89.3 66 13
40 12 117 70 85.6 66 10
Max (140) 12 132 69 90 68 8
Table 10.1: Adrenaline doses, hemodynamic measurements and participants sep-
arated into Young and Older and Young Male, Young Female and Older Male
and Older Female, respectively.
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10.2.4.2 Study 2: The Metabolic and Renal Effects of Adrenaline
and Milrinone in Patients with Myocardial Dysfunction
After Coronary Artery Bypass Grafting
In this study (Heringlake et al., 2007), during a 18-month period, 251 patients
were screened for low cardiac output (CO) upon ICU admission after coronary
artery bypass grafting (CABG) surgery. Approval of the local Ethics Committee
and preoperative written consent was obtained. Patients having a cardiac index
(CI) of less than 2.2 l/min/m2 upon ICU admission (despite adequate arterial and
filling pressures) were randomly assigned to 14-hour treatment with adrenaline
(n=7) or milrinone (n=11) to achieve a CI of greater then 3 l/min/m2.
Drugs were given by continuous infusion without a bolus. Treatment in the
ICU and the care provided to the patients was at the discretion of the clinical
staff in charge. With the exception of the hemodynamic goals given above and
the prohibition of using diuretics or hydroxyethylstarch preparations during the
treatment duration, no specific therapeutic instructions were given.
All patients had a radial arterial line, a central venous catheter and a pul-
monary artery catheter for continuous measurement of mixed venous oxygen sat-
uration (SvO2) and CI (Vigilance, Edwards Lifesciences LLC, Irvine, CA, USA).
Hemodynamics were recorded every two hours for a 14 hour treatment period af-
ter ICU admission. The hemodynamic variables recorded include: mean arterial
pressure (MAP), central venous pressure (CVP), mean pulmonary artery pressure
(MPAP), HR and CI. The following measurements are used for the parameter
identification process:
 heart rate (HR)
 mean arterial and mean pulmonary artery pressures (MAP, MPAP)
 cardiac index (CI)
 central venous pressure (CVP)
Overall, this data from (Heringlake et al., 2007) provided 8 data sets for use.
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Study 2: Course of time and hemodynamic measurements
Hour into study t0 t2 t4 t6 t8 t10 t12 t14
MAP (mmHg) 79 70 73 76 80 80 82 82
MPAP (mmHg) 24 26 24 24 23 23 23 20
CI (l/min/m2) 1.9 3.3 3.2 3.3 3.2 3.1 3.3 3.5
CVP (mmHg) 14 14 13 13 12 12 12 10
HR (min−1) 97 97 97 95 95 96 96 99
Table 10.2: Time course and hemodynamic measurements for study 2.
10.2.4.3 Study 3: Comparison of Norepinephrine and Dobutamine
to Epinephrine for Hemodynamics, Lactate Metabolism,
and Gastric Tonometric Variables in Septic Shock: a Prospec-
tive, Randomized Study
This study (Levy et al., 1997) included 30 patients with hyperdynamic septic
shock and was approved by the local Ethics Committee and written informed
consent was obtained from the patient’s closes relative. To be included in the
study after volume resuscitation and treatment with dopamine up to a dose of
20µg/kg/min, the patients had to have the following baseline condition:
 MAP ≤ 60mmHg
 signs of altered perfusion (oliguria, < 30ml/hr) or increased lactate level
(> 2.5mmol/l)
 CI > 3.5l/min/m2
Heart rate was monitored continuously and the routine clinical monitoring
included a thermodilution pulmonary artery catheter, with continuous monitor-
ing of mixed venous oxygen saturation (SvO2) and a radial and femoral artery
catheters. Measurements of MAP, CVP, MPAP were taken and CO was measured
by the thermodilution method. Each patient received either epinephrine or nore-
pinephrine + dobutamine. Epinephrine infusions were started at 0.3 µg/kg/min.
The infusion rate was titrated on MAP at 5-min intervals to obtain a MAP >
80mmHg, with a stable or increased CI.
Table 10.3 summarizes the adrenaline titration given. The following measure-
ments are used for the parameter identification process:
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 heart rate (HR)
 mean arterial and mean pulmonary artery pressures (MAP, MPAP)
 cardiac index (CI)
 central venous pressure (CVP)
Overall, 5 data sets were available for use in this study.
Study 3: Adrenaline titration, course of time
and hemodynamic measurements
Baseline h1 h6 h12 h24
Drug titration 0 0.45± 0.09 0.52± 0.07 0.48± 0.08 0.36± 0.08
(µg/kg/min)
MAP 60 89 93 96 89
(mmHg)
HR 121 114 109 115 108
(/min)
MPAP 25 31 29 28 26
(mmHg)
CI 4 5.1 4.5 4.1 4.1
(l/min/m2)
Table 10.3: Time course and drug titration for study 3.
10.2.5 Estimations and Prediction Process
Depending on the data available for each study, different assumptions about the
rest of the data had to be made. These assumptions and estimations are briefly
summarized below.
Generally, the prediction process uses some measure of past information on
how the patient responded towards a change in adrenaline dose to predict how
the patient is likely to respond towards a future change in dose. Depending on
the data available, the prediction process is adjusted for each of the 3 studies as
described below.
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10.2.5.1 Adrenaline-Specific Parameters
As discussed before, the effects of adrenaline can be summarized as an increase
in HR and contractility, vasoconstriction in most systemic arteries and veins
and an increase in the central blood volume. These effects in turn lead to an
increase in SV and systemic arterial pressure (SAP). Diastolic arterial pressure
(DAP) is decreasing, and thus a relatively constant mean arterial pressure (MAP)
results, but with a largely increased pulse pressure (PP). Consequently, from
these physiologically expected effects the model parameters that should be most
influenced by adrenaline, are:
 left and right ventricular end-systolic elastances (Eeslvf , Eesrvf ); also rep-
resenting the contractility
 arterial and pulmonary elastances Eao and Epa; as affected by the change
in pulse pressure
 systemic arterial resistance Rsys; as affected by vasoconstriction
 systemic elastance Esys (1/compliance); as affected by the increase in Vsys
As the most pronounced changes are expected in Eeslvf , Eesrvf , Eao and Epa,
these parameters are termed the adrenaline-specific parameters. Changes in these
parameters are therefore used for predicting the future response towards a change
in dose of adrenaline or over time. However, for studies 2 and 3 (Heringlake
et al., 2007; Levy et al., 1997), changes in Rsys and Esys were also included in
the prediction rules. This difference can be explained by the overall much longer
time periods for these 2 studies, where the hemodynamic status of the patients
is more likely to have changed caused by, for example, vasoconstriction and/or a
change in blood volume.
10.2.5.2 Study 1
This study provided the best data for the identification process, with very de-
tailed data reported over a variety of subjects and conditions. As this study was
a planned interventional clinical trial study, it took place in a very controlled
environment and adrenaline was administered into each participant following a
strict protocol. It is thus safe to assume it was administered in exactly the same
way, with the same dose, and over the same time, for each participant. Hence,
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this research mostly concentrates on this study for validating the CVS model for
both simulating the different effects of adrenaline and testing its predictive ability
for changes in dose.
All 16 individual data sets obtained from the study (6 data sets, one per
dose, for the Y and O groups plus one additional set for the YM, YF and OM,
OF groups at baseline, also see Table 10.1) were identified using the methods
described in (Starfinger et al., 2007b, 2008d,e). The changes in the adrenaline-
specific parameters (Eeslvf , Eesrvf , Eao and Epa) in the Y group were observed and
a linear fit was obtained for the 5 dose changes from baseline to 160 ng/kg/min.
This trend is used for prediction.
Note, that the groups YM, YF and OM, OF are subgroups of the two general
groups Y (Young) and O (Older). However, there are still 24 individual data sets
with different hemodynamic values, as shown in Table 10.1. The identification
was performed for all 6 data sets in the Y and O groups and 4 additional data
sets in the remaining 4 subgroups - resulting in a total of 16 identifications.
Predictions are performed for the O group and the YM, YF, OM and OF data
sets. The first prediction uses the baseline parameters for each of these groups
(O, OM, OF, YM, YF), as it is necessary to have a baseline solution vector for
the model parameters to begin with. The adrenaline-specific parameters (Eeslvf ,
Eesrvf , Eao and Epa) are then re-calculated based on the linear prediction rule, ob-
tained from the linear fit in the Y group. Having re-calculated these parameters,
the forward simulation is run and the predicted output signals for SAP, DAP,
MAP, LVEDVI, LVESVI and SV are compared to the clinical data from (White
& Leenen, 1997). Median absolute percentage errors and the inter-quartile range
(IQR) are calculated. It has to be mentioned, that the data sets (from the Y
group) used for obtaining the prediction rules are completely different to the
data sets used for prediction, as can also be seen in Table 10.1.
A second prediction is performed, which in comparison to prediction 1, uses
the previous parameter vector identified from the previous dose, rather than those
from the baseline parameter vector. The adrenaline-specific parameters (Eeslvf ,
Eesrvf , Eao and Epa) are re-calculated based on the linear prediction rule as before.
Similarly, the forward simulation is run again and the predicted output signals
for SAP, DAP, MAP, LVEDVI, LVESVI and SV are compared to the clinical
data. Median absolute percentage errors and the inter-quartile range (IQR) are
calculated.
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In this study, the pulmonary artery pressure is not given and has to be esti-
mated. The pulmonary artery pressure is estimated as a constant pressure over
all dosages and participant groups with a systolic value of 25 mmHg and a dias-
tolic value of 12 mmHg. Note, that this estimation is physiologically incorrect,
as the pulmonary artery pressure is expected to change with different doses of
adrenaline. However, this error can be much better managed if it is similar for
all identified segments. Naturally, information about the pulmonary circulation
is lost and the value of Epa will also not necessarily represent a true value in this
case.
10.2.5.3 Studies 2 and 3
These 2 studies are used as further validations. In particular, the potential to
correctly identify patient-specific parameters in the absence of diastolic and sys-
tolic pressure measurements, given only the mean arterial pressures MAP and
MPAP, is studied. In addition, these 2 studies do not provide end-systolic or
end-diastolic volumes, relying instead on the cardiac index.
Thus, these 2 studies measure a very minimal amount of data. Hence, several
assumptions have to be made:
 SV is calculated based on HR and CI with an assumed BSA = 2m2 in all
cases
 ESV is assumed as SV + 10ml
 EDV is calculated as ESV + SV
 left and right ventricular volumes are assumed to be the same
 systolic and diastolic pressures are estimated based on Figure 10.1 as ob-
tained from (Klabunde, 2004)
In these 2 studies, there is only a limited amount of data available. In comparison
to study 1, this data is very inhomogeneous and was not obtained in a controlled
study. Instead, it was taken observationally over time periods of 14 and 24 hours,
respectively. Therefore, these data sets were not intended to truly predict the
patient’s response towards a change in dose in adrenaline, or over the course of
time.
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The goal in these data sets is to show the accuracy of the identification process
by testing if an overall rule can be found that shows a consistent way of identifying
the main adrenaline-specific parameters. If such a simple, linear rule can be found,
using all or most of the data points available, then this rule would show that the
parameters evolved in a consistent manner. This rule could then be used to
predict the patient’s response for a specific point in time. If successful, it would
help validate the approach of using drug-specific rules and parameter changes to
enhance identification and prediction.
Figure 10.1: Change in diastolic and systolic blood pressure in comparison to
a relatively constant mean arterial pressure with administration of epinephrine
(adrenaline) over time, as obtained from (Klabunde, 2004).
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For study 2, prediction rules are obtained from the absolute percentage changes
in the parameters from one point in time to the next, except for the change from
baseline to t2. This percentage difference is not included because this change is
expected to be much higher, as the effect of adrenaline is expected to be more
pronounced compared to the other time points were the adrenaline dose is kept
at a more constant level. A total of 6 predictions are performed for study 2
from t4 to t14, using the previous solution as baseline solution in each case.
For example, for predicting the response at t4, the parameters from t2 are used
plus the re-calculated adrenaline-specific parameters using the overall population
rule, as described before. In contrast to study 1, where the adrenaline-specific
parameters are Eeslvf , Eesrvf , Eao and Epa, for this data set it was necessary
to also re-calculate the systemic and pulmonary arterial resistances Rsys and
Rpul and the systemic elastance Esys. These 3 additional parameters changed
significantly during the time course of the study and were thus included in the
overall population rule.
Similarly to study 2, the prediction rules for study 3 are obtained from the
absolute percentage changes in the parameters from one point in time to the next.
However, here only the change from h1 to h6 is used. The baseline change was
excluded for the same reason as in study 2. For similar reasons the change to h24
was excluded, as this change covers a long time period (12 hours). In addition,
while the doses for h1, h6 and h12 are similar, there is a much lower dose at h24.
Hence, only 1 prediction is performed for study 3 and this is the prediction for
h12, using the data obtained from h1 and h6.
This prediction from study 3 serves as another validation of the CVS model
and identification process. The goal is to show that all parameters are identified
in such a consistent way that h1-h6 adrenaline-parameter specific rules can be
found to predict h12. The adrenaline-specific parameters Eeslvf , Eesrvf , Eao and
Epa used with study 1 are augmented for study 3 to include Rsys, which changed
considerably during the long time course of this study. Figure 10.2 shows the
prediction rules obtained for studies 2 (solid line) and 3 (dashed line) for Eeslvf
and Eesrvf over a time period of 1 to 24 hours, where the similarity over disparate
studies indicates a consistent underlying behaviour.
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Figure 10.2: Linear prediction rules for Eeslvf (upper panel) and Eesrvf (lower
panel) for studies 2 (solid line, (Heringlake et al., 2007)) and 3 (dashed line, (Levy
et al., 1997)).
10.3 Results
10.3.1 Study 1
10.3.1.1 Identification Results
Figure 10.3 shows in the upper panel (solid line) the mean systolic arterial pres-
sure (SAP) over all 16 segments as given in (White & Leenen, 1997). These 16
segments are the 6 measurements for the young and older groups at baseline, 20,
40, 80, 120 and 160 ng/kg/min adrenaline (segments 1-6 young, 7-12 older), plus
4 measurements, which are obtained by separating the young and older groups
for male and female, respectively. The circles are the simulated CVS model out-
puts obtained when the CVS model is re-run with the identified patient-specific
parameters.
The middle panel shows as a solid line the mean arterial pressure (MAP)
as available in (White & Leenen, 1997) for all 16 segments. The circles depict
the CVS model output data when re-run using patient-specific parameters. The
lower panel shows the same results for the diastolic arterial pressure (DAP).
Figure 10.4 shows in the upper panel the left ventricular end-diastolic index
(LVEDVI) as given in (White & Leenen, 1997), whereas the lower panel shows
the left ventricular end-systolic index (LVESVI). A total of 16 identifications were
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performed, with 6 identifications each in the young and older group plus another
four identifications separated for male and female, as described previously. The
circles represent the CVS model output signals.
Table 10.4 gives an overview of how well the CVS model output data matches
the data given in (White & Leenen, 1997). The absolute median percentage error
is given as well as the inter-quartile range (IQR). These two values are calculated
over all 16 identified segments.
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Figure 10.3: Study 1: Clinical mean systolic (SAP), diastolic (DAP) and mean
(MAP) arterial pressure as obtained from (White & Leenen, 1997) vs simulated
pressures. Solid lines represent the clinical data and circles represent the CVS
model simulation output using identified patient-specific parameters.
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Figure 10.4: Study 1: Clinical mean left ventricular end-diastolic (LVEDVI)
and end-systolic (LVESVI) volume index as obtained from (White & Leenen,
1997) vs simulated volume indexes. Solid lines represent the clinical data and
circles represent the CVS model simulation output using identified patient-specific
parameters.
Absolute percentage error for measured and simulated pressures and volumes
SAP DAP MAP LVEDVI LVESVI SV
(%) (%) (%) (%) (%) (%)
median 3.27 1.70 1.94 2.15 6.79 3.37
IQR 3.06 1.77 2.44 1.76 7.22 1.05
Table 10.4: Study 1, identification: Median error and IQR in % for measured
and simulated pressures and volumes over all 16 identified segments. SAP =
systolic arterial pressure, DAP = diastolic arterial pressure, MAP = mean arterial
pressure, LVEDVI = left ventricular end-diastolic volume index, LVESVI = left
ventricular end-systolic volume index.
10.3.1.2 Prediction Results
Table 10.5 gives the median absolute percentage errors and IQR for prediction 1
in study 1. This prediction uses a population-specific rule obtained only from the
young population to describe the changes in the main adrenaline-specific model
parameters caused by an increase in the adrenaline dose from baseline and 20
ng/min/kg to 160 ng/min/kg. Note that the baseline solution vector was used
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as initial solution for each time step and only the adrenaline-specific parameters
were updated according to the population-specific rule.
Table 10.6 gives the median absolute percentage errors and IQR for predic-
tion 2 in study 1. This second prediction uses the same population-specific rules
as were used in prediction 1. However, in contrast to prediction 1, the previous
solution is used as initial solution, rather than the baseline solution. Thus, for ex-
ample, for predicting and calculating the parameters for a dose of 120 ng/min/kg,
the identified parameters for a dose of 80 ng/min/kg are used.
Absolute percentage error for measured and predicted pressures and volumes
SAP DAP MAP LVEDVI LVESVI SV
(%) (%) (%) (%) (%) (%)
median 11.03 11.47 10.21 3.49 0.48 7.66
IQR 5.76 13.81 9.58 4.88 11.35 4.45
Table 10.5: Study 1, prediction 1: Median error and IQR in % for measured and
predicted pressures and volumes over all 13 predicted episodes when the baseline
parameter vector is used as initial solution. SAP = systolic arterial pressure,
DAP = diastolic arterial pressure, MAP = mean arterial pressure, LVEDVI =
left ventricular end-diastolic volume index, LVESVI = left ventricular end-systolic
volume index.
Absolute percentage error for measured and predicted pressures and volumes
SAP DAP MAP LVEDVI LVESVI SV
(%) (%) (%) (%) (%) (%)
median 2.60 6.72 4.66 2.99 8.78 6.62
IQR 3.33 5.59 4.29 2.93 12.00 4.76
Table 10.6: Study 1, prediction 2: Median error and IQR in % for measured and
predicted pressures and volumes over all 13 predicted episodes when the previous
parameter vector is used as initial solution. SAP = systolic arterial pressure,
DAP = diastolic arterial pressure, MAP = mean arterial pressure, LVEDVI =
left ventricular end-diastolic volume index, LVESVI = left ventricular end-systolic
volume index.
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10.3.2 Study 2
10.3.2.1 Identification Results
Figure 10.5 shows in the upper panel (solid line) the mean arterial pressure (MAP)
over 14 hours as given in (Heringlake et al., 2007). The circles represent the
simulated CVS model outputs obtained when the CVS model is re-run with the
identified patient-specific parameters. The middle panel shows as a solid line the
mean pulmonary artery pressure (MPAP) as obtained from (Heringlake et al.,
2007) over the 14 hour study period. The circles depict the CVS model output
data when re-run using the identified parameters. The lower panel shows the
same results for the cardiac index (CI).
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Figure 10.5: Study 2: Clinical mean arterial (MAP), mean pulmonary artery
(MPAP) pressure and cardiac index (CI) as obtained from (Heringlake et al.,
2007) vs simulated pressures and CI. Solid lines represent the clinical data and
circles represent the CVS model simulation output using identified patient-specific
parameters.
Table 10.7 gives an overview of how well the CVS model output data matches
the data given in (Heringlake et al., 2007). The median absolute percentage error
is given, as well as the inter-quartile range (IQR). These two values are calculated
over all 8 identified segments for the total study period of 14 hours.
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Absolute percentage error for measured
and simulated arterial pressures and CI
MAP MPAP CI
(%) (%) (%)
median 0.99 3.05 1.57
IQR 0.94 1.67 0.45
Table 10.7: Study 2, identification: Median error and IQR in % for measured and
simulated pressures and volumes over all 8 identified segments. MAP = mean
arterial pressure, MPAP = mean pulmonary artery pressure, CI = cardiac index.
10.3.2.2 Prediction Results
Table 10.8 gives the median absolute percentage errors and IQR for predicting
the hemodynamic responses in MAP, MPAP and CI based on the time in the
study. Note, that the rules for the adrenaline-specific parameters were obtained
from the middle time segments at 2 to 12 hours. The hemodynamic responses
are predicted for 6 different time segments at 4, 6, 8, 10, 12 and 14 hours. The
previous parameter solution vector was used as initial solution for each predicted
segment.
Absolute percentage error for measured
and predicted arterial pressures and CI
MAP MPAP CI
(%) (%) (%)
median 4.26 5.51 4.50
IQR 3.73 4.46 2.95
Table 10.8: Study 2, prediction: Median error and IQR in % for measured and
predicted pressures and volumes over all 6 predicted segments when the previous
solution vector is used as initial parameter vector. MAP = mean arterial pressure,
MPAP = mean pulmonary artery pressure, CI = cardiac index.
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10.3.3 Study 3
10.3.3.1 Identification Results
Figure 10.6 shows in the upper panel (solid line) the mean arterial pressure (MAP)
over 24 hours as given in (Levy et al., 1997). The circles represent the simulated
CVS model outputs obtained when the CVS model is re-run with the identified
patient-specific parameters. The middle panel shows as a solid line the mean
pulmonary artery pressure (MPAP) as obtained from (Levy et al., 1997) over the
24 hour study period. The circles represent the CVS model output data when
re-run using the identified parameters. The lower panel shows the same results
for the cardiac index (CI).
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Figure 10.6: Study 3: Clinical mean arterial (MAP), mean pulmonary artery
(MPAP) pressure and cardiac index (CI) as obtained from (Levy et al., 1997)
vs simulated pressures and CI. Solid lines represent the clinical data and cir-
cles represent the CVS model simulation output using identified patient-specific
parameters.
Table 10.9 gives an overview of how well the CVS model output data matches
the data in (Levy et al., 1997). The median absolute percentage error is shown,
as well as the inter-quartile range (IQR). These two values are calculated over all
5 identified segments for the total study period of 24 hours.
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Absolute percentage error for measured
and simulated arterial pressures and CI
MAP MPAP CI
(%) (%) (%)
median 2.93 1.54 5.00
IQR 1.31 8.83 0.73
Table 10.9: Study 3, identification: Median error and IQR in % for measured and
simulated pressures and volumes over all 5 identified segments. MAP = mean
arterial pressure, MPAP = mean pulmonary artery pressure, CI = cardiac index.
10.3.3.2 Prediction Results
Table 10.10 gives the median absolute percentage errors for predicting the hemo-
dynamic responses in MAP, MPAP and CI based on the time in the study. The
rules for the adrenaline-specific parameters were obtained from the time segments
h1 and h6 to predict the response at h12. The parameter solution vector at h6
was used as initial solution for the prediction of h12.
Absolute percentage error for measured
and predicted arterial pressures and CI
MAP MPAP CI
(mmHg) (mmHg) (l/min/m2)
6.87 1.06 10.34
Table 10.10: Study 3, prediction: Absolute difference in % for measured and
predicted pressures and CI for predicted segment h12 when the parameter trends
for h1 to h6 are used. MAP = mean arterial pressure, MPAP = mean pulmonary
artery pressure, CI = cardiac index.
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10.4 Discussion
For all 3 studies, the model simulation output signals match the clinical data very
well, as can be seen in Figures 10.3 and 10.4 for study 1, and Figures 10.5 and
10.6 for studies 2 and 3, respectively. The absolute percentage errors (median
and IQR) between simulated and clinical data for arterial pressures (SAP, DAP
and/or MAP), ventricle volume indexes (LVEDVI and LVESVI), stroke volume
(SV) and/or cardiac index (CI) for all 3 studies are given in Tables 10.4-10.9. It
can clearly be seen, that all median identification percentage errors are less than
9%. This value is within or near expected measurement errors.
These results show the good overall accuracy of the identification method and
parameters found. It also validates the models ability to capture these dynamics
in physiologically expected ways, as well as the assumptions and estimations
made. In particular, such generally good identifications are not likely possible
without a fundamentally valid model and approach.
Table 10.5 shows the median absolute percentage errors and IQR for predic-
tion 1 for study 1. This first prediction used the population-specific rule obtained
only from the Y population to describe the changes in the adrenaline-specific
model parameters that are caused by an increase in the adrenaline dose from 20
ng/min/kg to 160 ng/min/kg. Predictions were performed for the O, YM, YF,
OM and OF groups with absolute percentage errors less than 14% in the pres-
sures and less than 8% for the stroke volume. This low level of prediction error is
a very good result, as bigger differences might be expected in the adrenaline dose
response between the young (Y) and older (O) group, and also between male (M)
and female (F) groups. Nevertheless, reasonably good predictions were obtained,
showing the general applicability of the CVS model and methods.
More specifically, MAP in the older (O) group was consistently under-predicted
(median absolute percentage error 10%). However this bias is in accordance with
the results from (White & Leenen, 1997), where MAP decreases more in the Y
group then it does for the O group. Thus, this trend, when calculating the pre-
diction rules from the Y group, is transferred to the predictions in the O group.
However, these prediction errors are still within clinically reasonable or acceptable
ranges. This result also shows that some cohorts may well require cohort-specific
rules, even if the general trends are similar.
Table 10.6 shows the median absolute percentage errors and IQR for predic-
tion 2 for study 1. This second prediction uses the same population-specific rules
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as used in prediction 1. However, in contrast to prediction 1, the previous solution
is used as initial solution and not the baseline solution. Thus, better information
is included in the prediction process, especially for predictions at the end of the
study (for higher doses) where it would be expected that the remaining model
parameters have also changed slightly over the longer time scale of the study.
Hence, better prediction results are obtained with median errors less than 7% for
arterial pressures and stroke volume.
These 2 predictions in study 1 show how the CVS model could potentially
be used in a real clinical application. Firstly, a baseline solution for the spe-
cific patient needs to be obtained. Prediction rules, likely pre-existing, for the
adrenaline-specific parameters are then used to predict the response to, for exam-
ple, an increase in the current adrenaline dose. This first prediction might well
yield a reasonable result, and different doses can be tested and predicted with
the most appropriate chosen for the patient. However, as time progresses and
the dose changes, much better predictions will be obtained when the previous
solution vector, for example at 60 ng/kg/min or time=2hr, is used as the ini-
tial parameter set for the prediction at 80 ng/kg/min or time=3hr. Hence, once
started the process enables the ability to track patient evolution in response,
which is a potential clinical datum on its own right.
Tables 10.8 and 10.10 show the absolute percentage errors for the predictions
performed for studies 2 and 3. The median prediction errors are less than 6%
and less than 11% for studies 2 and 3, respectively. These are good results when
the very limited data available in these 2 studies is considered. In particular, all
the minimum and maximum arterial pressures and volumes had to be estimated
creating a substantial level of potential error for a limited result. Nevertheless,
reasonably good prediction results are obtained, illustrating the robustness of the
estimations and identification process.
Comparisons of the adrenaline-specific prediction rules between the 3 studies
are not fully possible. Study 1 is based on a dose change for a short time, where
each infusion lasts 8 minutes, in healthy subjects. In contrast, studies 2 and 3 are
observational studies in an ICU environment over a much longer time period of
14 and 24 hours with different doses in between. Hence, the different time scales
prevent direct comparison.
However, the linear prediction rules for studies 2 and 3 are, despite the many
assumptions that have to be made, relatively similar, as seen in Figure 10.2. The
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upper panel shows the prediction rule for Eeslvf for study 2 (solid line) and 3
(dashed line), the lower panel shows the prediction rule for Eesrvf . In particular,
it should be noted how the right ventricular contractility Eesrvf decreases, instead
of the expected increase. This result could be due to inaccurate estimations in the
right ventricle volume based on the assumptions made and/or due to the under-
lying cardiac and circulatory dysfunctions present in the critically ill patients for
studies 2 (myocardial dysfunction after CABG) and 3 (septic shock). This type
of inconclusive result is the expected limitation of using severely restricted data
and making compensatory assumptions that may not hold for broader cohorts.
Obviously, more studies are needed to confirm these initial results. The overall
goal remains to develop an overall adrenaline-specific parameter rule that can
easily be adjusted to the individual patient regarding age, sex, current drug dose
and underlying disease state. Such a rule could then directly be used in a clinical
application and only one baseline solution would be necessary, rather than a
whole set of identifications as in this current study. However, despite limitations,
this study has been able to demonstrate the potential. Particularly, when there
is clinically dense data.
10.5 Conclusion
The integral-based optimization method successively identified patient-specific
parameters for the minimal cardiac model for 3 studies of adrenaline therapies.
This validation study shows the ability of the model to adequately and realisti-
cally capture (with unique values) the impact of pressure-volume changes with
adrenaline in healthy subjects as well as in critically ill patients.
Furthermore, the integral-based optimization led to the successful definition
of adrenaline-specific parameters for the CVS model. These adrenaline-specific
parameter values were used to validate the predictive ability of the model. This
further validation shows the ability of the model to adequately and realistically
simulate the impact of pressure-volume changes with adrenaline in healthy sub-
jects and critically ill patients. Moreover, such rules can be similarly derived and
used to predict the response towards a variety of interventions, while errors or
deviations from them can point out developing disease states or hemodynamic
instabilities. This research thus increases the confidence in the clinical applica-
bility and validity of this model and its use in clinical diagnostic monitoring and
drug dose guidance.
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Chapter 11
Conclusions and Future Work
The first section of this chapter summarizes the main conclusions that can be
drawn from the research presented in this thesis. The second section describes
the future work that could be integrated into the CVS model or the parameter
identification process to make this approach to model-based diagnosis and therapy
guidance more applicable in a clinical environment.
11.1 Conclusions
The motivation behind the research presented in this thesis is the creation of
(minimal) models and methods to enable CVS diagnostic and decision support
systems in critical care.
The main accomplishments of this research include extending the CVS model
of Smith et al. (2004) to allow for a more accurate and physiological representation
of the cardiovascular system. This extension includes accounting for the effects
of spontaneous and mechanical ventilation. Secondly, the theoretical parameter
identification framework based on the integral methods of Hann et al. (2006)
has been transferred into a real-time clinically applicable identification process.
Third, parameter relationships have been analyzed and rules formulated that
allow the prediction of patient response to interventions such as administering
a fluid bolus, changing PEEP and increasing the dose of adrenaline. Finally,
the models and methods developed are validated on: porcine experiments of
pulmonary embolism (PE), porcine experiments of PEEP titrations at varying
volemic levels, two different sets of induced septic shock and human adrenaline
data found in the literature.
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Extending the CVS model added complexity and adjustments had to be made
to the identification process. It is important to remember that there has to be a
balance between model complexity and clinical applicability. Figure 11.1 shows
the model complexity versus clinical applicability with the optimal model for a
given intended purpose.
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Figure 11.1: Clinical applicability of a model as given by the model complexity.
As can be seen in Figure 11.1, when the model is too simple and thus does
not adequately represent the system to be modelled, the clinical applicability is
small. An example is the simplified original CVS model (Smith, 2004; Smith
et al., 2004). In that model there is no separation between the systemic arterial
and venous sides, making the correct simulation of mechanical ventilation and
cardiopulmonary interactions difficult.
When the model complexity is increased, the clinical applicability increases,
but only to a certain point. The model at this point could be termed the optimal
model for the intended purpose or application. For example, the optimal CVS
model for a general ICU may not need a highly detailed simulation of the ventric-
ular interaction and heart valve mechanics. In contrast, a CVS model, intended
for the use in a cardiology unit, for example before and after heart surgery, might
not be useful without these characteristics.
If even more complexity is added, the clinical applicability tends to decrease
again. Adding more complexity is usually only warranted for improving simula-
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tion results, as it allows a more detailed simulation. For example, the current
CVS model could easily be extended by adding the 2 atria and thus providing
a more accurate representation of the physiology and anatomy. However, these
extensions might significantly hinder the correct identification of the system, and
more parameters would have to be fixed at population values and unknown vol-
umes and/or pressures would have to be estimated. These requirements would
increase not only the computational time, but also the likelihood of incorrectly
identified parameters and poor clinical results.
Therefore, the model approach chosen in this thesis is guided by the principle
of parsimony, i.e. the goal is to apply the simplest model to be effective and
the CVS model structure is only extended where results and physiology dictate
to do so. This approach is fundamentally different to the approach of creating a
larger, more physiological model and reducing the model structure until the model
becomes identifiable and applicable for use in a real-time clinical environment.
In this thesis, Chapters 7 to 10 clearly demonstrate how the extended CVS
model and patient-specific parameter identification process created can success-
fully be applied to capture critical measures and expected physiological responses
in the presence of noise using real clinical data. This diagnostic identification pro-
cess is successfully adjusted to the number of measured input signals available,
which is critical for accounting for different clinical environments. For the iden-
tification of porcine PE (Chapter 7), the full set of hemodynamic signals were
measured continuously and, importantly, both ventricle volumes (Vlv, Vrv) as
well as the pulmonary artery pressure (Ppa) were measured. However, even in
the absence of direct volume measurements, as was the case for the PEEP ex-
periment (Chapter 8), good clinically valid identification results and predictions
were obtained.
The identification process was further extended to account for only discrete
measurements, such as the minimum and maximum ventricle volumes and arterial
pressures. These methods were then further developed and extended by volume
estimations for Vlv and Vrv and the other CVS model volume compartments,
based on a known blood distribution and the measured values GEDV and PBV.
As a result, several difficult to measure or unknown values are better or more
robustly accounted for in the diagnostic parameter identification process. This
approach significantly increases potential clinical utility with no loss of efficacy.
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The extended CVS model and methods are now much more applicable to an
ICU environment where it is very unlikely that ventricle volumes are recorded.
The methods developed and, more specifically, the way the volume compartments
are estimated have also been proven to be robust as in the case of the porcine
septic shock experiment of Chapter 9. This septic shock experiment is made up
of 2 different experiments where different hemodynamic signals were recorded. In
the first experiment of induced septic shock with hemofiltration (HF), all main
hemodynamic signals (Pao, Ppa, Vlv and Vrv) were recorded. However, in the sec-
ond experiment without HF, only the right heart signals were recorded and the
left ventricle volume had to be estimated. The CVS model was nevertheless able
to capture the main hemodynamic changes required for effective diagnostics dur-
ing septic shock, showing the engineering and clinical robustness of the developed
methods.
Overall, the model has been able to aggregate diverse measured data into a
clear, clinically and physiologically relevant diagnostic picture as the condition
develops. Furthermore, methods were developed that allow the prediction of the
patient’s response towards interventions. This research thus increases confidence
in the clinical applicability and validity of this overall diagnostic monitoring and
therapy guidance approach.
11.2 Future Work
This section investigates and summarizes potential further changes and extensions
to the CVS model structure that would enable it to more accurately simulate
some aspects of CVS or CPS function. Additional ideas are described related to
improving the computational time of the identification process and thus making
the methods developed more applicable for the effective real-time assessment of
cardiac and circulatory function.
11.2.1 O2 and CO2 Gas Exchange
Despite the many options available, most ICUs still only monitor and display
heart rate and blood pressure, however, they do usually measure oxygen satu-
ration by pulse oximetry (SpO2). Furthermore, especially for the hemodynamic
monitoring of septic shock patients, where microcirculation is impaired, it is vital
to keep the oxygen supply and demand in balance. Hence, over the past several
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years, tissue and organ perfusion became more and more important concepts and
are now monitored as part of the standard care in most ICUs. A variety of new
hemodynamic monitoring techniques have also been developed, such as sublingual
PCO2 monitoring, near infrared spectroscopy for tissue oxygenation and tissue
hemoglobin monitoring, as well as fluorescence spectroscopy for monitoring the
mitochondrial energy state.
In addition, for mechanically ventilated patients, information about the in-
and expired O2 and CO2 concentration is now available. Blood gas analysis
(BGA) also provides information about the amounts of O2 and CO2 in the blood.
BGA thus evaluates, how effectively the lungs are delivering O2 to the blood and
are eliminating CO2 from it. BGA studies are usually done in patients with
respiratory diseases to assess their lung status and in patients who receive O2
therapy. In addition, the pH value gives insight into the patient’s acid-base
balance and thus provides information about the kidney function.
Consequently, it would be desirable to make use of these additional signals
and thus the additional amount of information they provide. For example, oxy-
genation parameters such as the arterial and mixed venous O2 saturation (SaO2,
SvO2), the O2 delivery and consumption index (DO2I, V O2I) could be incorpo-
rated into the model. The arterial-venous O2 content difference (C(a− v)O2) on
the other hand, can be used to evaluate the amount of shunting in the lung, i.e.
the amount of air that bypasses the normal gas exchange route. More specifically,
the fraction of pulmonary blood flow that passes from the right to the left heart
without undergoing complete oxygenation by the lung. Details of models and
methods that incorporate O2 and CO2 components can be found in a variety of
reports (Batzel et al., 2005; Harada et al., 2005; Hardman et al., 1998; Kappel
et al., 2007; Lu et al., 2003).
11.2.2 Blood Volume Calculations
A very basic exponential relationship has been presented in Section 4.2.3.2 and
Equation 4.21 for characterizing the total effective blood TBVeff as based on
blood losses or infusions, taking into account the reflex mechanisms of constriction
and/or dilation. However, as already mentioned, better models are needed here.
For example, there are diseases and circulatory dysfunctions where no blood is
lost to the outside and thus BV = 0. However, blood can be lost into the tissues
or shifted to other organs, etc.
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This scenario is currently not well studied and improvements should be made
in the modelling of these blood shifts. Equation 4.21 should take these effects
into account by allowing for a different representation of BV. For example, BV
should not only represent the change in TBV as caused by external fluid losses
or infusions, but also serve as an internal BV, thus taking into account any blood
shifts that occur inside the body.
A first and very simple idea would be to relate this internal BV to the mea-
sured SV. This makes physical sense, as a reduced effective circulating blood
volume (Vsyseff ) will cause a drop in VR and thus a consequent reduction in SV.
Hence, Equation 4.21 could be extended:
BVinternal [in%] = ν · SVreduction [in%] (11.1)
with for example ν = 0.25, stating that a 40% reduction in SV is modelled by a
10% reduction in effective circulating volume.
11.2.3 Additional Diseases and Treatments
It is beneficial to know how to simulate the most common diseases and dysfunc-
tions typically found in an ICU environment, using the CVS model. Because only
then correct diagnosis and the following patient-specific forward simulations and
decision support predictions can be performed. A first step is made in Chapter 10,
where the effects of the Catecholamine Adrenaline are investigated. Other drug
simulation studies should be included. For example, the commonly used Nore-
pinephrine and Dobutamine would be obvious first steps and data may already
exist in the literature.
11.2.4 Modelling the Septum and Activation Function
This part of the research is completely based on simulations, as validation studies
for this particular behaviour are very hard to obtain. It would be desirable to
concentrate more specifically on the septum volume calculation and cardiac acti-
vation (driver) function. For example, for patients who suffer from arrhythmias
and/or abnormal electrical impulse conduction, such improvements, if clinically
validated, would help offer better insight into local heart function.
A first step is made in Section 3.2.1, where a left bundle branch block (LBB) is
simulated. However, the current driver function is based on a very simple system
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of Gaussian terms. The CVS model is able to handle 3 different driver functions
to account for time differences in the activation of the left and right ventricle
and the septum, as also presented in Section 3.2.1. However, these 3 different
representations are based on the same shape given by Equation 3.46 and Table
3.3. As the driver function shape is kept constant throughout the identification
process and largely also over different subjects (for comparability of the identified
parameters), some errors are introduced. For example, the ventricle pressure
waveform may not be matched by the CVS model output due to differences in
the simulated electrical activation of the ventricle.
These differences in the ventricle pressures in turn have effects. For example,
they will impact the filling periods of the ventricles, as filling (diastole) is defined
by the pressure gradient of the ventricle pressure and the corresponding pressures
Ppu and Pvc, respectively. These differences in the filling periods will then, in turn,
cause a difference in the ventricle volumes.
Hence, it would be desirable to improve the driver function definition and
make it more physiologically accurate. This change would also have potential
benefits on more accurately capturing ventricle pressures. However, this change
should be done with caution, as changing the driver function throughout the
identification process will have significant effects on all other CVS parameters.
Therefore, any changes should be made after evaluating the effects on all other
CVS model parameters.
To improve the matching of the filling and ejection times (diastolic and systolic
times), it is planned to integrate electrocardiogram (ECG) data as an additional
input signal into the identification process. The ECG will not only give insights
into any conduction disorders, but also provide some indication for filling and
ejection times. More specifically, the systolic times are roughly given by the
beginning of the QRS-complex (the R-peak) and the end of the T-wave. These
ejection and filling times can then be used to match the ventricle volumes more
correctly to the true signals, thus improving the quality of the model fit.
11.2.5 Extended Scaling Function
During the iterative identification process, CVS model output signals are scaled to
match the true, recorded signals. These scaled signals are then used to identify
the model parameters. The CVS model parameters are used to re-run a new
simulation and produce new output signals, which in turn are scaled to match
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the true signals. This iterative process is stopped, when a set tolerance between
simulated model output and true signal is reached.
At the moment, the scaling function only takes the minimum and maximum
volume and pressure values (EDV, ESV and SAP, DAP) into account, ignoring
the signal waveform and time axis. For future work, the scaling function could
be extended to also allow a time scaling, taking into account the filling and
ejection times, thus better matching the signal waveform. Information about
ejection (systolic) and filling (diastolic) times can either be obtained from the
measured signal waveform itself or from the ECG. Commonly, direct waveform
measurements of the volumes are not available in a clinical setting, however the
ECG is routinely recorded and hence, information about the different filling and
ejection times is available.
Improving the scaling function and thus the better and more physiologi-
cally accurate matching of the simulated and true signals might significantly
improve the parameter identification. More specifically, it is aimed to use the
new extended scaling function in simpler CVS models, for example separated
for left/right heart and systemic/pulmonary circulation, to create model output
signals and waveforms that can then be used in the identification process. These
output signals, which will be used as initial input signals for the identification
process, will then potentially reduce the time it takes for convergence in the
iterative identification process.
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CVS Model Equations
Equations which are used in the CVS model:
Ventricle volumes and flows:
Vlv = Vlvf + Vspt (A.1)
Vrv = Vrvf − Vspt (A.2)
Vpcd = Vlv + Vrv (A.3)
Ppcd = P0pcd · (eλpcd(Vpcd−V0pcd) − 1) (A.4)
Pperi = Ppcd + Pth (A.5)
Q˙av =
(Plv − Pao −Qav ·Rav)
Lav
(A.6)
˙Qmt =
(Ppu − Plv −Qmt ·Rmt)
Lmt
(A.7)
Q˙pv =
(Prv − Ppa −Qpv ·Rpv)
Lpv
(A.8)
Q˙tc =
(Pvc − Prv −Qtc ·Rtc)
Ltc
(A.9)
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Pressures:
Ppu = Epu · (Vpu − Vdpu) + Pth (A.10)
Ppa = Epa · (Vpa − Vdpa) + Pth (A.11)
Pvc = Evc · (Vvc − Vdvc) + Pth (A.12)
Pao = Eao · (Vao − Vdao) (A.13)
Psys = Esys · (Vsys − Vdsys) (A.14)
Pcap = Ecap · (Vcap − Vdcap) (A.15)
Volumes:
V˙pv = Qpulout −Qmt (A.16)
V˙pa = Qpv −Qpulin (A.17)
V˙vc = Qvr −Qtc (A.18)
V˙ao = Qav −Qsys (A.19)
V˙sys = Qsys −Qvr (A.20)
V˙cap = Qpulin −Qpulout (A.21)
Flows:
Qsys =
(Pao − Psys)
Rsys
(A.22)
Qvr =
(Psys − Pvc)
Rvr
(A.23)
Qpulin =
(Ppa − Pcap)
Rpulin
(A.24)
Qpulout =
(Pcap − Ppu)
Rpulout
(A.25)
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Activation (driver) function:
e(t) =
3∑
i=1
Ai · e−Bi(t−Ci)2 (A.26)
Driver Function e(t)
Parameter [Unit] i = 1 i = 2 i = 3
Ai[unitless] 0.9556 0.6249 0.018
Bi[s
−2] 255.4 225.3 4225.0
Ci[s] 0.3060 0.2026 0.2491
Table A.1: Driver Function e(t) parameters.
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Ventricular interaction and septum volume:
Plv = Plvf + Pperi (A.27)
Prv = Prvf + Pperi (A.28)
Plvf = driL · Eeslvf · (Vlvf − Vdlvf )
+ (1− driL) · P0lvf · (eλlvf (Vlvf−V0lvf ) − 1) (A.29)
Prvf = driR · Eesrvf · (Vrvf − Vdrvf )
+ (1− driR) · P0rvf · (eλrvf (Vrvf−V0rvf ) − 1) (A.30)
Plv = Plvf + Pperi (A.31)
Prv = Prvf + Pperi (A.32)
Pspt = driS · Eesspt(Vspt − Vdspt) + (1− driS) · P0spt(eλspt(Vspt−Vospt) − 1) (A.33)
Vspt = a/b (A.34)
with a and b defined:
a =
(
driS · Eesspt · Vdspt
+ driL · Eeslvf · (Vlv − Vdlvf )
− driR · Eesrvf · (Vrv − Vdrfv)
− (1− driS) · P0spt · (bspte−λsptVospt − 1)
+ (1− driL) · P0lvf · (blvfeλlvf (Vlv−Volvf ) − 1)
− (1− driR) · P0rvf · (brvfeλrvf (Vrv−Vorvf ) − 1)
)
(A.35)
b =
(
driS · Eesspt
− driL · Eeslvf − driR · Eesrvf
+ (1− driS) · P0spt · aspte−λsptVospt
− (1− driL) · P0lvf · alvfeλlvf (Vlv−Volvf )
+ (1− driR) · P0rvf · arvfeλrvf (Vrv−Vorvf )
)
(A.36)
240
where aspt, alvf , arvf , bspt, blvf and brvf are defined:
x1 = Vspt,old +4Vspt (A.37)
x2 = Vspt,old −4Vspt (A.38)
aspt =
eλsptx2 − eλsptx1
x2 − x1 (A.39)
alvf =
eλlvfx2 − eλlvfx1
x2 − x1 (A.40)
arvf =
eλrvfx2 − eλrvfx1
x2 − x1 (A.41)
bspt = e
λsptx1 − (eλsptx2 − e
λsptx1
x2 − x1x1) (A.42)
blvf = e
λlvfx1 − (eλlvfx2 − e
λlvfx1
x2 − x1x1) (A.43)
brvf = e
λrvfx1 − (eλrvfx2 − e
λrvfx1
x2 − x1x1) (A.44)
where Vspt,old is the Vspt in the previous time step and 4Vspt = 0.1ml.
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Appendix B
CPS Model Equations
Equations which are used in the CPS (cardiopulmonary and circulatory) model:
Volume calculations:
Vdsys = Vunstressed + Vextravascular (B.1)
LV EDV = GEDV · 0.6 · 0.4 (B.2)
RV EDV = GEDV · 0.6 · 0.6 (B.3)
PBV =
GEDV
4
(B.4)
ITBV = GEDV + PBV (B.5)
ITBV = 1.25 ·GEDV (B.6)
Vcapeff = PBV · 0.4 (B.7)
Vpv = PBV · 0.6 (B.8)
Vvc = κ · SV (B.9)
Vsyseff = TBVeff − Vao − LV EDV −RV EDV (B.10)
− Vpa − Vcapeff − Vpv − Vvc
Vdsys = TBVineff · 0.8 (B.11)
Vdcap = TBVineff · 0.2 (B.12)
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TBVeff,norm = (25 +4)[ml/kg] (B.13)
TBVineff,norm = (60−4)[ml/kg] (B.14)
TBVeff = TBVeff,norm ·KG+BV (B.15)
TBVineff = TBVineff,norm ·KG (B.16)
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